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￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿
 
The TNF-ligand and TNF-receptor family 
Tumor necrosis factor (TNF) ligand family members and their cognate receptors of the 
TNF receptor family activate several signaling pathways, eliciting activities ranging from 
cell-proliferation to the induction of apoptosis. TNF like ligands (TNF-L) and TNF like 
receptors (TNF-R) are involved in a variety of biological processes, such as host defense, 
development, (auto)immunity, inflammation and tumor surveillance
1-3. TNF-L and TNF-R 
like  molecules  have  been  identified in a wide range of  metazoans,  from Drosophila to 
mammals
4.  Currently,  nineteen  TNF-ligands  and  twenty-nine  TNF-receptors  have  been 
identified in humans (table 1)
2,5. Several ligands have multiple receptors, and conversely, 
some receptors also bind multiple ligands (figure 1). 
 
 
Figure 1. Interactions between human TNF-L and TNF-R family members. NGFR interacts with members of 
the Nerve growth factor family members and EDAR and EDR2 are splice variants. 
The  TNF-ligand  family  is  characterized  by  a  conserved  C-terminal  domain,  the  TNF 
homology domain (THD). The sequence identity between THDs of different TNF-L family 
members is ~20-30%. The THD causes trimerization of the TNF-L and is responsible for 
receptor  binding.  Sequence  homology  is  highest  between  the  (aromatic)  residues 
responsible  for  trimer  formation.  All  monomeric  subunits  of  TNF-ligands  consist  of 
antiparallel b-sheets, organized in a jellyroll topology, and these subunits self associate in 
bell-shaped homotrimers, the bioactive form of the ligand. A trimer binds three subunits of 
a cognate receptor, each receptor subunit binds usually in the grooves between two adjacent 
monomer subunits. The ligands are type II transmembrane proteins (i.e. intra-cellular N-
terminus and extra-cellular C-terminus), but the extracellular domain of some members can 
be proteolytically cleaved from the cell surface, yielding a bioactive soluble form of the 
ligand
1,2,6.  
The  distinguishing  feature  of  the  extra-cellular  part  of  the  TNF-like  receptors  is  the 
cysteine-rich  domain  (CRD).  These  CRDs  are  pseudo-repeats  of  ~40  amino  acids  and 
typically contain six cysteine residues which are involved in the formation of three intra-
chain disulfide bonds. The number of CRDs in a particular receptor varies usually from one 
Symbol LTA TNF LTB TNFSF4 TNFSF5 TNFSF6 TNFSF7 TNFSF8 TNFSF9 TNFSF10 TNFSF11 TNFSF12 TNFSF13 TNFSF13B TNFSF14 TNFSF15 TNFSF18 EDA EDA
acronym TNFB TNFA TNFC OX-40L CD40L FASL CD70 CD30LG 4-1BB-L TRAIL RANKL TWEAK APRIL BAFF LIGHT TL1A GITRL EDA1 EDA2
TNFRSF1A TNF-R1 x x x
TNFRSF1B TNF-R2 x x x
LTBR TNF-R3 x x
TNFRSF4 OX40 x
TNFRSF5 CD40 x
TNFRSF6 FAS x
TNFRSF6B DcR3 x x x
TNFRSF7 CD27 x
TNFRSF8 CD30 x
TNFRSF9 4-1BB x
TNFRSF10A DR4 x
TNFRSF10B DR5 x
TNFRSF10C DcR1 x
TNFRSF10D DcR2 x
TNFRSF11A RANK x
TNFRSF11B OPG x x
TNFRSF12 DR3 ? x
TNFRSF12A FN14 x
TNFRSF12L DR3L
TNFRSF13B TACI x x
TNFRSF13C BAFF-R x
TNFRSF14 HVEM x x
NGFR NGFR
TNFRSF17 BCMA x x
TNFRSF18 GITR x
TNFRSF19 TROY
TNFRSF19L RELT
TNFRSF21 DR6
EDAR EDAR x
EDA2R XEDAR x
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to four. TNF-R family members have an elongated shape due to the repeated arrangement 
of the CRDs. Most of the TNF-R family members are type I transmembrane proteins (i.e. 
intra-cellular C-terminus and extra-cellular N-terminus). However, several exceptions exist; 
for example some receptors lack a C-terminal part and are secreted as soluble receptors 
(OPG  and  DcR3)  or  are  covalently  linked  to  the  cell  membrane  via  a 
glycophosphatidylinositol  (GPI)  anchor  (DcR1)  and  some  other  transmembrane  TNF-R 
family  members  lack  a  signal  peptide  sequence  and  are  consequently  type  III 
transmembrane  proteins
1,2,6.  The  canonical  model  of  TNF  ligand-receptor  signaling 
proposes that three receptor monomers are recruited upon binding of a trimeric ligand into a 
signaling  complex  with  3:3  stoichiometry  (ligand-monomer:  receptor-monomer)
1,2,6. 
Receptor monomers cross-linked in this manner by the ligand subsequently transduce the 
signal into the cell. This simple model has been challenged by the fact that several TNF-R 
family members contain a pre-ligand assembly domain (PLAD) which allows the receptors 
to self-assemble in the absence of a ligand
7,8. Binding of a TNF ligand would then cause a 
rearrangement of the pre-assembled TNF-R complex and allow transduction of the signal. 
In addition, certain receptors are not fully activated upon stimulating with a soluble TNF-L 
but require the membrane bound form of the ligand for full activation. 
Depending on whether the cytoplasmic or intra-cellular tail of a particular TNF-R harbors a 
death domain (DD) or TNF receptor-associated factor (TRAF) binding domain, two main 
modes of signaling can be recognized: signaling events governed by TRAF proteins or by 
DD containing molecules
1. TRAF proteins physically and functionally connect TNF-Rs to 
downstream  signaling  pathways  involved  in  regulation  of  diverse  cellular  responses, 
including  activation,  differentiation  and  survival
9.  A  particular  subset  of  TNF-receptors 
contains an intra-cellular DD and hence are known as “death receptors”. Binding of a TNF-
L to these receptors typically cause the recruitment of adaptor proteins such as TNF-R-
associated DD protein (TRADD) or Fas-associated DD protein (FADD). Recruitment of 
these adaptors will cause the recruitment of caspase 8 or 10 and can ultimately result in cell 
death by a process called apoptosis or programmed cell death
10,11. 
 
Figure 2. Structure of the TRAIL trimer and DR5. A) Sideview of the TRAIL trimer, the individual TRAIL 
monomers are depicted in different shades of green. The zinc atom in the center of the TRAIL trimer is depicted as 
a red sphere. B) DR5 receptor monomer, disulphide bridges are depicted in yellow. In this orientation, the cell 
membrane of the DR5 containing cell is at the bottom of the figure. Picture is based on the structure of Cha et 
al.,
12. Introduction and scope 
- 13 - 
TRAIL and its receptors 
A  member  of  the  TNF-ligand  family,  Tumor  necrosis  factor  (TNF)  related  apoptosis 
inducing-ligand  (TRAIL,  Apo2L)  is  attracting  great  interest  as  a  potential  anti-cancer 
therapeutic as it selectively kills various types of tumor cells, and unlike other apoptosis 
inducing TNF-ligand family members, appears to be inactive against normal cells
13. TRAIL 
kills tumor cells by inducing apoptosis and normal cells appear to be relatively resistant 
towards TRAIL induced apoptosis. Reports in which TRAIL induces apoptosis in normal 
cells  could  be  attributed  to  the  specific  preparations  of  TRAIL  used
14,15.  TRAIL  is 
expressed as a transmembrane protein and it can be released from the cell membrane by 
proteolytic cleavage. Upon cleavage a soluble form of TRAIL is generated, both the soluble 
and the cell membrane-bound form are able to induce apoptosis. Like other TNF-ligand 
family members, TRAIL is a trimeric ligand and the b-sheets in a monomer are organized 
in a jellyroll topology (Figure 2A)
16-18. Unlike other TNF-like ligands, TRAIL contains a 
single cysteine residue, which is involved in chelating a zinc ion located at the center of the 
TRAIL trimer
17. This zinc binding center is essential for the stability and biological activity 
of (soluble) TRAIL. The TRAIL trimer binds three receptor molecules, each at the interface 
between two of its monomers (figure 3A and B)
16,18. 
 
 
Figure 3. Structure of the 3:3 TRAIL-DR5 complex. A) side view (same orientation as in figure 1). B) top view 
along the N-terminal to C-terminal axis of the DR5 receptor (i.e. looking towards the cell surface of DR5). Picture 
is based on the structure of the TRAIL-DR5 complex of Cha et al.,
12. 
 
TRAIL is a promiscuous ligand as it binds to five different cognate receptors of the TNF-
receptor family; to the death receptor 4 (DR4, TRAIL-R1), death receptor 5 (DR5, TRAIL-
R2,  KILLER,  TRICK-2)  and  to  the decoy  receptor  1  (DcR1,  TRAIL-R3,  TRIDD)  and 
decoy  receptor  2  (DcR2,  TRAIL-R4,  TRUNDD)  and  to  the  soluble  secreted  receptor 
osteoprotegerin (OPG)
19. The death- and decoy receptors consist of two complete CRDs 
and one partial N-terminal CRD with unknown function (figure 2B)
16,18. Binding of TRAIL 
to the DR4 and DR5 receptors induces apoptosis by activating the cell-extrinsic or death 
receptor-mediated  apoptosis  pathway.  Upon  binding  with  TRAIL  the  death  receptors 
trimerize and an intracellular death-inducing signaling complex (DISC) is assembled; the 
intracellular death domains of DR4 and DR5 recruit FADD
20-22, which bind and activate the Chapter 1 
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apoptosis  initiator  caspases  8  and  10
23-26.  This  leads  to  the  activation  of  the  apoptosis 
executioner caspase 3, followed by the activation of other proteases and nucleases resulting 
finally in apoptosis
27,28. This process can be inhibited by the cellular FLICE like-inhibitory 
protein (cFLIP), an  inhibitor of caspase  activation
29. DcR1  or DcR2 do not contain an 
intracellular death domain or contain a truncated death domain, respectively. Binding to 
these  receptors  does  not  induce  apoptosis,  in  contrast,  it  could  prevent  apoptosis  by 
sequestering available TRAIL or by interfering in the formation of a TRAIL-DR4 or DR5 
signaling complex
30. Recently, it was demonstrated that the PLADs overlapping the partial 
N-terminal CRD of DR5 and DcR2 were able to form pre-assembled hetero complexes in 
the absence of TRAIL and that DcR2 by virtue of this pre-assembled complex with DR5 
was able to inhibit TRAIL-induced apoptosis
31. 
 
At  present,  clinical  phase  I  studies  are  performed  with  recombinant  human  TRAIL 
(Genentech, South San Francisco, USA). This recombinant TRAIL version is a fragment of 
the C-terminal extra-cellular part of human TRAIL comprising amino acids 114-281 and is 
expressed in Escherichia coli bacteria as a soluble protein without additional exogenous 
sequences (rhTRAIL WT)
13. This TRAIL protein is purified as a trimer and optimized for 
its zinc content. No hepatotoxicity was observed in chimpanzees
32 after administration of 
rhTRAIL  and  neither  was  toxicity  observed  in  human  hepatocytes  or  other  normal 
cells
13,14,32.  However,  rhTRAIL  will  probably  be  rapidly  cleared  as  it  half-life  in 
chimpanzees was only 25 minutes
32. 
 
￿ ￿ ￿ ￿ ￿ ￿￿ ￿ ￿￿ ￿ ￿ ￿￿ ￿ ￿ ￿ ￿ ￿ ￿
 
Protein therapeutics currently are of increasing importance as approximately twenty five 
percent  of  all  new  therapeutics  entering  the  market  are  protein  based  therapeutics. 
However, since endogenous proteins are not “designed” by Nature, or more accurately, not 
evolved  to  function  as  therapeutic  agents,  additional  optimization  might  be  required. 
Traditionally,  expert  design  or  directed  evolution  techniques  were  used  to  improve  the 
characteristics of protein therapeutics. Computational protein design methods are a more 
recent  powerful  technology  which  is  able  to  improve  various  properties  important  for 
protein therapeutics, such as stability, receptor specificity and immunogenicity. Application 
of this technology potentially allows a faster transition from laboratory bench to clinic for 
protein therapeutics. As yet, however, computational protein design is hardly applied for 
the  improvement  of  protein  therapeutics.  In  this  thesis,  the  feasibility  of  computational 
protein design technology is demonstrated with the improvement of therapeutically relevant 
properties of the protein therapeutic rhTRAIL. Chapter 2 in this thesis describes the recent 
progress  in  the  use  of  computational  protein  design  methods  to  improve  protein 
therapeutics  and  other  potential  applications  of  these  methods  in  the  field  of  medical 
biotechnology.  Chapter  3  reports  the  design  of  rhTRAIL  variants  with  higher 
thermostability. Chapter 4 describes the design of rhTRAIL variants selective for DR5, 
whereas the design of rhTRAIL variants selective for DR4 is described in chapter 5. The 
added value of using a DR5 selective rhTRAIL variant compared to using rhTRAIL WT in 
combination with radiation therapy or chemotherapy is demonstrated in chapter 6. Finally, 
in chapter 7 the results of the studies described in this thesis are summarized and future 
perspectives are discussed.  
 
2 
Computational design methods for optimising 
 protein therapeutics 
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￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿
The use of computational methods in the (re)design of various properties of proteins 
has made an impressive progress in recent years. In this review we will discuss the use 
and  impact  of  these  methods  in  the  design  of  biopharmaceuticals  and  in  medical 
biotechnology. Computational protein design 
- 17 - 
￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿
 
Until the nineteen eighties the only available protein therapeutics were those purified from 
material of human, animal or microbial origin. The advent of recombinant DNA (rDNA) 
technology in the early seventies enabled the introduction of the first human recombinant 
protein therapeutic, human insulin, in 1982. In the twenty plus years since, this has resulted 
in the introduction of over 70 recombinant protein therapeutic products currently on the 
market and approximately another 80 at various stages in clinical development
33. The first 
recombinant protein therapeutics did have identical amino acid sequences as their natural 
counterpart. However, as natural occurring proteins are not evolved to be used as drugs, 
additional structure optimization might be required. Sequence optimization can be a useful 
strategy to improve several properties of a potential protein drug, such as stability, affinity, 
specificity, solubility, immunogenicity and pharmacokinetic (PK) properties, in order to 
obtain a variant with the desired characteristics. 
 
Several methods have been developed to obtain optimized protein variants. These can be 
classified into three main categories: (I) “classical” protein engineering approaches (expert 
design),  (II)  molecular  or  directed  evolution  methods  and,  more  recently,  (III) 
computational protein design. Classical protein engineering methods or expert design can 
be  defined  as  hypothesis  driven  sequence  alternations  based  on  structural  information 
and/or  information  obtained  from  sequence  alignments  with  a  high  degree  of  human 
intervention
34. A disadvantage of this approach is that only a relatively small amount of 
possible sequence changes can be assessed; only a very small part of the total possible 
“sequence space” is sampled. 
 
Directed evolution methods are being based on the creation of random sequence variation 
and subsequent selection of improved variants
35. Several rounds of selection are generally 
employed and after each round the sequence alterations yielding improved variants can be 
recombined into a single variant. These methods allow for sampling of a much larger part 
of sequence space. Error-prone PCR (ep-PCR) mutagenesis is often used for the creation of 
random (DNA) sequence variation
35. With epPCR genetic libraries encoding up to ~10
15 
unique  variants  can  practically  be  created  (assuming  a  1000  bp  gene)
36.  Saturation 
mutagenesis techniques can be used to create libraries with codons encoding all 20 natural 
amino-acids at certain site specific positions. Saturation of several sites in one template 
gene  results  in  a  “combinatorial  explosion”  of  library  size;  a  library  “saturated” 
(randomized)  at  only  9  different  codon  positions  already  consists  of  5.1x10
11  unique 
variants. However, the majority of the introduced sequence variation will be detrimental or 
neutral  for  protein  function;  only  a  small  portion  of  the  variants  contain  sequence 
alterations (or mutations) beneficial for protein function. For less complex libraries with 
sizes up to ~10
6 variants high-throughput screening (HTS) might be used to select out the 
variants with optimized characteristics, however, for complex libraries with larger sizes 
such a screening approach is not feasible
37. In these cases phage, cell or ribosome based 
display techniques are used to select out the improved variants. These techniques have in 
common a genotype/phenotype linkage, with the protein variant (phenotype) displayed on 
the outside of the cell or phage and the gene encoding the variant (genotype) inside the cell 
or  phage.  Using  a  “panning”  procedure  library  members  with  superior  binding Chapter 2 
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characteristics are selected from the vast pool of non-functional members or members with 
inferior binding characteristics. In a panning procedure the displayed library is incubated in 
the presence of immobilized target protein, a subsequent wash removes all the non-bound 
library members and finally the bound members are eluted from the target protein. Eluted 
library members are propagated and the panning procedure is generally repeated several 
times.  This  results  in  a  gradual  enrichment  of  members  with  superior  binding 
characteristics.  With  DNA  shuffling  methods  independent  advantageous  sequence 
alterations can be recombined. The amino acid sequence of thus improved members can be 
determined indirectly by DNA sequencing, taking advantage of the genotype/phenotype 
linkage
35,37.  
Although  directed  evolution  methods  are  powerful  and  have  been  very  successful  in 
improving binding or enzymatic properties of various proteins, several potential drawbacks 
can be noted. The practical obtained library size is often much smaller than the theoretical 
library size; the practical library size is restricted by physical and biological limitations 
such as transformation efficiency
38. 
 
More recently, development of computational methods allows for combining rational and 
mathematical modeling of biophysical (and biological) knowledge in algorithms combining 
both  approaches:  computer  design  steps  with  in  silico  screening/selection,  permitting 
screening of a much larger sequence space (up to 10
80) than is experimentally possible with 
selection methods or high-throughput screening techniques
39. The use of structure based 
computational algorithms in recent years has resulted in impressive results such as several 
de novo design examples, for example the design of a new amino acid sequence able to fold 
into  a  predetermined  structure
40  to  the  design  of  a  completely  new  globular  fold  and 
structure
41. Efficient algorithms are needed to search the vast sequence space and accurate 
scoring  functions  are  required  in  order  to  rank  the  best  designs
39,42.  Structure  based 
computational design algorithms employ usually an inverse protein folding approach, i.e. 
the algorithm determines which amino acid sequence is most compatible with a protein 3-
dimensional  backbone  structure.  A  particular  3-dimensional  structure  will  have  many 
sequences compatible with it while any given amino acid sequence only has one compatible 
3-dimensional  structure.  This  makes  inverse  folding  more  tractable  to  solve 
computationally  than  protein  folding  problems
39.  The  algorithm  places  discrete 
conformations (rotamers) of the naturally occurring amino acids at the positions considered 
for  design.  After  simultaneous  optimization  of  the  conformations  of  the  amino  acids 
interacting  with  the  substituted  amino  acid  the  energy  of  the  structure  is  determined, 
favorable substitutions are retained and unfavorable substitutions are discarded. In many 
algorithms and depending on the particular design problem, the details of this basic scheme 
will  differ.  Due  to  computational  reasons  the  backbone  conformation  of  the  protein 
structure is often considered as being fixed, a reduced amino acid repertoire can be used or 
a  backbone  dependent  rotamer  library  with  only  the  common  observed  discrete 
conformational states of amino acids can be employed. However in certain types of design 
problem it is necessary to increase precision at expense of computational time. In such 
cases  a  certain  degree  of  backbone  flexibility  can  be  considered  or  the  use  of  a  more 
continuous amino acid conformational state distribution by use of an expanded rotamer 
library, e.g. the common amino-acid discrete conformational states are expanded by several 
standard deviations around their rotatable bonds. The energy functions used to score the Computational protein design 
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fitness of the designs are based on several approaches such as physical models, statistical 
analysis,  empirically  derived  functions  and  many  of  the  successful  algorithms  use  a 
combination hereof. These functions typically include van der Waals interactions, hydrogen 
bonding and electrostatic potentials, an implicit solvation term and side chain and backbone 
entropy terms
43,44. Depending on the design problem and the particular algorithm, various 
search algorithms are used to find low-energy solutions to the design problem. There are 
two general classes of search algorithms; Stochastic methods and deterministic methods
45. 
Using  stochastic  methods,  such  as  Genetic  algorithms
46  and  Monte  Carlo  simulated 
annealing (MC)
47 the outcome is probabilistic. Self consistent mean field optimization
48 and 
dead end elimination (DEE)
49 are deterministic methods; upon rerunning a simulation these 
algorithms will produce the same outcome providing that the same parameters are used. 
Only the DEE algorithm can ensure, upon convergence, that the global minimum energy 
conformation is found. However, this algorithm can only be applied when the combination 
of sequence positions that need to be redesigned is relatively small. When DEE does not 
converge or in larger design problems several simulations using a stochastic method such as 
MC  might  be  used  to  sample  sequence  and  conformational  space  to  find  low  energy 
solutions. The primary advantage of computational design algorithms is the much larger 
fraction of the sequence/conformational space that can be sampled in search for an optimal 
solution when compared with expert design or directed evolution methods. Moreover, these 
functions are objective and require a lower level of human intervention than both other 
methods.  
 
In this review we will describe various computational protein engineering methods and 
their (potential) use in the design of protein therapeutics and other applications in the field 
of medical biotechnology. 
 
￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿
￿
Protein  thermal  stability  is  important  for  therapeutic  proteins,  both  influencing  the 
pharmacokinetic and pharmacodynamic properties and for stability during production and 
shelf-life of the final product. Stability issues concerning these latter two points can be 
addressed by protein formulation technology. However it is also possible to enhance the 
intrinsic stability of a protein structure by redesigning its amino acid sequence; an often 
used read out for structural stability is to measure the thermostability of a protein. Several 
strategies are used to augment the thermal stability of proteins
50,51. Both rational
52-55 and 
directed evolution methods
56-58 have been successfully used to improve stability. However, 
suitable selection/screening procedures are required, which often rely on the susceptibility 
of partly unfolded proteins to proteases, and the finally improvement in stability is limited 
to the temperature used in the selection assay were the host (phage, bacteria) is still viable. 
More recently, both sequence based algorithms and structure based computational design 
algorithms have been successfully employed to enhance stability of various proteins. 
 
Structure based computational design algorithms have been used for example, to generate a 
hyper-thermophilic variant of streptococcal Gb1 domain protein
59, to enhance the stability 
of  the  spectrin  SH3  domain
60,  to  completely  redesign  nine  globular  proteins
61  and  to 
increase the thermostability of yeast cyosine deaminase
62. Computational design algorithms Chapter 2 
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were also proven successful in the improvement of (thermo) stability of therapeutically 
interesting proteins. Dahiyat and co-workers used their PDA algorithm to design variants 
with enhanced stability of human granulocyte-colony stimulation factor (hG-CSF)
63 and 
human growth hormone (hGH)
64. In order to reduce the risk of an immunogenic response 
directed against the mutated proteins, only buried and partial buried amino acids in the 
interior  of  the  protein  were  amendable  for  mutation  in  the  design  process.  Besides 
immunological reasons, focusing the design on (partial) buried amino acids also had the 
added advantage that the design process became more straightforward as charge-charge 
interactions did not have to be taken into account. Using a homology model of hG-CSF, 
based on a crystal structure of bovine G-CSF, multiple residues in the interior of the protein 
were changed. The resulting hG-CSF designs, each having 10 to 14 mutations, showed a 
significant  improvement  in  thermal  stability  of  up  to  13 
oC.  This  increase  in  thermal 
stability  resulted  in  improvement  of  pharmaceutically  relevant  properties;  shelf-lives  of 
these  hG-CSF  designs  were  extended  between  5  and  10  fold.  These  designs  were 
biologically  active  in  vitro  and  one  of  the  designs  showed  a  2-fold  increase  in  bio-
availability, after subcutaneous administration. However, after intra venous administration 
this  variant  showed  an  enhanced  clearance
63.  Employing  similar  methodology,  hGH 
designs containing 6 to 10 mutations showed improvements in thermal stability of up to 16 
oC
64. As these and other examples show, modifications (“repacking”) of the interior of a 
protein results often in multiple interdependent amino acid substitutions. To prevent the 
complete  “repacking”  of  the  protein  core  of  the  trimeric  Tumor  necrosis  factor-related 
apoptosis-inducing  ligand  (TRAIL)  and  to  reduce  the  amount  of  required  amino  acid 
substitutions, Van der Sloot et al., used a TNF-ligand family alignment to focus the design 
on non-conserved residues only
65. Conserved residues are often retained in a family for 
good reason, such as structural stability (see below). Focusing on non-conserved residues 
only left the existing stability causing amino acid residue networks intact and, as additional 
benefit,  this  approach  also  reduced  the  use  of  computational  resources.  The  automated 
design  algorithms  PERLA/FOLD-X  were  subsequently  employed  to  identify  favorable 
substitutions at those non-conserved residue positions. A TRAIL variant containing only 2 
mutations  showed  an  8 
oC  increase  in  thermal  stability  and,  in  an  accelerated  thermal 
stability study, retained full biological activity upon incubation for 1 hour at 73 
oC
65.  
 
In  addition  to  structure  based  computational  design  approaches  also  sequence  based 
approaches  are  used  to  improve  the  stability  of  proteins  without  explicitly  using  3d 
structural information. Serrano and co-workers used a combination of expert design and the 
helix/coil  transition  theory  algorithm  Agadir,  which  calculates  the  helical  behavior  of 
monomeric peptides, to stabilize the 4-helix bundle cytokine Interleukin-4 and improve its 
refolding yield
66. A sequence based approach was used by Lehmann et al., to construct 
thermostable phytase variants
67. It was already known that information extracted from a 
sequence comparison of homologous proteins could be useful to stabilize proteins
52,68-70, 
this  premise  was  extended  by  Lehmann  et  al.,  into  the  “consensus  approach”
71.  The 
consensus approach is based on the hypothesis that in an amino acid sequence alignment of 
homologous proteins, at any given residue position, the respective consensus amino acid 
contributes more than average to the stability of  the protein than  non-consensus amino 
acids. This was demonstrated for fungal phytases, based on a sequence alignment of several 
homologous  mesophylic  phytases,  consensus  amino  acid  sequences  were  calculated  for Computational protein design 
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phytases. These consensus phytases proved to be 15-33 
oC more stable than the parent 
phytases while retaining enzymatic activity
67,72. Despite the large improvement in thermo 
stability of the consensus phytases, a subsequent analysis revealed that, of the 24 residue 
positions analyzed, only 10 consensus residues contributed positively to the increase in 
stability, 4 residue showed a neutral contribution to stability and 10 consensus residues had 
a negative impact on stability
72. Applying the consensus approach to stabilize fibroblast 
growth  factor  1  (FGF-1)  yielded  a  quadruple  mutant  variant  having  its  thermostability 
improved by 7.8
  oC. Upon structural inspection, non-conserved residues in the receptor 
binding interface or involved in heparin binding were excluded from optimization as were 
mutations  judged  to  have  a  detrimental  effect  on  stability
73,74.  Other  sequence  based 
approaches  make  use  of  machine  learning  methods.  A  neural  network  algorithm  was 
employed  to  predict  stability  changes  in  Staphylococcal  nuclease  upon  mutation
75. 
Although  no  structural  data  is  required  in  this  particular  implementation,  experimental 
stability data needs to be available or to be generated in order to train the network and it can 
only  predict  stability  changes  for  residue  positions  it  was  trained  to  work  with
75.  Two 
machine  learning  approaches,  using  support-vector-machine  algorithms,  overcome  this 
limitation. These methods do not rely on the availability of external training data sets and 
works  on  all  positions  in  the  protein  sequence.  Predicting  capabilities  of  these  two 
algorithms with regard to stability changes upon mutation are almost equally well when 
only relying on sequence information compared when there is also structural information 
available
76,77. 
 
 
￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿
 
Aggregation of proteins and peptides into insoluble deposits constitutes a serious problem 
during production, storage and administration of (potential) protein therapeutics
78. It results 
in a decrease in activity of the drug formulation and it can induce immune responses, which 
can  result  in  resistance  to  the  drug  by  antibody  mediated  clearance  or  in  allergic 
responses
79.  Two  algorithms  have  recently  been  developed  that  are  able  to  predict  the 
aggregation  propensity  of  a  given  sequence  irrespectively  of  the  morphology  (amyloid, 
non-amyloid) of the aggregated product; the Zyggregator algorithm developed by Dobson 
and co-workers
80,81 and the statistical mechanics algorithm TANGO algorithm by Serrano 
and co-workers
82. Recently, aggregation resistant variants of human calcitonin (hCT) were 
designed using the Zyggregator algorithm
83. The 32 residue peptide hormone hCT shows an 
extremely high tendency to self aggregate thereby limiting its clinical potential. Salmon CT 
(sCT) has a much lower tendency to aggregate and is therefore the clinically preferred 
agent.  However,  the  sequence  identity  between  sCT  and  hCT  is  only  50%  and 
immunogenic  responses could cause  antibody  related secondary  resistance in long  term 
treatment with sCT
84. More than 600 sequence variants of hCT were evaluated in silico for 
their aggregation propensity and three of these sequences were selected for experimental 
validation. All three variants had a sequence identity of more than 80% with hCT and 
showed a much decreased tendency to aggregate while the physiological activity of the 
variants was improved when compared to both sCT and hCT
83.  
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Increasing the affinity for a target receptor or reducing receptor binding promiscuity of a 
protein  with  therapeutic  potential  can  have  beneficial  implications  for  its  use  as  a 
therapeutic agent. A higher affinity for a particular target receptor can result in increased 
physiological activity and use of the therapeutic agent at a lower dose. Reducing receptor 
binding  promiscuity  by  preventing  interactions  with  non-target  receptors  can  limit 
undesirable physiological activities and reduce side-effects. 
 
In recent years, computational design has successfully been employed in the redesign of 
affinity and specificity of a wide variety of protein-protein interactions, previously this was 
the realm of phage display and related techniques. Some of the first proofs of concept are 
for example; Reina et al., applied the PERLA algorithm in redesigning the specificity of the 
protein-protein interactions of PDZ domains, resulting in the recognition of novel target 
sequences  by  the  designed  PDZ  domains 
85.  Coiled-Coil  interfaces  were  designed  by 
Havranek and Harbury which direct the formation of either homodimers or heterodimers
86. 
The substrate specificity of calmodulin towards smooth muscle myosin light chain kinase 
was improved by Shifman and Mayo using their ORBITAL algorithm
87,88. Kortemme et al., 
used the Rosetta algorithm to design new colicin E7 DNase/Im7 inhibitor protein pairs
89. In 
addition,  analogous  to  experimental  alanine-scanning  mutagenesis
90,  computational 
alanine-scanning  can  be  employed  to  analyze  important  interactions  in  protein-protein 
interfaces
91-93.  Although  details  differ,  the  strategy  for  improving  affinity  or  binding 
specificity of a protein with one of its binding partners is not that different from the ones 
used  to  design  more  stable  proteins  using  the  structure  based  computational  design 
algorithms. However, instead of finding a sequence compatible with the structure of the 
parent but with a lower energy, a sequence is obtained that is compatible with the structure 
of the parent in complex with its binding partner and having a lower energy when it is in 
complex with the binding partner. When improving only the affinity of a certain protein-
protein interaction such a stabilization of a desired interaction is sufficient, this is also 
known as a positive design strategy. On the other hand, in order to improve the specificity 
of an interaction one would ideally optimize the interaction with the target binding partner 
but  also  make  interactions  with  any  non-target  partner  less  favorable.  In  addition  to  a 
positive design strategy a negative design strategy can then be used
86. Using a negative 
design  strategy,  interactions  with  any  competing  non-target  binding  partners  are 
destabilized. For closely related target binding partners and competing non-target binding 
partners the use of a negative design strategy was found to be essential in attaining binding 
specificity
86,94. Focusing only on improving the charge complementary between patches of 
charged residues of a pair of interacting proteins can also be used to improve the affinity 
between two interacting partners, instead of optimizing all the interactions in the binding 
interface  between  two  partners.  Schreiber  and  co-workers  improved  the  Coulombic 
complementary of the b-lactamase inhibitor protein BLIP for TEM-1 b-lactamase, their 
electrostatic optimization algorithm PARE predicted amino acid substitutions in the vicinity 
of—but not in—the TEM-1 binding surface of BLIP with enhanced complementary to the 
BLIP binding area of TEM-1. Because of this enhanced electrostatic complementary, the 
BLIP  mutants  showed  a  250-fold  enhanced  rate  of  association  (kon)  upon  complex 
formation  with  TEM-1  while  the  dissociation  rate  constant  (koff)  was  unchanged.  This Computational protein design 
- 23 - 
improvement in kon resulted in an improved affinity constant KD because of the relationship 
KD = koff / kon (for a 1:1 interaction)
95. This work, and one using similar methodology to 
design Ral mutants which bind faster and tighter to Ras
96, show that not only the direct 
contact interface might be targeted to improve an interaction but also surface patches in the 
vicinity  but  outside  the  actual  interface  might  be  targeted  to  improve  affinity.  This 
electrostatic  optimization  approach  has  the  advantage  that  it  requires  a  less  detailed 
knowledge of the short range interactions (h-bonds, salt-bridges, hydrophobic and van der 
Waals interactions) governing the interaction between two proteins although it does not use 
the available possibilities in the interaction interface itself to stabilize the interaction as it is 
not able to decrease the koff in a predictable manner.  
 
Structure based computational design algorithms have already been used to improve the 
affinity and/or receptor binding specificity of several proteins in order to create promising 
novel protein therapeutic agents. Antibody (Ab) based protein therapeutics are currently the 
most widely used format of biopharmaceuticals. Apart from improving the affinity of an 
antibody for its antigen any further for therapeutic reasons, it is usually also required for 
antibodies after humanization as the CDR-grafting process generally reduces the antigen 
binding  affinity.  Clark  et  al.,  used  several  computational  protein  design  approaches  to 
improve the affinity of an antibody fragment to the I-domain of the integrin VLA-1
97. The 
affinity could be improved by an order of magnitude, despite the moderate resolution (2.8 
Å) of starting crystal structure of template antibody in complex with VLA-1 and the already 
reasonable  high  affinity  (7  nM).  Employing  two  different  methodologies,  e.g.  fixed 
backbone  side-chain  repacking  using  the  Dezymer  algorithm  and  an  electrostatic 
optimization method, yielded 9 mutants with improved affinity out of 40 mutants total. 
Although  most  of  the  individual  mutations  contributed  <1  kcal/mol,  subsequent 
combination of four of the higher affinity mutations yielded a ~10 fold improvement in 
affinity. Use of a side chain repacking protocol incorporating backbone flexibility only 
yielded  one  mutant  with  improved  affinity
97.  An  electrostatic  optimization  method  was 
used by Marvin and Lowman to enhance the rate of association (kon) of an Ab directed 
against VEGF 6-fold which resulted in a 2.5 fold improvement in affinity at physiological 
ionic strength
98. 
The therapeutic efficacy of Abs is not only determined by the affinity for its antigen but 
also  with  its  ability  to  trigger  (immune)  effector  activity.  The  complement-dependent 
cytotoxicity (CDC) is determined by interactions between the IgGs Fc domain and hinge 
region with C1qs. Interaction of the IgG Fc domain with receptors of Fcg family (FcgRs) 
cause  different  effector  functions,  such  as  Ab-dependent  cell-mediated  phagocytosis 
(ADCP)  and  Ab-dependent  cell-mediated  cytotoxicity  (ADCC).  Depending  on  the 
interaction with the specific type of FcgR, an effector activating response (FcgRI, FcgRIIa/c 
and  FcgRIIIa)  or  an  inhibitory  (FcgRIIb)  response  is  obtained.  Furthermore,  also  the 
pharmacokinetics (plasma half-life) of IgG type Abs is governed by the interaction of the 
Fc domain with the FcgRn type of receptor. Engineering Fc domains of antibodies in order 
to modulate binding to C1qs and FcgRs might therefore improve the clinical efficacy of 
Abs. For example, it has been demonstrated that activation FcgR receptors are necessary for 
the  effect  of  ritximab  and  trastuzumab  and  that  inhibitory  FcgRIIb  receptor  have  a 
detrimental effect on the efficacy of these Abs
99. To address this issue, Dahiyat and co-
workers engineered the antibody Fc domain to obtain a set of Fc domains with enhanced Chapter 2 
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effector function due to improved affinity and specificity for activation receptors. Using the 
crystal structure of the Fc/FcgRIIIb and homology models of other complexes, interactions 
between  the  Fc  domain  and  the  activating  receptors  were  directly  optimized  or  library 
combining  “directed  diversity”  and  “quality  diversity”  was  generated.  This  library 
contained sequences consisting of variants enriched for stability and solubility. Variants 
having the desired receptor binding properties were finally selected using a semi-automated 
in vitro screen receptor binding assay. The antibodies having an engineered Fc domain 
showed >100 fold improvement in in vitro effector function and enhanced cytotoxicity in 
an in vivo preclinical macaque model. Moreover, these variants bound also tighter to both 
the  high  affinity  Val158  allelic  form  of  the  FgRIIIa  activating  receptor  and  the  more 
common but less responsive low affinity Phe158 allelic form
100.  
In addition to have been used in optimizing the therapeutic potential of antibody based 
therapeutics, structure based computational design methods have also been employed in 
optimizing  binding  specificity  and  affinity  of  several  non-antibody  protein  molecules. 
Springer  and  co-workers  designed  Intercellular  adhesion  molecule-1  (ICAM-1)  variants 
with increased affinity for its receptor integrin lymphocyte function-associated antigen-1 
(LFA-1). The interaction between ICAM-1 and LFA-1 is critical for immunological and 
inflammatory  reactions  and  inhibiting  this  interaction  can  be  beneficial  in  autoimmune 
disease  and  allograft  rejection
101,102.  Soluble  ICAM-1  could  be  used  as  a  competitive 
antagonist, blocking the binding of endogenous membrane bound ICAM-1 to LFA-1. The 
affinity between ICAM-1 and LFA-1 is relatively low (185 nM) enhancing the affinity of 
soluble ICAM-1 with its target receptor is therefore essential for therapeutic applications. 
Using a combination of expert design, design algorithms (PDA/SPA and Rosetta) and a low 
throughput  in  vitro  empirical  screen,  Springer  and  co-workers  succeeded  in  generating 
ICAM-1  variants  with  twenty  fold  enhanced  affinity  for  LFA-1,  in  spite  of  the  low 
resolution crystal structure of ICAM-1/LFA-1 (3.3Å). The design algorithms were most 
successful  in  predicting  non-polar  and  aromatic  stabilizing  mutations  in  the  interaction 
interface  and  less  successful  in  predicting  favorable  electrostatic  interactions  or  in 
optimizations of the hydrogen bond network. Furthermore, predictions of the two design 
algorithms were complementary as some of the predicted mutations were not suggested by 
the other algorithm
103. Molecules that inhibit tumor necrosis factor-alpha (TNF-a) signaling 
have demonstrated clinical efficacy. The currently used molecules are antibodies or soluble 
TNF receptors which sequester TNF-a. Steed et al., used the PDA algorithm to design 
dominant negative TNF-alpha (DN-TNF) variants that prevent formation of active TNF-a 
trimers
104. These DN-TNF variants were designed to show a significantly reduced binding 
to the TNF-R1 and TNF-R2 receptors. In the presence of endogenous TNF-a the subunits 
exchange and TNF-a/DN-TNF heterotrimers are formed, which are unable to transduce 
signals, and consequently, is inhibited. Using crystal structures of TNF-a and a TNF-a 
variant as templates, a total of 151 variants were designed and tested. By applying an in 
silico screen, only non-immunogenic amino acid substitutions were selected and considered 
for testing. Empirical validation showed both in vitro and in vivo a large reduction in TNF-
a mediated effects
104. One of these DN-TNF variants will become the first example of a 
protein  therapeutic  designed  by  computational  design  algorithm  to  enter  in  a  phase-1 
clinical trial end of 2006. Another member of the TNF ligand family, tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL), draws a lot of interest as a potential anticancer 
drug that selectively induces apoptosis in a variety of cancer cells
105,106. TRAIL induces Computational protein design 
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apoptosis by interacting with death receptors DR4 and DR5. TRAIL can also bind to decoy 
receptors (DcR1, DcR2 and OPG) that cannot induce apoptosis. Use of TRAIL receptor-
selective variants could permit a more tumor-specific therapy through escape from decoy 
receptor-mediated  antagonism.  Moreover,  irradiation  appears  to  specifically  up-regulate 
DR5 receptor expression and the combination of irradiation and TRAIL treatment has been 
demonstrated to have an additive or synergistic effect
107. Using a crystal structure of the 
TRAIL/DR5  complex  and  homology  models  of  TRAIL  in  complex  with  the  other 
receptors,  van  der  Sloot  et  al.,  designed  DR5  selective  TRAIL  variants  employing  the 
FOLD-X protein design algorithm
108. Both positive design (improved affinity for DR5) and 
negative design (decreased binding to DR4, DcR1 and DcR2) was used. To prevent the 
complete redesign of the receptor binding interface, which would increase the chance of 
introducing immunogenic epitopes, only single amino acid substitutions were considered in 
the initial design, subsequently double substitution variants sufficiently separated in the 
structure  were  generated  by  combining  single  substitution  variants.  An  in  vitro  surface 
plasmon resonance based receptor binding screening assay was used to select the variants 
with the most favorable DR5 specificity characteristics. In vitro receptor binding assays and 
biological activity assays demonstrated that the designed DR5 variants showed indeed an 
increase in affinity and a much improved specificity for the DR5 receptor, a double mutant 
variant was not capable of binding to the DR4 receptor at all
108. Interestingly, Kelley et al., 
used phage display to generate DR4 and DR5 selective TRAIL variants. Their best DR5 
selective  variant  contained  six  amino  acid  substitutions.  After  a  partial  dissection  to 
determine the role of each individual mutation in selectivity of the phage display variants, 
Kelley  et  al.,  concluded  that  it  was  not  possible  to  eliminate  any  mutation  without 
compromising selectivity and/or losing biological activity
109. The phage display approach 
did  not  identify  any  of  the  selectivity  causing  mutations  as  determined  with  the 
computational design approach. These last two studies demonstrate the power of the use of 
computational design algorithms and show that both computational design algorithms and 
directed evolution methods can be complementary.  
 
Not only protein-protein interactions are subjected to design. Interactions involving proteins 
with  small  molecule  receptor  functionality,  enzyme-substrate  and  protein-nucleic  acid 
interactions have been modified—or created—using computational design approaches
110. 
Proteins having novel ligand binding properties or catalytic properties can for example be 
used  in  diagnostics,  drug  delivery  devices,  as  biosensors,  in  molecular  therapeutics,  as 
components in nanotechnology or as devices in synthetic biology or in systems biology. For 
gene therapy applications, DNA binding proteins can be designed into new transcription 
factors  able  to  trigger  the  activation  of  specific  genes  or  the  design  of  site  specific 
endonucleases stimulating gene targeting and promoting the repair of disease associated 
genes by gene specific homologous recombination
111. The targeting and repair of specific 
genes was recently demonstrated using site-specific zinc finger nucleases, indiscriminate 
nuclease domains coupled to a site specific zinc finger
112-115. Catalytic efficacy might be 
improved by incorporating the DNA binding and nuclease functionality in one structural 
unit. Chevalier et al., designed an artificial and highly specific homing endonuclease by 
fusing  domains  of  I-DmoI  and  I-CreI  and  subsequently  using  computational  design  in 
combination with an in vivo protein folding screen to engineer a new interface between 
these  (protein)  domains.  The  new  enzyme  bound  specifically  to  long  chimeric  DNA Chapter 2 
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sequence  with  nanomolar  affinity  and  the  cleaving  rate  was  similar  to  the  parent 
enzymes
116. Continuing on this, Ashworth et al., redesigned the DNA binding and cleavage 
specificity of the homing endonuclease I-MsoI directly. In order to redesign the cleavage 
specificity, an in silico screen was performed to search for base-pair changes predicted to 
disrupt binding of the parent enzyme. This was followed by redesign of amino acids in the 
vicinity of the substituted base in order to accommodate and stabilize the new base-pair. 
Experimental  characterization  show  that  the  redesigned  enzyme  binds  and  cleaves  the 
redesigned recognition site approximately 10.000 times more effectively than the wild-type 
enzyme
117. 
 
Considerable advances have also been made in the design of metal-ion binding sites and 
small molecule ligand binding sites in proteins. Hellinga and co-workers introduced a zinc 
binding site in maltose binding protein (MBP), a member of the periplasmic binding protein 
(PBP)  superfamily.  Amino  acid  residues  interacting  directly  with  metal  according  to  a 
predefined geometry, the primary coordination sphere (PCS), were introduced using the 
Dezymer algorithm
118. However, surrounding residues interacting with the PCS make also 
important contributions to metal affinity. Residues in this second coordination sphere (SCS) 
were  optimized  after  the  introduction  of  a  zinc  PCS  in  ribose  binding  protein,  another 
member of PBP superfamily. Zinc binding RBPs with an optimized SCS, in comparison 
with RBPs having only a zinc binding PCS, had a significantly improved affinity for zinc 
(Kd 1-2 mM) and improved thermostability. These zinc binding RBPs were subsequently 
used to control in vivo gene expression in E. coli by coupling the zinc binding RBP to a 
synthetic signal transduction pathway. In response to Zn
2+, b-galactosidase reporter gene 
expression  response  showed  a  6-10  fold  increase
119.  Similar  methodology  was  used  to 
construct  a  calcium binding site PCS with high  coordination number (seven) in the N-
terminal domain of the cell surface adhesion receptor CD2
120. Degrado and co-workers 
used  computational design  to  construct  a  four-helix  bundle  protein  de  novo  capable  of 
selectively binding a non-biological metalloporphyrin cofactor
121.  
 
 
Members of the E. coli periplasmic binding protein (PBP) superfamily comprising novel 
ligand  binding  properties  were  designed  by  Hellinga  and  co-workers.  Trinitrotoluene 
(TNT), l-lactate or serotonin bindingsites were engineered in the PBPs in place of the wild-
type sugar or amino acid ligands. Starting from high resolution crystal structures of the 
PBSs,  the  algorithm  identified  amino  acid  sequences  forming  a  complementary  surface 
with  the  novel  ligand.  The  method  combined  a  docking  procedure  with  amino  acid 
mutations in the vicinity of the binding site. The combinatorial problem (10
53-10
76 choices) 
was  solved  with  an  algorithm  based  on  dead-end  elimination  theorems,  the  resulting 
designs  contained  12-18  mutations.  Affinities  of  top  scoring  designs  for  the  respective 
ligands  were  experimentally  determined;  PBPs  for  TNT,  l-lactate  or  serotonin  were 
obtained  having  affinities  in  the  low  micro-molar  range  (<5  mM)  one  particular  TNT-
binding PBP did even have an affinity for TNT in the low nanomolar range (2 nM). For 
creating  the  high  affinity  interactions  fine  grained  sampling  using  a  highly  expanded 
rotamer library was required. Subsequent incorporation of a TNT and a l-lactate binding 
PBP into a bacterial synthetic signal transduction pathway allowed E. coli to respond with 
gene  expression  in  the  presence  of  extracellular  TNT  or  l-lactate
122.  Using  similar Computational protein design 
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methodology, a biosensor for the organophosphate surrogate of the nerve agent Soman was 
designed
123. 
The  next  challenge  after  the  engineering  of  novel  ligand-binding  sites,  the  design  of 
enzymatic activity, requires not only providing stabilizing interactions between protein and 
ligand for a single state of the ligand but for all the intermediate (transition) states along the 
reaction coordinate. Moreover,  amino acid residues and co-factors have  to be precisely 
positioned and the binding surface has to be stereochemically complementary to all the 
intermediate states. The binding surface needs also to adapt to the different requirements of 
the various stages of catalysis (substrate binding, catalysis and product release)
124,125. Not 
surprisingly, design of catalytic activity presents a formidable challenge and is testing the 
current understanding of the mechanics and forces governing enzyme catalysis.  
Bolon and Mayo used their Orbital algorithm to create novel enzymatic functionality—p-
nitrophenyl  acetate  hydrolysis—using  the  catalytically  inert  E.  coli  thioredoxin  as  a 
scaffold. The designed enzyme exhibited a 25-fold rate enhancement over the
 uncatalyzed 
reaction
126. Kaplan and Degrado designed de novo a catalytic scaffold capable of catalyzing 
the two-electron oxidation of 4-aminophenol to the corresponding
 quinone monoimine by 
using a diiron cofactor. The four-helix bundle was designed using computational design 
while the catalytic activity was introduced by expert design
127. Hellinga and co-workers 
designed the catalytically inert bacterial ribose-binding protein (RBP) into analogs of the 
glycolytic triose phosphate isomerase enzyme using the Dezymer algorithm. The design 
process consisted of three parts. First, a geometrical definition of constraints governing key 
interactions with catalytic residues (His, Gln, Lys) was defined. Secondly, positions were 
identified  were  substrate  and  catalytic  residues  simultaneously  satisfied  the  constraints 
using  a  combinatorial  search  algorithm.  Third,  the  complementary  surface  around  the 
substrate  was  generated  using  the  receptor  design  algorithm.  The  resulting  designs 
contained 18 to 22
 mutations and exhibited 10
5- to 10
6-fold rate enhancements over the
 
uncatalyzed reaction
128. Although these rate enhancements are still a factor 100 below that 
of the natural occurring TIM enzyme, the designed enzyme was able to sustain growth in an 
E. coli TIM knockout strain. This methodology will allow the design of enzymatic reactions 
and, eventually, metabolic pathways not seen in nature and can for example be used in the 
“bio”synthesis of pharmaceuticals. 
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Pharmacokinetics is a critical factor in the efficacy of protein therapeutics. Most protein 
drugs  are  delivered  by  injection  and  the  in  vivo  half-lives  vary  from  minutes  to  days. 
Elimination and disposition mechanisms of protein drugs differ considerably from those of 
small-molecule drugs. Elimination is governed by several specific and non-specific events, 
such as; renal clearance (depending on size and charge), specific and aspecific proteolysis, 
receptor-mediated  clearance  or  antibody  mediated  mechanisms  in  addition  to  structural 
stability and solubility of the protein
129,130. Susceptibility to proteolysis can be attenuated by 
removing protease recognition sites. Pegylation or engineering of additional glycosylation 
sites in protein drugs can reduce renal clearance and improve plasma half-life. A substantial 
part of a cytokine protein drug can also be cleared due to interaction with (one of) its target 
receptors.  Due  to  the  generally  high  affinity  constants—with  low  off-rates—of  protein 
drugs with its target receptor in combination with the relatively large fraction of the drug Chapter 2 
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bound to the target receptor, are the pharmacokinetic properties of the protein drug also 
closely coupled to the turnover of the target receptor. For example, protein therapeutics 
bound to their target receptor can be internalized and degraded inside the cell or the protein 
drug can be subjected to phagocytosis. In order to engineer a G-CSF with a longer half-life, 
Lauffenburger and co-workers addressed the issue of receptor mediated endocytosis of G-
CSF
131. Their method suggests being broadly applicable to enhance the PK/PD properties 
of protein therapeutics. G-CSF is rapidly depleted from the bloodstream by neutrophils 
expressing the G-CSF receptor (G-CSFR). A computational design approach was used to 
design  histidine  (His)  substitution  variants  of  G-CSF.  The  introduced  histidines  should 
function as a pH activated switch; at neutral pH these variants should retain high binding 
affinity towards the G-CSFR (neutral His) but upon internalization of the G-CSF/G-CSFR 
complex the complex should dissociate due to the acidic pH in the endosomal compartment 
(positively charged His). Based on a crystal structure of G-CSF in complex with G-CSFR 
favorable candidate sites in the receptor interface for substitution with His were identified. 
After in silico mutagenesis to neutral His and positively charged His the electrostatic free 
binding energy of the mutant complexes was calculated in both cases. Mutants calculated to 
have a similar affinity for C-GSFR as wild-type at neutral pH but a reduced affinity for the 
C-GSFR at acidic pH were selected for experimental validation. Despite the fact that two 
predicted Asp to His substitution variants had a slightly decreased or unchanged affinity for 
the  C-GSFR  at  neutral  pH,  these  variants  were  shown  to  have  an  order  of  magnitude 
increase in (medium) half-life along with an enhanced potency due to enhanced endocytic 
recycling
131. Antibodies directed against the protein drug or soluble variants of the target 
receptor  (or  closely  related  receptors),  so  called  “decoy”  receptors,  can  sequester  a 
substantial fraction of the available drug and thereby reducing the drugs efficacy. Antibody 
mediated  antagonism  can  be  alleviated  by  reducing  the  proteins  immunogencity  and/or 
increasing its thermostability and/or reducing aggregation propensity (see above). Van der 
Sloot et al., used a computational design strategy to reduce the affinity of TRAIL for its 
decoy receptors (see above)
108. 
 
Immunogenicity  of  biopharmaceuticals  is  both  associated  with  safety  and  efficacy 
concerns
79,132,133. Neutralizing antibodies directed against the biopharmaceutical can cause 
loss of efficacy and failure of the therapy
134. In some cases neutralizing antibodies are not 
only directed to the protein therapeutic but also cross reacting with the native counterpart. 
This  was  for  example  demonstrated  in  patients  treated  with  a  particular  recombinant 
erythropoietin product (Eprex J&J); in this case patients developed antibodies against both 
the  recombinant  product  and  the  native  product  which  resulted  in  pure  red  cell 
anaplasia
135,136. One of the major determinants of eliciting an immunogenic response is the 
amino acid sequence of a protein. The degree of sequence divergence  from the human 
amino acid sequence determines the immunogenic response proteins elicit. However, also 
proteins similar in amino acid sequence as the native counterpart can illicit an immunogenic 
response and, in contrast, proteins that differ in sequence from the native counter do not 
have  to  induce  an  (considerable)  immunogenic  response  (e.g.  consensus  IFN-a  and 
methionyl hGH)
79. Physicochemical factors are another important determent; aggregated or 
partly  unfolded  proteins  can  induce  an  immunogenic  response  as  can  oxidation  or 
deamidation  of  amino  acid  residues.  Other  factors  connected  to  the  induction  of 
immunogenic responses, but not further discussed here are for example: deglycosylation, Computational protein design 
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the production host, production impurities, formulation and storage, route of administration 
and dose and length of treatment
79. Physicochemical  factors can be  addressed applying 
computational design methods as discussed above, structural stability and solubility can be 
improved and the tendency to aggregate can be reduced. Residues prone to oxidation or 
deamidation  can  be  substituted  with  another  amino  acid  without  sacrificing  structural 
stability and functionality. Pegylation or glycosylation can also be used to improve the 
solubility of a protein, in addition, both pegylation and glycosylation are thought to shield 
hydrophobic immunogenic epitopes at the surface of the protein. Several algorithms are 
available that scan amino acid sequences for MHC I or II binding epitopes, this information 
can subsequently be used to de-immunize a potential protein therapeutic. Reviewed in
137-139. 
Immuno dominant epitopes can be removed using a structure based algorithm, this allows 
the removal of such an epitope without sacrificing structural stability or functionality.  
 
￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿ ￿ ￿ ￿ ￿ ￿￿ ￿￿ ￿ ￿ ￿ ￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿
 
Although the number of sequences that can be screened or, especially, selected appears to 
be enormous, it is even for a small protein only a tiny fraction of the potential sequence 
space that can be sampled. Moreover, only a fraction of the library created by traditional 
means  (ep-pcr,  saturation  mutagenesis)  is  compatible  with  a  viable  protein  structure. 
Computational design in combination with in silico screening allows sampling of a much 
larger fraction of the total sequence space (~10
60 sequences)
140-142. Therefore computational 
design allows for the creation of high quality libraries, only targeting sequence positions 
that can be changed without compromising structural integrity  of the protein. These  in 
silico screened libraries can therefore contain an increased diversity of viable structures 
which can result in obtaining more sequences with the desired property as well as being 
more improved for the desired property. Voigt et al., used a structure based computational 
method  applying  mean-field  theory  to  probe  each  residue’s  structural  tolerance.  This 
tolerance is defined by the residue’s local sequence entropy, e.g. the number of amino acids 
that are permitted at that site. Mutations casing increase in stability or activity are most 
likely to accumulate at sites having high sequence entropy. Therefore, libraries focusing on 
positions most likely to lead to improvement of desired properties can be constructed
140. In 
vitro  recombination  libraries  can  also  be  optimized  using  computational  tools.  The 
SCHEMA algorithm identifies fragments that can be recombined without disturbing the 
structural integrity of a protein. Libraries with targeted crossover points can be generated in 
order  to  increase  the  fraction  of  folded  and  functional  variants
143.  This  was  recently 
demonstrated  by  Arnold  and  coworkers  applying  the  SCHEMA  algorithm  to  create  an 
artificial family of Cytochromes P450
144. The IPRO computational procedure allows for the 
one step optimization of the entire library by identifying mutations in the parent sequences 
which upon propagation in the combinatorial library systematically optimize the desired 
properties of offspring sequences
145.  
The value of designing a quality enriched library was demonstrated by selecting a library of 
TEM-1 b-lactamase variants for improved resistance to the antibiotic cefotaxime. Starting 
from the TEM-1 b-lactamase crystal structure residues within 5 Å of the active site residues 
were considered for the library construction. This resulted in 7 x 10
23 sequences, a number 
that can be easily screened in silico, but not experimentally. The PDA algorithm was used 
in combination with Monte Carlo simulated annealing to calculate a rank ordered list of the Chapter 2 
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1000 lowest energy sequences and amino acid occurrences were subsequently counted for 
all the variable positions. In case an amino acid had a greater than 10% probability of 
occurrence  at  a  position  it  was  included  in  the  library,  this  resulted  in  library  with  a 
diversity of 172000 unique sequences. After just one round of selection with this library, 
variants were obtained showing an almost 1300 fold increase in cefotaxime resistance and 
all the resistance causing mutations identified from this library were not identified before in 
directed evolution experiments or in naturally occurring TEM-1 b-lactamase variants
146.  
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The use of computational methods in the (re)design of various properties of proteins has 
made an impressive progress in recent years. Several of the described methodologies are 
already being applied in the development of protein therapeutics or will be used in the near 
future. The thermostability and structural stability of a protein can be effectively enhanced 
by applying both structure based computational design methods or sequence based methods 
with a high rate of success. Sequence based algorithms and structural based computational 
design algorithms can also be interfaced, for example a sequence based algorithm can be 
used  to scan  the  protein sequence  for  immuno-dominant  epitopes  or  aggregation  prone 
regions followed by a structural based algorithm finding an optimal solution to remove 
these sequence motives without sacrificing structural stability and activity. Both structure 
based methods which optimize all relevant interactions and structure based methods which 
only  focus on improving the electrostatic complementary  of protein-protein interactions 
have  been  successfully  applied  in  improving  affinity  or  engineering  the  specificity  of 
protein-protein interactions. In these cases the design process is frequently combined with a 
small screening assay to remove any false positives due to usually greater complexity of 
redesigning  protein-protein  interactions  when  compared  to  improving  the  stability  of  a 
single  protein.  Although  the  examples  of  design  of  affinity  and  specificity  of  protein-
nucleic  acid  or  protein  small  molecule  interactions  and  the  design  of  novel  enzymatic 
activity are yet relatively sparse, in coming years more examples, in areas such as medical 
biotechnology, will undoubtly follow. The combination of computational design methods in 
combination  with  the  design  of  libraries  and  high-throughput  screening  or  selection 
methods  also  holds  great  promise,  providing  higher  quality  libraries  with  increased 
diversity in properly folded and functional members.  
 
Despite  the  progress  made,  several  challenges  remain  to  be  addressed.  Structure  based 
algorithms require 3d structural information, in general the rule is that a higher resolution of 
the  design  target’s  (crystal)  structure  yields  a  more  reliable  design  outcome. 
Notwithstanding  this  requirement,  several  design  exercises  described  in  this  review 
successfully relied (partly) on low resolution structural  models or homology  models as 
template structure. Normally, in such cases  one could use multiple sequence alignment 
information  to  guide  the  design  process  and  screen  several  of  predicted  sequences 
experimentally  to  increase  the  success  rate  and  to  remove  false  positives
147.  Structural 
genomics  initiatives  will  make  an  increasing  proportion  of  the  protein  sequence  space 
amendable to design by structure based computational design algorithms either by directly 
using  an  experimentally  determined  structure  or  providing  structural  templates  to  build 
reliable homology models
148. Recent progress in de novo protein structure prediction, using Computational protein design 
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structure based computational design algorithms, could in the future also contribute to make 
an even larger proportion of the sequence space amendable to structure based design
149. 
Protein design algorithms, in addition, are continuously improved as well. The development 
of more accurate energy functions used to evaluate the designs requires improvement in 
variety of factors, such as, backbone flexibility, (surface) electrostatics, hydrogen bonding 
potentials,  solvent  (water)  mediated  interactions  and  the  statistical  terms  describing 
entropy
150-152.  Expanding  the  design  algorithms  with  parameterization  for  various  non-
natural amino acids, as for example developed by Schultz and co-workers
153, will allow the 
design of protein sequences possessing entirely new chemical functionality and reactivity. 
Improvements  in  search-  and  sampling  optimization  algorithms  will  allow  finding  low 
energy  solutions  more  efficiently  by  covering  a  larger  fraction  of  sequence-  and 
conformational space in a reduced amount of time
154. Improvements in statistical analysis 
of multiple sequence alignments will allow sequence based algorithms to extract higher 
order information encoded in these alignments. For example statistical coupling analysis 
was used to construct artifical WW domain sequences able to fold into a native structure
155. 
These improvements in protein design algorithms will favor both future protein design and 
de novo structure prediction. 
 
The examples discussed in this review show that protein design algorithms have matured 
enough to be a valuable addition to the protein engineers’ toolbox, in addition to expert 
design and directed evolution methods. Application of current protein design methodology 
and  future  developments  will  allow  development  of  novel  medical  biotechnology 
applications.  Furthermore  it  permits  the  design  of  protein  therapeutics  with  enhanced 
clinical efficacy by optimizing their amino acid sequences for various clinical important 
properties  such  as  potency,  specificity,  immunogenicity  and  pharmacokinetics.  By 
addressing these clinical properties of biopharmaceuticals early on in drug discovery and 
development as well as the optimization of its production properties, these computational 
methods will allow a faster transition from laboratory bench to clinic. 
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￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿
Protein thermal stability is important for therapeutic proteins, both influencing the 
pharmacokinetic  and  pharmacodynamic  properties  and  for  stability  during 
production and shelf-life of the final product. In this study we show the redesign of a 
therapeutically  interesting  trimeric  all  beta-sheet  protein,  the  cytokine  TRAIL, 
yielding  variants  with  improved  thermal  stability.  A  combination  of  TNF  ligand 
family alignment information and the computational design algorithm, PERLA, were 
used  to  propose  several  mutants  with  improved  thermal  stability.  The  design  was 
focused  on  non-conserved  residues  only,  thus  reducing  use  of  computational 
resources. Several of the proposed mutants showed a significant increase in thermal 
stability  as  experimentally  monitored  by  far-UV  CD  thermal  denaturation. 
Stabilization of the biologically active trimer was achieved by monomer subunit or 
monomer-monomer interface modifications. A double mutant showed an increase in 
apparent Tm of 8 
oC in comparison to rhTRAIL WT and remained biologically active 
after  incubation  at  73 
oC  for  1h.  To  our  knowledge,  this  is  the  first  study  that 
improves  the  stability  of  a  large  multimeric  b b b b-sheet  protein  structure  by 
computational redesign. A similar approach can be used to alter the characteristics of 
other multimeric proteins, including other TNF ligand family members. 
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Besides influencing the final pharmacokinetic and pharmacodynamic properties of a protein 
therapeutic, stability is also important throughout the production process and for the shelf-
life of the final product
156. Several strategies are used to augment the thermal stability of 
proteins
50,51. Both rational
52-55 and directed evolution methods
56-58 have been successfully 
used to improve stability. A disadvantage of a rational approach is that one can design only 
a limited number of potentially improved variants. In contrast, directed evolution methods 
allow  large  numbers  of  variants  to  be  generated  and  screened.  However,  suitable 
selection/screening procedures are required, which are often not available or are very labour 
intensive.  More  recently,  computational  redesign  algorithms  have  been  employed  to 
enhance  stability,  amongst  other  properties,  of  proteins
59-61,157.  These  methods  combine 
computer  design  steps  with  in  silico  screening,  permitting  screening  of  a  much  larger 
sequence space than is experimentally possible with high-throughput techniques. Efficient 
algorithms are needed to search the vast sequence space and accurate scoring functions are 
required in order to rank the best designs
39,42. Recently, computational redesign has been 
used to generate a hyper-thermophilic variant of streptococcal Gb1 domain protein
59, to 
enhance the stability of the spectrin SH3 domain
60 and to improve the (thermal) stability of 
the therapeutically interesting four helix bundle cytokines, granulocyte-colony stimulation 
factor (G-CSF)
63 and human growth hormone (hGH)
64. 
 
In this study, we use the automated computer algorithm PERLA
158,159 and the empirical 
forcefield FOLD-X
160 to improve the thermal stability of a multimeric all b-sheet protein, 
tumor necrosis factor-related apoptosis inducing ligand (TRAIL; TNFSF10)
161,162. TRAIL 
is a member of the tumor necrosis factor ligand family. Ligands belonging to this family are 
involved  in  a  wide  range  of  biological  activities,  ranging  from  cell  proliferation  to 
apoptosis, and they share similar structural characteristics. All monomeric subunits of these 
ligands consist of antiparallel b-sheets, organized in a jellyroll topology, and these subunits 
self  associate  in  bell-shaped  homotrimers,  the  bioactive  form  of  the  ligand.  Sequence 
homology is highest between the  aromatic  residues responsible for  trimer  formation. A 
trimer  binds  three  subunits of  a  cognate  receptor,  each  receptor  subunit  binding  in  the 
grooves between two adjacent monomer subunits. The ligands are type II transmembrane 
proteins, but the extracellular domain of some members can be proteolytically cleaved from 
the cell surface, yielding a bioactive soluble form of the ligand. Recent reviews of the TNF 
ligand-family are readily available
1,2.  
 
TRAIL in its soluble form selectively induces apoptosis in tumor cells in vitro and in vivo, 
by  a  death  receptor  mediated  process
19.  Unlike  other  apoptosis-inducing  TNF  family 
members, it appears to be inactive against normal healthy tissue, therefore attracting great 
interest as a potential cancer therapeutic
13. Several crystal structures of TRAIL
17,163 and 
TRAIL in complex with the death receptor 5 (DR5)
12,16,18 are available. Unlike other TNF 
family members TRAIL has a zinc binding site in its trimeric core and the presence of the 
zinc ion is known to be vital for the trimeric structure and bioactivity
17,164. Several versions 
of recombinant soluble TRAIL with different N-terminal fusions tags have been reported, 
however these versions appear to have different bioactivity profiles in comparison to the Chapter 3 
- 36 - 
non-tagged ‘wild-type’ soluble TRAIL encoding amino acids 114-281
105. The increased in 
vitro toxicity towards certain normal healthy cells is especially noticeable in the presence of 
exogenous tags
14. We therefore chose to increase the stability of TRAIL by modification of 
the soluble ligand version (114-281), without addition of any exogenous tags. In view of a 
possible  use  as  a  therapeutic  protein;  a  close  resemblance  to  the  wild-type  structure  is 
desirable. To our knowledge, this is the first study that shows improvement of the stability 
of a large multimeric protein structure by computational redesign. Methods used in this 
study are also applicable to other TNF family ligands. 
 
￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿
 
Computer screening. 
Novel  mutants  of  TRAIL  have  been  designed  in  order  to  increase  the  stability  of  the 
bioactive  trimer.  Predictions  were  based  on  the  automated  computer  algorithm, 
PERLA
158,165, as  described in the methods section.  Briefly, the program performs strict 
inverse folding: a fixed backbone structure is decorated with amino acid side chains from a 
rotamer library. Relaxation of strain in the protein structure is achieved via the generation 
of subrotamers. Most terms of the scoring function are balanced with respect to a reference 
state, to simulate the denatured protein. The side chain conformers are all weighted using 
the  mean-field  theory  and  finally  candidate  sequences  with  modelled  structures  (PDB 
coordinates) are produced. Energy evaluation of the modelled structures was carried-out by 
a modified version of FOLD-X
150,160, available at (http://fold-x.embl-heidelberg.de). The 
force field module evaluates the properties of the structure, such as its atomic contact map, 
the accessibility of its atoms and residues, the backbone dihedral angles, in addition to the 
H-bond  network  and  electrostatic  network  of  the  protein.  The  contribution  of  water 
molecules making two or more H-bonds with the protein is also taken into account. The 
algorithm then proceeds to calculate all force  field components: polar and hydrophobic 
solvation energies, van der Waals’ interactions, van der Waals clashes’, H-bond energies, 
electrostatics, and backbone and side chain entropies. 
 
Selection of the template sequence 
The template selected was 1DU3
12. The crystal structure at 2.2 Å resolution contains the 
trimeric structure of human TRAIL in complex with the ectodomain of the DR5 receptor. 
The TRAIL monomer lacks an external, flexible loop (130-146), not involved in receptor 
binding  or  in  monomer-monomer  interaction.  To  complete  the  molecule,  this  loop  was 
modeled using the structure of 1D4V (2.2  Å)
18, a monomeric TRAIL in complex with DR-
5 receptor, having the atomic coordinates of the loop. Finally, the TRAIL molecule was 
isolated by removing the receptor molecules from the PDB file. 
 
Computational design of mutants 
The visual inspection of the isolated monomers, monomer-monomer interface and central 
core of TRAIL showed several residues as potential candidates for mutagenesis. The highly 
conserved hydrophobic residues were discarded from this list. After generating the mutants 
we  identified  if  there  were  residues  involved  in  receptor  binding.  These  residues  in 
principle could not be mutated without disrupting interactions with the receptor. However, 
it could be that a small decrease in binding affinity could be compensated by an increase in Stabilization of TRAIL using computational redesign 
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stability. Thus one TRAIL variant (M2), that showed a significant predicted increase in 
stability  but  also  contained  residues  involved  in  receptor  interaction,  was  retained  for 
subsequent experimental analysis. 
 
Table 1. Residues initially considered for design 
Monomer Set  Dimer Set  Trimer Set  Misc. Set 
       
E194
†  H125  R227
†  A123 
I196
†  F163  C230  A272 
  Y185  Y240  S225
† 
  Q187    V280 
  S232    F163 
  D234    A123 
  Y237
† (D203,Q205)    V208 
  L239     
  S241     
  E271
†     
  F274     
† Used in subsequent rounds of design 
Mutants in parenthesis were added in subsequent rounds as interaction partners 
 
 
The sequence space search for  every position was simplified by checking the naturally 
occurring amino acids in a multiple sequence alignment of proteins belonging to the TNF 
ligand  family,  thus  decreasing  the  computing  time,  and  subsequently  focusing  on  non-
conserved residues. The use of protein rational design and force field algorithms allowed 
the identification of a list of mutant sequences with potential relevance for TRAIL stability. 
Four sets of residues were selected for design (Figure 1b and Table 1): (1) non-conserved 
residues at the surface of the monomer (‘monomer’ set), (2) non-conserved residues near 
positions close to the interface between two monomers (‘dimer’ set), (3) non-conserved 
residues along the central trimeric axis (‘trimer’ set) and (4) a miscellaneous set (‘misc. 
set’). The automated computer design algorithm was applied as previously described
166. 
Amino  acid  substitutions  were  introduced  at  the  non  conserved  residue  positions  in 
conformations (side chain rotamers) compatible with the rest of the structure. Subsequently, 
favorable mutations were combined and evaluated in terms of free energy (kcal mol
-1), and 
unfavorable combinations (e.g. high Van der Waal clashes) were eliminated. An output of 
sequences  and  coordinates  was  produced  and  ranked  in  terms  of  free  energy  and 
subsequently reintroduced in the design algorithm for a 2
nd, 3
rd or 4
th round of design, if Chapter 3 
- 38 - 
necessary. Table 1 summarizes the list of mutants assayed in silico for increased stability of 
TRAIL.  Some  of  these  predictions  were  discarded  directly  after  theoretical  energy 
calculations, without further experimental analysis. 
 
 
Figure 1. A) Side view of the TRAIL trimeric complex, showing the three monomers in red, blue and green. B) 
Top view of the same complex but viewed along the longitudinal axis, depicting the different sets used for design. 
Structure figures were generated using MOLMOL
167. 
 
Description of the tested mutations 
Predicted mutants were energy minimized and subsequently analyzed with FOLD-X. The 
energy  values  obtained  were  compared  to  that  of  the  wild-type  structure  and  used  for 
discrimination  of  candidates.  Mutants  were  selected  based  on  an  improvement  in  free 
energy relative to TRAIL WT (Table 2). In the monomeric set, M1 (E194I, I196S) was 
selected because of the large improvement of energy compared to TRAIL WT (DDG = -9.7 
kcal  mol
-1  monomer
-1). This low energy value is due to the fact that a trimer is being 
studied, in addition to the presence of significant van der Waals’ clashes in the crystal 
structure (~5 kcal mol
-1 monomer
-1), which are removed upon mutation. The mutations are 
located in the external loop connecting the C and D anti-parallel beta strands (CD loop), 
following the notation according to Eck
168. The predicted increase in stability of M1 can be 
explained since Glu 194 is surrounded by hydrophobic groups (Trp 231, Phe 192, Ala 235) 
and  the  carboxyl  group  is  uncompensated.  The  mutation  Glu  194  to  Ile  rectifies  this 
situation  by  replacing  the  charged  residue  for  a  medium  sized  hydrophobic  residue. 
Conversely, Ile 196 is surrounded by polar residues (Asn 202, Lys 233) and is very close to 
the backbone, resulting in probable van der Waals clashes. Mutation to Ser avoids clashes 
and allows formation of a hydrogen bond to Asn 202, located in the opposite part of the CD 
loop  (Figure  2a).  Both  mutations  improve  polar  solvation  energy,  in  addition  to 
ameliorating side chain and backbone entropy. 
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Figure 2. A) Comparison, between rhTRAIL WT and M1, of the local environment around residues 194 and 196. 
B) Comparison between rhTRAIL WT and M2. Backbones of the two adjacent monomers are in green and blue, 
respectively, and the backbone of the DR5 receptor is in grey. Hydrogen bond interactions are depicted in dashed 
green lines. 
 
In the dimeric set (Table 2), the design of M2 (D203I, Q205M, Y237F) leads to the creation 
of  a  hydrophobic  cluster  to  stabilize  the  interaction  between  residues  203  and  205  (D 
strand) of one monomer, and residue 237 (F strand) of the adjacent monomer. Gln 205 and 
Tyr 237 together form an intermolecular hydrogen bond, and Asp 203 points to a gap in the 
monomer-monomer interface. Mutation to Ile (203), Met (205) and Phe (237) breaks the 
Q205-Y237 hydrogen bond, but facilitates the tight packing of these residues, improving 
van der Waals interactions, hydrophobic and polar solvation energies of the entire TRAIL 
molecule, without a further increase of van der Waals clashes (Figure 2b). Although FOLD-
X predicted that the affinity of M2 for the DR5 receptor is lower (DDGbinding=7.3 kcal mol
-1 
monomer
-1)  than for TRAIL WT, this mutant was retained as a control to evaluate the 
accuracy of the procedure. 
Residue 225 of M3 (S225A), belonging to the ‘Miscellaneous set’, is located in strand E 
and is solvent exposed in the monomeric form. However, after trimerization, this position 
becomes buried in a small pocket, leaving the side chain of the hydrogen bond donor Ser 
uncompensated. After mutation to Ala, the energy of the model is better than TRAIL WT 
for both polar and hydrophobic solvation energies, in addition to side chain entropy. 
The Arg 227 residues of the trimeric set mutant (M4) are located in strand E, equidistantly 
opposed in a central position along the longitudinal axis of the TRAIL trimer. The three 
arginines are surrounded by hydrophobic (Ile242), polar (Ser241, Ser225) and aromatic 
(Tyr 240, Tyr 243) residues. These tyrosines direct the hydroxyl groups away from Arg 
227, thus creating a rather hydrophobic cavity. The high concentration of positive charges 
is apparently not well compensated, since it forms only hydrogen bonds with the backbone 
(carbonyl groups of Ser241). Thus, the mutation of these positions to Met could help to 
accommodate  the  hydrophobic  environment,  as  well  as  to  decrease  the  repulsion  of 
monomers due to uncompensated positive charges. 
 
Mutagenesis and Purification of Mutants 
The highest ranking mutant from each of the four sets was selected for further experimental 
analysis  (Table  2).  A  mutant  (C1)  combining  the  mutations  of  M1  and  M3  was  also Chapter 3 
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constructed.  All  the  designed  TRAIL  mutants  were  expressed  in  E.  coli  and  purified 
successfully with a protein yield of ~ 0.7-2 mg/l. Far-UV CD wavelength spectra indicated 
that all mutants were properly folded with characteristics of a b-sheet containing protein, 
similar to that of rhTRAIL WT. Gel-filtration and dynamic light scattering measurements 
showed that all mutant protein solutions contained a single molecule species, consistent 
with a trimeric oligomerization state. Analytical ultracentrifugation with rhTRAIL WT and 
M1 corroborated this finding (data not shown). 
 
Table 2 Computational design results 
  D D D DD D D DGstability
*  D D D DD D D DGbinding
*‡  Set  Mutations 
M1  -9.7  0.4  Monomer  E194I, I196S 
M2  -4.0  7.3  Dimer  D203I, Q205M, Y237F 
M3  -7.0  -0.5  Misc.  S225A 
M4  -9.1  -1.2  Trimer  R227M 
C1  -11.4  -0.9  Combination  M1+M3 
* Energy in kcal mol
-1, calculated per monomer 
‡ DGbinding= DG complex-(SDG chain); DDGbinding=DGbinding mutant -DGbinding wild-type 
 
 
Thermal unfolding 
The  thermal  unfolding  of  rhTRAIL  WT  and  TRAIL  mutants  was  monitored  by  CD, 
measuring changes in molar ellipticity at 222 nm upon heating. Figure 3 shows the heat 
induced changes of rhTRAIL WT and TRAIL mutants. TRAIL shows an onset of unfolding 
at approximately 70 
oC and has a transition midpoint of 77 
oC. The TRAIL mutants show 
however,  onset  of  unfolding  at  increased  temperatures  and  higher  transition  midpoints 
(Figure 3). For M1 the onset of unfolding was at approximately 76
 o C and the transition 
midpoint was at 85 
oC. M2 showed an onset of unfolding at approximately 74
 oC. M3 gave 
intermediate values between those of rhTRAIL WT and M1, with an onset of unfolding of 
73
 oC and a transition midpoint of 80
 oC. Mutant C1, representing the combined mutations 
of M1 and M3 showed values comparable to that of M1. The mutant belonging to the 
trimeric  set  (M4),  however,  showed  an  experimentally  determined  stability  of 
approximately 3 ºC less than rhTRAIL WT, and was therefore discontinued. The initial 
increase in molar ellipticity around 76 
oC for M2 is due to an overall change of the far UV 
spectrum, reflecting a loss of structural properties of the starting material (data not shown). 
Upon  cooling  all  protein  solutions  were  turbid,  indicating  irreversible  aggregation, 
therefore no thermodynamic parameters could be derived. Far and near UV wavelength CD 
scans at increasing temperatures confirmed the above findings (data not shown). Stabilization of TRAIL using computational redesign 
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Figure  3.  Thermal  denaturation  profiles  of  rhTRAIL  WT  (closed  circles),  M1  (closed  squares),  M2  (open 
squares), M3 (open squares) and C1 (closed triangles). 
 
Figure 4. Binding of rhTRAIL WT (closed circles), M1 (closed squares) and M2 (open circles) to DR5 (dotted 
lines) and DR4 (solid lines) receptors. Chapter 3 
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In vitro bioactivity and binding of designed mutants 
Bioactivity of the TRAIL mutants was assessed in vitro using the Colo205 human colon 
cancer cell line with a MTT based viability assay. A reduction in viability was measured 
using increasing concentrations of rhTRAIL WT or TRAIL mutants relative to the control. 
While M1, M3 and C1 showed a bioactivity comparable to that of rhTRAIL WT (ED50 ~5 
ng/ml), M2 exhibited bioactivity of nearly one order of magnitude lower (ED50 ~50 ng/ml). 
Real-time binding of rhTRAIL WT and TRAIL mutants to the death receptors DR4 and 
DR5  was  assessed  using  surface  plasmon  resonance  with  a  Biacore  3000  instrument. 
Sensorgrams of M1, M3 and C1 were identical to that of rhTRAIL WT. In contrast M2, 
whilst showing a similar level of binding to both receptors, displayed an increased off-rate 
when compared to the rhTRAIL WT sensorgram (Figure 4). 
 
Accelerated thermal stability study 
In  order  to  test  the  stability  of  TRAIL  and  TRAIL  mutants  over  time,  an  accelerated 
thermal stability measurement was performed. The temperature of 73 
o C was chosen to 
measure effects on stability within a 1 h timeframe. At this temperature rhTRAIL WT starts 
to unfold, while the mutants are still properly folded (Figure 3). Protein solutions with the 
same concentration as used in the thermal unfolding measurements were incubated at 73 
oC 
for 1 h and changes in molar ellipticity at 222 nm were measured (Figure 5). The ellipticity 
of rhTRAIL WT decreased from the onset, giving a half-life of approximately 13 min. The 
signal  for  the  M1,  M2  and  C1  mutants  remained  essentially  constant,  indicating  an 
increased  thermal  stability.  M3  showed  a  half-life  of  approximately  24  min.  These 
measurements, however, are not indicative of the bioactive trimeric structure of the TRAIL 
molecule, but of the secondary structure of the monomeric unit. To monitor a concomitant 
increase  in  biological  activity  at  elevated  temperatures  of  the  mutants  with  unchanged 
biological activity (M1, M3 and C1), protein solutions with the same concentrations as used 
in the thermal unfolding measurements were incubated at 73 
o C and samples were taken at 
regular intervals for 1 h. Samples were subsequently diluted in tissue culture medium and 
added to Colo205 cells, resulting in a final concentration of 100 ng/ml. After overnight 
incubation  the  viability  of  the  cells  was  measured  using  a  MTT  assay.  RhTRAIL  WT 
showed decrease in bioactivity after 20 min of incubation, while M1 and C1 retained full 
bioactivity after incubation at 73 
o C for 1 h (Figure 6). M3 displayed an intermediate 
bioactivity between rhTRAIL WT and the other mutants. The increases in thermal stability 
of  the  mutants  as  measured  with  CD  could  therefore  be  correlated  with  a  more  stable 
biologically active trimeric molecule. 
 
 ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿  
 
Others have previously applied computational engineering techniques to improve thermal 
stability  of  alpha-helical  proteins  or  monomeric  beta-sheet  molecules
55,169,170.  However, 
frequently, monomeric proteins of less than 100 amino acids were used as targets. To our 
knowledge, this report is the first example of computational redesign of a large trimeric all-
b-sheet  protein  towards  a  more  thermal  stable  variant.  Significantly,  it  shows  that  the 
principles learned from design and engineering of small proteins can also be applied for 
large multimeric protein complexes. Stabilization of TRAIL using computational redesign 
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Figure 5. Stability of rhTRAIL WT (closed circles), M1(closed squares), M2 (open circles), M3 (open squares) 
and C1 (closed triangles) at 73
 oC for 60 min. 
 
 
Figure 6. Remaining biological activity of rhTRAIL WT, M1, M3 and C1 (from left to right) upon incubation at 
73
 o C during 60 min. Biological activities are calculated relative to the value observed at 0 min. Chapter 3 
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The rhTRAIL WT (114-281) molecule has a relatively high thermal stability if compared to 
some members of the TNF ligand family. Human tumor necrosis factor alpha (TNF-a), for 
example, has an apparent Tm of 65 
oC as measured with CD
171 and the CD40L receptor 
binding  domain  has  an  apparent  Tm  of  60 
oC  as  measured  with  differential  scanning 
calorimetry  (DSC)
172.  In  parallel  investigations,  we  can  show  using  CD  that  RANKL 
however, is more thermal stable than TRAIL, with an apparent Tm of 5 
oC higher than 
rhTRAIL WT, confirming another study
173. In this study, we investigated the possibility of 
further  increasing  the  thermal  stability  of  TRAIL,  as  a  model  for  all-b-sheet  proteins, 
through the use of computational engineering.  
 
We succeeded in extending the thermal stability of the b-sheet protein by more than 5 
oC by 
using a combined approach, employing both TNF ligand family alignment information and 
an  automated  computational  design  algorithm.  Due  to  the  non-reversible  nature  of  the 
unfolding reaction, the apparent Tm is not a perfect indication of an increase in stability. 
From a functional point of view, therefore, it also makes sense to study the time taken for 
the protein to denature at high temperature and to relate this to an effect on biological 
activity. The accelerated thermal stability study showed that the increase in thermal stability 
of the mutants as measured with CD spectroscopy (Figure 5) can be correlated with the 
preservation of overall structural characteristics as highlighted by the lasting bioactivity of 
M1 during the experimental timeframe (Figure 6). When measuring the residual bioactivity 
of rhTRAIL WT and TRAIL mutants upon incubation at 73 
oC for 1 h, it was shown that, 
while  rhTRAIL  WT  was  all  but  thermally  inactivated  after  ~20  min,  the  mutants, 
significantly, had an improved stability with respect to rhTRAIL WT (Figure 5). According 
to  the  Arrhenius  equation  a measured  increase  in stability  for  M1  at  73 
oC  could  also 
correlate with an increase in stability for M1 at more relevant temperatures, such as 37 
oC 
or room temperature, provided that the type of degradation mechanism is the same at both 
temperatures. Although not tested in this study, it has been shown that in case of certain 
therapeutically interesting proteins, improvement of thermal stability can also be indicative 
of an improved in vivo half-life
174,175. This could be of particular interest for the therapeutic 
use of TRAIL. Preclinical studies showed that rhTRAIL WT was rapidly eliminated from 
both rodents and non-human primates, with half-lives ranging from 3.6 min (mouse) to 27 
min (Chimpanzee)
32. 
 
It  is  advantageous  to  use  alignment  information  in  order  to  focus  the  design  on  non-
conserved residue positions. The reason being that conserved residues are usually retained 
in a family for a good reason and it is probable that any mutation will decrease protein 
stability
69,176.  On  the  other  hand,  regions  with  high  sequence  variability  are  tolerant  to 
mutation and it can be expected that variants that stabilize the protein can be found in these 
regions
69. To accomplish our goal of redesigning a b-sheet protein, TRAIL, and to generate 
stable variants with the minimum number of mutations, the conserved residues forming the 
trimeric interface were therefore largely excluded from the prediction/optimization strategy. 
This resulted in an approach which focused mainly on improvement of the stability of the 
monomer  (intra-chain  stabilization;  monomeric  set)  or  improving  monomer-monomer 
contacts (inter-chain stabilization; dimeric set). See Table 1. 
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M1, M2, M3 and C1 showed, in agreement with our predictions, an increase in thermal 
stability (Table 2; figure 3, 5, 6). Different basic principles were used in the M1, M2 and 
M3 designs. M1 shows an example of intra-chain stabilization. Stabilization of the flexible 
CD loop at the surface of each TRAIL monomer results in an increased stability of the 
entire trimer. This loop is not directly involved in receptor binding and is disordered in un-
complexed rhTRAIL WT structures
17,163, but becomes ordered on binding to DR5
12,16,18. 
M2,  however,  illustrates  the  optimization  of  the  interactions  between  two  adjacent 
monomers,  i.e.  inter-chain  stabilization.  Although  we  were  successful  with  the  above 
designs, in other cases like the combination mutant, C1 (M1 and M3 combined) or the M4 
mutant, we failed in our predictions. There could be several reasons behind it, but it also 
shows the limitations of design methods. Inherent limitations on force fields, resolution of 
the structures used as templates and the omission of protein dynamics in the exercise are 
some of the factors behind protein design failures. 
 
The increase in thermal stability did not affect the biological activity of M1, M3 and C1. 
M2 was more stable than rhTRAIL WT but the formation of an electrostatic interaction 
between Gln 205 and Arg 154 of the DR5 receptor was prevented (Figure 6b). This resulted 
in a subsequent 10-fold decrease in biological activity when compared to rhTRAIL WT, as 
predicted by FOLD-X (DDGbinding= 7.3 kcal mol
-1 monomer
-1). Our findings confirmed an 
earlier study showing decreased bioactivity of alanine mutants at these positions
17. Analysis 
of binding to the DR4 and DR5 receptors, using surface plasmon resonance, shows an 
increased off-rate for M2, indicating a lower affinity for both receptors, when compared to 
rhTRAIL WT and M1 (Figure 2). Since ligand-receptor binding sites are normally “high 
energy regions”, the M2 mutations were expected to stabilize the TRAIL molecule. Thus, 
this  could  be  regarded  as  an  example  of  a  possible  increase  in  stability  which  is 
counterbalanced in evolution by loss of function.  
 
Frequently, other computational redesign studies limited the screening for improvement of 
thermal  stability  to  the  core  of  the  molecule
59,174,175.  Here  we  show  that  computational 
redesign  techniques  can  also  involve  inter-chain  interfaces  and  surface  residues  of  the 
molecule, to successfully stabilize the structure. 
 
Performance of PERLA/FOLD-X was successful in the case of the intra-chain (monomer) 
set,  the  inter-chain  (dimeric)  set  and  the  miscellaneous  set.  The  experimental  data 
corresponding to these designs showed all variants within these sets were more stable than 
rhTRAIL WT. Significantly, we could show that stabilization of the CD loop in a single 
monomer resulted in stabilization of the entire trimeric molecule (Figure 2a).  
 
Our studies have shown that computer redesign of a more thermal stable multimeric all b-
sheet protein is achievable. Computational protein redesign is therefore a valuable addition 
to other protein engineering methodologies, such as directed evolution or experimental high 
throughput  approaches,  as  a  tool  for  the  improvement  of  protein  properties.  Since  the 
computational method used in our study is general applicable, our findings can be further 
applied to design other TNF ligand family members with improved thermal stability. 
 Chapter 3 
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All  reagents  were  of  analytical  grade  unless  specified  otherwise.  Isopropyl-b-D-1-
thiogalactoside  (IPTG),  ampicillin  and  dithiotreitol  (DTT)  were  from  Duchefa. 
Chromatographic  columns  and  media  were  from  Amersham  Biosciences.  Restriction 
enzymes used were purchased from New England Biolabs. All other chemicals were from 
Sigma. 
 
Computational design of mutants 
A detailed description of the protein design algorithm, PERLA, is available elsewhere
159 
(http://ProteinDesign.EMBL-Heidelberg.DE)  and  its  use  has  been  previously 
described
60,85,158,165.  In  the  case  of  oligomeric  proteins  such  as  TRAIL,  protein  design 
requires the following steps: Firstly, residues of a monomer that could establish specific 
interactions with the contiguous monomer must be identified and selected. Secondly, side 
chains  that  contact  the  residues  to  be  mutated,  must  be  identified  to  allow  side  chain 
movements  that  are  necessary  to  accommodate  the  new  residues  introduced  by  the 
algorithm.  The  algorithm  automatically  selects  these  residues  based  on  a  geometrical 
approach  that  takes  Ca-Ca  distances  and  the  angle  between  Ca-Cb  vectors  into 
consideration.  Thirdly,  the  algorithm  places  the  amino  acid  repertoire  at  each  position 
selected from a set of naturally occurring amino acids in a multiple sequence alignment of 
the TNF ligand family, and eliminates those side chain conformations and amino acids that 
are not compatible with the rest of the structure. Fourthly, all possible pair-wise interactions 
are explored to eliminate those combinations that are less favorable. Finally, an output of 
sequences and PDB coordinates corresponding to the best calculated solution (in terms of 
energy)  is  produced.  The  resultant  PDB  files  containing  the  mutations  were  energy 
minimized  using  GROMOS  43B1  as  implemented  in  Swiss-PdbViewer  v3.7b2
177,  and 
evaluated  by  FOLD-X
160  (http://fold-x.embl-heidelberg.de).  The  final  energies  of  the 
models are compared to the reference rhTRAIL WT structure and expressed as ￿￿G (kcal 
mol
-1). 
 
Cloning and PCR 
cDNA  corresponding  to  human  soluble  TRAIL  (aa  114-281)  was  cloned  in  pET15B 
(Novagen) using NcoI and BamHI restriction sites. The N-terminal sequence encoding a 
His-tag and protease recognition site was therefore removed. Mutants were constructed by 
PCR using the Quick Change Method (Stratagene) or a modified megaprimer method
178. 
The  polymerase  used  was  Pfu  Turbo  supplied  by  Stratagene.  Purified  mutagenic 
oligonucleotides were obtained from Invitrogen. Introduction of mutations was confirmed 
by DNA sequencing. 
 
Expression and purification of rhTRAIL WT and mutants 
The rhTRAIL WT and TRAIL mutant constructs were transformed to Escherichia Coli 
BL21 (DE3) (Invitrogen). RhTRAIL WT and M1 were grown at a 5 l batch scale in a 7.5 l 
fermentor (Applicon) using 4 x LB medium, 1 % (w/v) glucose, 100 mg/ml ampicillin and 
additional trace elements. The culture was grown to mid-log phase at 37 
oC, 30 % oxygen 
saturation and subsequently induced with 1 mM IPTG. ZnSO4 was added at a concentration 
of 100 mM to promote trimer formation. Temperature was lowered to 28 
oC and the culture Stabilization of TRAIL using computational redesign 
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was grown until stationary phase. Other mutants were grown in shake flasks at a 1 l scale at 
250 rpm, using a similar protocol. Protein expression was induced when the culture reached 
OD600 0.5 and induction was continued for 5 h. In this case, the medium used was 2 x LB 
without additional trace elements. 
 
The isolated pellet was resuspended in 3 volumes extraction buffer (PBS pH 8, 10% (v/v) 
glycerol, 7 mM b-mercapto-ethanol). Cells were disrupted using sonication and extracts 
were clarified by centrifugation at 40,000 g. Subsequently, the supernatant was loaded on a 
nickel-charged IMAC Sepharose fast-flow column and rhTRAIL WT and TRAIL mutants 
were purified as described by Hymowitz
17 with the following modifications: 10 % (v/v) 
glycerol  and  a  minimal  concentration  of  100  mM  NaCl  were  used  in  all  buffers.  This 
prevented  aggregation  during  purification.  After  the  IMAC  fractionation  step,  20  mM 
ZnSO4 and 5 mM of DTT (instead of b-mercapto-ethanol) was added in all buffers. Finally, 
a gelfiltration step, using a Hiload Superdex 75 column, was included. Purified proteins 
were more than 98 % pure as determined using a colloidal Coomasie brilliant blue stained 
SDS-PAGE gel. Purified protein solutions were flash frozen in liquid nitrogen and stored at 
-80
  
oC. 
 
CD Spectroscopy 
Circular dichroism (CD) spectra were recorded on a Jasco J-715 CD spectrophotometer 
(Jasco  Inc.)  equipped  with  a  PFD350S  Peltier  temperature  control  unit  (Jasco  Inc.). 
Rectangular quartz cuvettes with a pathlength of 0.2 cm were used. Protein samples were 
dialyzed  against  PBS  pH  7.3  and  adjusted  to  a  final  concentration  of  100  mg/ml. 
Wavelength spectra were recorded between 250-205 nm using a 0.2 nm stepsize and 1 nm 
band-width at 25 
oC. Temperature scans from 25-98 
oC were performed at 222 nm with a 
scan rate of 40 
oC/h. Thermal decay measurements were performed at 73 
oC for 1 h at 222 
nm. 
 
Bioactivity of TRAIL mutants in vitro 
Bioactivity of rhTRAIL WT and TRAIL mutants was determined using a viability assay 
according to the manufacturer’s instructions (Celltiter Aqueous One, Promega). Colo205 
human  colon  carcinoma  cells  (ATCC  number  CCL-222)  were  cultured  in  RPMI  1640 
Glutamax containing 10 % heat inactivated fetal calf serum and 100 units/ml Penicillin-
Streptomycin.  All  reagents  were  supplied  by  Invitrogen.  A  concentration  series  of  the 
rhTRAIL WT or TRAIL mutants was made in cell culture medium. Fifty ml of each dilution 
was added to a 96-well tissue culture micro plate (Greiner) and 100 ml of cell suspension 
was added, to a final cell number of 1x10
4 cells/well. Mixtures were incubated for 16 h at 
37
 oC under a humidified atmosphere containing 5 % CO2. Subsequently, 20 ml of MTS 
reagent was added. Cell viability was determined after 30 min incubation by measuring the 
absorption at 490 nm.  
 
Receptor binding 
Binding experiments were performed using a surface plasmon resonance-based biosensor 
Biacore  3000  (Biacore  AB,  Uppsala,  Sweden),  at  25
  oC.  Recombinant  receptors  were 
ordered from R&D systems (R&D systems, Minneapolis, MN, USA). Immobilization of 
the receptors on the sensor surface of a Biacore CM5 sensor chip was performed following Chapter 3 
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a  standard  amine  coupling  procedure  according  to  the  manufacturer’s  instructions.  A 
reference  surface  was  generated  simultaneously  under  the  same  conditions  but  without 
receptor injection and used as a blank to correct for instrument and buffer artifacts. Purified 
rhTRAIL WT and TRAIL mutants were injected in two-fold at a concentration of 2 mg/ml 
and at a flow rate of 20 ml/min. Binding of ligands to the receptors was monitored in real-
time.  The  receptor/sensor  surface  was  regenerated  using  3  M  sodium  acetate  pH  5.2 
injections. 
 
￿ ￿ ￿ ￿￿ "￿ ￿ ￿ ￿ ￿ ￿￿ ￿￿ ￿ ￿
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￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿
Tumor  necrosis  factor-related  apoptosis  inducing  ligand  (TRAIL)  is  a  potential 
anticancer  drug  that  selectively  induces  apoptosis  in  a  variety  of  cancer  cells,  by 
interacting  with  death  receptors  DR4  and  DR5.  TRAIL  can  also  bind  to  decoy 
receptors  (DcR1,  DcR2  and  OPG  receptor)  that  cannot  induce  apoptosis.  The 
occurrence  of  DR5  responsive  tumor  cells  indicates  that  a  DR5-receptor  specific 
TRAIL variant will permit new and selective tumor therapies. Using the automatic 
design algorithm FOLD-X, we successfully generated DR5-selective TRAIL variants. 
These variants do not induce apoptosis in DR4-responsive cell lines but show a large 
increase in biological activity in DR5-responsive cancer cell lines. Even rhTRAIL WT 
insensitive ovarian cancer cell line could be brought into apoptosis. In addition, our 
results demonstrate that there is no requirement for antibody mediated cross-linking 
or membrane bound TRAIL to induce apoptosis via DR5. Designed DR5 selective TRAIL variants 
 
  - 51 - 
￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿
 
Tumor  necrosis  factor  (TNF)  related  apoptosis  inducing-ligand  (TRAIL)  is  currently 
attracting great interest as a potential anti-cancer therapeutic. TRAIL in its soluble form 
selectively  induces  apoptosis  in  tumor  cells  in  vitro  and  in  vivo,  by  a  death  receptor 
mediated process. Unlike other apoptosis inducing TNF family members, soluble TRAIL 
appears to be inactive against normal healthy tissue
13. Reports in which TRAIL induces 
apoptosis in normal cells could be attributed to the specific preparations of TRAIL used
14. 
TRAIL shows a high degree of promiscuity as it binds to five cognate receptors; DR4 
(TRAIL-R1) and DR5 (TRAIL-R2) and to the decoy receptors DcR1 (TRAIL-R3), DcR2 
(TRAIL-R4)  and  Osteoprotegerin  (OPG)
19.  Upon  binding  to  TRAIL,  DR4  and  DR5 
receptors recruit Fas associated death domain (FADD), which bind and activate the initiator 
caspase  8,  leading  to  apoptosis
23-25.  DcR1  or  DcR2  do  not  contain  a  death  domain  or 
contain a truncated death domain, respectively, and therefore could prevent apoptosis by 
sequestering available TRAIL or by interfering in the formation of a TRAIL-DR4 or -DR5 
signaling complex
30.  
 
Use  of  TRAIL  receptor  selective  variants  could  permit  better  tumor  specific  therapies 
through  escape  from  the  decoy  receptor-mediated  antagonism,  resulting  in  a  lower 
administrated dose, with possibly less side effects and as alternatives to existing agonistic 
receptor antibodies
179-181. In experimental anti-cancer treatment, the receptors DR4 and/or 
DR5 were shown to be up-regulated after treatment with DNA damaging chemotherapeutic 
drugs and the response to TRAIL-induced apoptosis was significantly increased
19,182. In 
addition, irradiation appears to specifically up-regulate DR5 receptor expression and the 
combination of irradiation and TRAIL treatment has been demonstrated to have an additive 
or synergistic effect
107. Thus, we choose to develop DR5 receptor selective TRAIL variants 
using  a  computational  design  strategy.  Computational  design  methods  have  been 
successfully employed to redesign several protein-protein interactions
85-87,89, but have as yet 
hardly  been  applied  to  therapeutic  proteins.  One  exception  is  the  design  of  dominant 
negative TNF-a variants that prevent formation of active TNF-alpha trimers
104. Using the 
automatic  design  algorithm  FOLD-X
150,160,183,  we  were  able  to  redesign  TRAIL  into 
exclusively DR5-specific agonistic variants. Since the computational method used in our 
study is based on general applicable principles and has been successfully tested on a variety 
of proteins
65,85,183-185, our method can be further applied to design other protein therapeutics 
with reduced promiscuity and improved receptor binding characteristics. 
 
￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿
 
Modeling of TRAIL-receptor complexes 
Monomeric subunits of TRAIL self associate in  bell-shaped homotrimers,  the bioactive 
form of the ligand, like other members of the TNF ligand-family
1,2. A trimer binds three 
subunits of a cognate receptor, with each receptor subunit bound in the grooves between 
two adjacent monomer ligand subunits
16,18. At present only crystal structures of TRAIL in 
complex with the DR5 receptor are known
12,16,18. The sequence alignment of the different 
TRAIL receptors (figure 1A), shows a large overall sequence identity (except for OPG), 
practically  no  insertions  or  deletions  and  conservation  of  all  cysteines  involved  in  the Chapter 4 
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formation of internal disulfide bridges. Consequently, good quality homology models of 
DR4, DcR1 and DcR2 could be build, but not of OPG. The homology models were built 
using the  WHAT IF web interface
186. Afterwards, these models were  refined using  the 
protein  design  options  of  FOLD-X,  removing  incorrect  side  chain  torsion  angles, 
eliminating Van der Waals clashes and accommodating TRAIL and receptor residues to 
their new interface. 
 
Figure 1. (A) Sequence alignment of the four different TRAIL membrane receptors. Both cystein rich domains 
involved  in  receptor  binding  are  highly  conserved.  From  the  sequence  alignment  of  the  different  TRAIL 
receptors
187 it is observed that the receptor cysteine rich domains (CRDs) involved in the interaction with TRAIL 
(CRD2 and CRD3) are highly conserved and the overall sequence identity when compared to DR5 is higher than 
50%, with the exception of the soluble receptor OPG (not shown). In addition, there are neither insertions nor 
deletions in the sequence alignment (with the exception of a glycine deletion in the middle of CRD3 in DcR1) and 
all the cysteines involved in the formation of internal disulfide bridges are conserved. Position Asp 120 of DR5 
and corresponding residues of the other receptors are depicted in bold, residues of CRD2 in red and residues of 
CRD3 in orange. Identical amino acids to DR5 are boxed. (B) Side view of TRAIL receptor binding interface 
formed by two TRAIL monomers, highlighted in light red are all amino acids selected for the in silico screening. 
Tyr216 (depicted in green) was used as a reference and control. 
The accuracy of the models and the force field was tested using the data derived from the 
alanine scanning of rhTRAIL WT as performed by Hymowitz et al.
17. The predictions of 
the energy change in the complex formation correlates with the changes in the dissociation 
constants measured (figure 2). The calculated R
2 factor is 0.6 (R
2 factors calculated for 
DR4  and  DR5  individually  also  amount  to  0.6).  However,  several  factors  involved  in 
accuracy should be taken into account. The methodology used focuses on energy changes 
in ligand-receptor complex formation, some mutations to alanine might be predicted as not 
changing receptor binding affinity but only producing slight changes on TRAIL stability, 
thereby affecting the correlation. The prediction error is on average within the error of this 
methodology  (0.6  –  0.7  kcal/mol).  Since  many  changes  in  affinity  as  measured  in  the 
alanine scanning are within this error it is not possible to obtain a better correlation. Taken 
together, this implies that our method can reliably predict mutations in the receptor binding 
interface that will most severely affect the complex formation. 
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Figure 2. Correlation of the predicted changes in binding affinity compared with the experimental results of an 
alanine scanning performed by Hymowitz et al.
17 (open circles) and of the DR5 selective TRAIL variants (closed 
circles). 
 
Computational design of the variants 
For the computational screening, all residues from the TRAIL interface were considered. 
TRAIL residues interacting with a conserved amino acid environment in all four receptors 
were disregarded. Amino acids finally considered were Arg130, Gly131, Arg132, Lys145, 
Leu147,  Gly148,  Arg149,  Lys150,  Glu155,  Arg158,  Gly160,  His161,  Tyr189,  Arg191, 
Phe192,  Gln193,  Glu195,  Asn199,  Thr200,  Lys201,  Asp203,  Gln205,  Val207,  Gln208, 
Tyr209, Thr214, Asp218, Asp234, Glu236, His264, Ile266, Asp267 and Asp269. Tyr216 
was  included  as  a  positive  control  due  to  its  already  known  implication  in  receptor 
binding
16,18 and Ser165, located far away from the receptor binding interface, was used as a 
negative  control  (figure 1B). At each of the selected positions, FOLD-X placed the 20 
natural amino acids whilst moving the neighbouring residues, obtaining a library of 2720 
models in total (34 amino acid positions x 20 amino acids x 4 receptors). The energy of 
interaction was obtained calculating the sum of the individual energies of the receptor and 
ligand subunits and subtracting them from the global energy of the complex. In this way, a 
set of predicted energetic values for the complex formation was obtained and compared 
with the TRAIL WT values. After studying these values together with visual inspection of 
the mutant models, those in which a change in selectivity was predicted, were selected for 
experimental studies (Table 1). 
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Table 1. Predicted difference in binding energy (DD DD DD DDG) of DR5-selective variants binding to different 
receptors when compared with TRAIL WT 
Mutations  DR4  DR5  DcR1  DcR2 
R130E  0.75  -0.2  1.76  1.52 
G160M  -1.11  -1.52  -0.18  -0.65 
E195R  0.11  -1.11  0.2  -0.79 
T214R  1.85  -0.17  1.94  1.89 
D269H  3.52  -1.6  3.78  4.43 
D269R  1.95  -1.95  2.45  3.28 
D269K  2.43  -1  2.94  3.71 
Variants comprising these mutations were selected in the pre-screen assay from an initial set of 10 
design proposals. Change in energy is measured in kcal/mol and applies to the change of a single binding 
interface bound to a single receptor.   
 
Pre-screen for selective receptor binding  
A fast surface plasmon resonance (SPR) based receptor binding pre-screen was used to 
further refine the in silico selection. TRAIL variant cell extracts were evaluated for binding 
to DR4, DR5 and DcR1 immobilized Ig fusion proteins. The ratios of binding to DR4 and 
DcR1 receptor with respect to DR5 receptor were calculated and compared to the ratio 
obtained for rhTRAIL WT. An increase in DR5/DR4 binding ratio of ￿25 % relative to the 
ratio of rhTRAIL WT was set as indicative of DR5 selectivity. Several variants comprising 
a substitution (His, Lys or Arg) at position Asp 269 and variants with a double mutation 
D269H/E195R  and  D269H/T214R  with  a  reduced  binding  to  the  DR4  and  increased 
binding  to  the  DR5  receptor  were  chosen  for  further  analysis.  R191E/D267R,  R130E, 
G160M, I220M and E195R were also selected, as they also showed an increased DR5/DR4 
binding ratio. The effects, however, were smaller than that of the Asp 269 variants (data not 
shown). 
 
Determination of Receptor binding  
Selected  TRAIL  variants  were  purified  as  described  before
65.  Analytical  size  exclusion 
chromatography  (SEC)  and  dynamic  light  scattering  (DLS)  confirmed  that  the  purified 
TRAIL  variants  were  in  a  trimeric  state  and  that  higher  order  oligomeric  species  or 
aggregates were absent (data not show). Binding of the purified variants to immobilized 
DR4, DR5, DcR1 or DcR2 Ig receptor was assessed in real time using SPR. The TRAIL 
proteins were initially analyzed at two concentrations (30 and 60 nM). TRAIL variants 
R191E/D267R  and  G160M  showed  stability  and  folding  problems  and  were  therefore 
discarded. Binding curves of variants showing a significant change in the ratio DR5/DR4 
binding were subsequently recorded for concentrations ranging from 0.1 to 250 nM. The 
D269H/T214R variant had a comparable improvement as the D269H single mutant variant 
in DR5 Ig binding, however no detectable binding to DR4 Ig was found (figure 3A and B). 
Apparent  Kd  values  for  DR5  binding  ranged  from  0.6  nM  (D269H/E195R)  to  2.5  nM 
(TRAIL),  and  for  DR4  binding  from  7.2  nM  (TRAIL)  to  244  nM  (D269H).  For 
D269H/T214R, D269K and D269R a proper apparent Kd for DR4 binding could not be 
determined. Binding of D269H and D269H/E195R towards the decoy DcR1 Ig receptor 
was >20 fold reduced when compared to rhTRAIL WT. Up to the highest concentration 
tested (250 nM) D269H/T214R did not show any observable binding to DcR1 Ig (figure Designed DR5 selective TRAIL variants 
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4A). D269H and D269H/E195R showed also reduced binding to DcR2 Ig, however this 
reduction  was  much  less  pronounced  as  the  reduction  observed  in  DcR1  binding.  In 
contrast,  D269H/T214R  showed  a  large  decrease  in  binding  to  DcR2  Ig  relative  to 
rhTRAIL  WT  (figure  4B).  Binding  to  OPG  Ig  was  also  reduced  for  these  three  DR5 
selective  variants,  with  D269H/E195R  showing  the  largest  decrease  in  binding  to  this 
receptor (figure 4C). A competition ELISA experiment measuring the binding of TRAIL or 
variants towards immobilized DR5-Ig in the presences of soluble DR4, DR5 or DcR1 Ig 
corroborated the findings of the receptor binding experiment. Whereas TRAIL binding to 
immobilized DR5-Ig could be competed by soluble DR4, DR5 and DcR1, binding of the 
variants could only be antagonized by soluble DR5 Ig (figure 5). 
 
 
Figure 3. (A) Receptor binding of TRAIL and DR5 selective variants towards DR5-Ig as determined by SPR. (B) 
or towards DR4-Ig. Receptor binding is calculated relative to the response of rhTRAIL WT at 250 nM. 
 
 
Figure 4. (A) Receptor binding of TRAIL and DR5 selective variants towards DcR1-Ig as determined by SPR, (B) 
towards DcR2-Ig or (C) towards OPG-Ig. Receptor binding is calculated relative to the response of rhTRAIL WT 
at 250 nM. 
 
Comparison between predictions and experimentally obtained results  
In order to calculate the correlation between predicted and experimentally obtained results 
of our DR5 selective variants, we compared the calculated DDG values for DR4 and DR5 
binding  (table  1)  with  the  DDG  values  that  stem  from  the  experimentally  determined 
apparent  Kd  values  (see  above).  The  calculated  R
2  factor  between  these  predicted  and 
experimental DDG values is 0.88. Adding these values to the alanine scan data set improved 
the overall calculated R
2 from 0.6 to 0.7 (figure 2). Chapter 4 
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Figure 5. Competition ELISA. (A) Competition ELISA using soluble DR5-Ig as competitor, (B) soluble DR4-Ig 
as  competitor  or  (C)  soluble  DcR1-Ig  as  competitor. Percentage  bound  to  immobilized  DR5-Ig  is  calculated 
relative to the amount bound at 0 ng/well soluble competitor. The selectivity of the DR5 selective variants towards 
the DR5 receptor in the presence of another TRAIL receptor was assessed using a competitive ELISA experiment. 
RhTRAIL WT or receptor selective variants were pre-incubated with 0-500 ng/well DR4, DR5 or DcR1 Ig during 
30 min. Pre-incubated solutions were added to micro titer wells coated with DR5 Ig. Binding of the selective 
variants at various concentrations of soluble receptor towards the immobilized DR5 Ig was calculated relative to 
the value measured in the presence of 0 ng/well soluble receptor. Increasing concentrations of soluble DR4 Ig or 
DR5 Ig showed competition with immobilized DR5 Ig for rhTRAIL WT binding. In contrast, soluble DR4 Ig 
showed no competition with immobilized DR5 Ig for binding with the DR5 selective variants. However, soluble 
DR5  Ig  displayed  competition  for  binding  with  the  immobilized  DR5  Ig.  Pre-incubation  with  increasing 
concentrations of DcR1  Ig  did not affect the binding of the DR5 selective variants to immobilized DR5 Ig. 
RhTRAIL WT showed, in contrast, a 10-15% decrease in binding to immobilized DR5 when pre-incubated with 
the highest concentration of DcR1 Ig. The difference in level of competition of rhTRAIL WT binding between 
DcR1 Ig and DR5 Ig is caused by a ~100 fold difference in affinity of rhTRAIL WT for the two receptors, 200 nM 
and <2 nM, respectively
188. 
Table 2. EC50 values Colo205 and A2780 Cells. 
  Colo205  A2780 
Ligand  EC50 (+/- s.d)  Max. Effect  EC50 (+/- s.d)  Max. Effect 
  (ng/ml)  %Cell death  (ng/ml)  %Cell death 
TRAIL  8.6 (0.9)  78% (8%)  15.6 (3)  41% (3%) 
D269H  1.8 (0.5)  80% (4%)  4.7 (0)  70% (5%) 
D269H E195R  1.5 (0.4)  80% (6%)  4.2 (1)  69% (2%) 
D269H T214R  5.1 (2.6)  66% (9%)  12.1 (4)  66% (11%) 
   
Biological activity 
To assess the biological activity related to DR5 binding, various cancer cells were used. 
Colo205 colon carcinoma cells and ML-1 chronic myeloid leukemia cells express all four 
TRAIL receptors on the cell surface as shown using FACS analysis, (figure 6A and B), and 
are sensitive to TRAIL-induced apoptosis. In order to test the involvement of DR4 versus 
DR5 in TRAIL-induced cell death Colo205 cells were treated with neutralizing anti-DR4 or 
anti-DR5 antibody for 1 h prior to addition of TRAIL. Both antibodies reduced TRAIL-
mediated  cell  death  and  had  an  additive  effect  when  used  in  combination  (figure  7A). 
However, the DR5 neutralizing antibody was approximately 3 times more effective than the 
DR4 neutralizing antibody, demonstrating that TRAIL-induced apoptosis in Colo205 cells 
is  primarily  mediated  by  DR5.  In  contrast,  the  DR4 pathway  is  the  major  mediator  of 
TRAIL-induced apoptosis in ML-1 cells (figure 7A). In order to examine whether the DR5 
specific TRAIL variants induce cell death in Colo205 cells via the DR5 receptor, 1 mg/ml 
of  neutralizing  anti-DR4  or  anti-DR5  antibodies  were  administered  1  h  prior  to  ligand Designed DR5 selective TRAIL variants 
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treatment. The presence of the anti-DR4 antibody failed to prevent death induced by the 
DR5 specific variants. On the other hand 1 mg/ml of anti-DR5 antibody could significantly 
reduce the amount cell death (figure 7B). 
 
Colo205 and ML-1 cells were then treated with increasing concentrations of TRAIL or the 
DR5  specific  variants  D269H,  D269H/E195R  and  D269H/T214R  and  their  cytotoxic 
potential  was  measured  with  a  MTT  assay.  In  Colo205  cells  all  TRAIL  ligands  were 
biologically active and induced cell death at levels that were either comparable to that of 
rhTRAIL WT or were up to five fold more active (figure 7C; table 2). Contrary to Colo205 
cells, only TRAIL was able to induce cell death in ML-1 cells (figure 3D). Similar results 
were obtained using EM-2 chronic myeloid leukemia cells expressing only DR4 receptor 
and lacking the DR5 receptor, and the ovarian cancer cell line A2780 which expresses DR5 
but lacks DR4 on its surface and is relatively insensitive towards TRAIL-induced cell death 
(S.  de  Jong,  personal  communication).  Although  EM-2  cells  were  sensitive  to  TRAIL 
induced cell death (50 ng/ml TRAIL initiating more than 80% cell death), treatment with 
any of the DR5 mutants failed to induce significant cell death (figure 8A). In A2780 cells, 
on the other hand, the cytotoxic activity of D269H, D269H/E195R and D269H/T214R is 
significantly  increased,  showing  both  an  increased  maximum  response  and  drastically 
decreased EC50 values when compared to rhTRAIL WT (figure 7E; table 2). An additional 
experiment using D269H/E195R in wild-type BJAB cells responsive to both DR4- and 
DR5-mediated cell death (BJAB
wt), BJAB cells deficient in DR5 (BJAB
DR5 DEF) and BJAB 
cells deficient in DR5 and stably transfected with D R5 (BJAB
DR5 DEF+DR5)
189 confirm our 
findings. D269H/E195R was able to induce cell death in BJAB
wt cells but was unable to 
induce significant cell death in BJAB
DR5 DEF cells when compared to rhTRAIL WT. In the 
DR5 transfected BJAB
DR5  DEF+DR5 cells, however, the cytotoxic potential was restored 
(figure 7F). The cytotoxic effects of these TRAIL variants on non-cancerous cells human 
umbilical vein endothelial cells (HUVEC) was assessed by incubating these cells in the 
presence of 100 ng/ml rhTRAIL WT or TRAIL variants. However, no cytotoxic effects 
were observed for rhTRAIL WT and the receptor selective TRAIL variants (figure 8B). 
Taken together, the results obtained with the Colo205, ML-1, A2780 and BJAB cell lines 
show that the biological activity of the D269H, D269H/E195R and D269H/T214R variants 
is specifically directed towards the DR5 receptor. 
 
Figure 6. Cell surface expression of TRAIL receptors in A) Colo205 cells and B) ML-1 cells. Left panel: DR4 and 
DR5 receptor. Right panel: DcR1 and DcR2. Chapter 4 
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Figure 7. (A) Apoptosis inducing activity of 100 ng/ml TRAIL in the presence of 1 mg/ml DR4 (aDR4), DR5 
(aDR5)  or  DR4  and  DR5  (+aDR4+aDR5)  receptor  neutralizing  antibodies  in  Colo205  and  ML-1  cells.  (B) 
Apoptosis inducing activity in Colo205 cells of 100 ng/ml TRAIL or DR5 selective variants without the presence 
of neutralizing DR4 or DR5 antibodies (no AB) or in the presence of neutralizing antibody (aDR4 or aDR5, or 
both, aDR4a DR5). Cytotoxic potential (%Cell death) of TRAIL or DR5 selective variants in: (C) Colo205 cells, 
(D) ML-1 cells, (E) A2780 cells and (F) of 1, 10 or 100 ng/ml TRAIL (WT) or D269H/E195R (DE) relative to 
cycloheximide control (0.33 mg/ml) in BJAB cells responsive to both DR4 and DR5 mediated cell death (BJAB
wt), 
BJAB cells deficient for DR5 (BJAB
DR5  DEF)
189 and BJAB cells deficient for DR5 stably transfected with DR5 
(BJAB
DR5 DEF+DR5)
189. 
￿
 
Figure 8. (A) Cytotoxic potential (%Viability) of TRAIL or DR5 selective variants in EM-2 cells. EM-2 cells 
express DR4 but not DR5. (B) Cytotoxic potential (%Viability) of rhTRAIL WT or DR5 selective variants in 
HUVEC cells. 
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 ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿
￿
Since DR5 receptor is a good target for TRAIL cancer therapy (see Introduction) we choose 
to develop  DR5 receptor selective variants of TRAIL by using a computational design 
strategy. 
 
Structural basis for the changes in selectivity. 
This study shows that residue 269 is one of the most important residues for DR5 selectivity. 
From the crystal structure of TRAIL in complex with DR5, it can be observed that this 
amino acid is not interacting directly with the receptor. Studying the models of TRAIL in 
complex with the other three receptors, reveals that Asp269 from TRAIL is interacting with 
Lys120 from the receptor. This lysine residue is conserved among the DR4, DcR1 and 
DcR2 receptors. In contrast, DR5 has an aspartate at this position (figure 9 A and B; figure 
1A). 
 
 
Figure 9. Area of interaction of TRAIL and DR4/DR5 receptor around position 269: A) TRAIL; B) D269H 
variant and around position 214: C) TRAIL; D) T214R variant. Ribbons color is red for receptor and blue for 
TRAIL. Residues in DR5-complexes are in dark green and residues in DR4-complexes in light green. Arg 191 and 
Asp 267 are key TRAIL amino acids for DR5 receptor binding in the corresponding binding pocket of the 
receptor, as observed in the crystal structure of TRAIL in complex with DR5. 
 
Changing this amino acid to another with opposite charge, shows two cumulative effects. 
On one hand, breaking the Asp269-Lys120 interaction in the complex between TRAIL and 
receptors  DR4,  DcR1,  and  DcR2,  would  decrease  TRAIL  affinity  towards  them; 
furthermore, Lys120 has little space for re-accommodation, and this may even introduce 
some Van der Waals clashes in the area. On the other hand, Asp120 from DR5 receptor 
may  interact  with  the  protonated  His269  of  TRAIL,  improving  binding  towards  this 
receptor. In summary, this explains why a single mutation alone can greatly change the 
selectivity  towards  DR5,  resulting  in  better  binding  to  DR5  receptor  and  a  substantial 
decrease in binding towards the other receptors. Residue 214 is also important for achieving 
DR5 selectivity. FOLD-X predicts for the T214R mutation a decrease in binding affinity 
for all receptors except DR5 (Table 1). This is due to the presence of a phenylalanine at 
position  111  in  DR4  and  a  proline  in  DcR1  and  DcR2,  which  prevent  proper 
accommodation  of  Arg214  upon  complex  formation.  As  a  result  the  arginine  displaces Chapter 4 
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Asp254 and breaking intra-molecular H-bonds. In DR5 a leucine at position 111 allows 
accommodation  of  Arg214  without  displacement  of  Asp254  (Fig.  4C  and  D).  Additive 
effect of mutations towards selectivity can be expected in the cases where the positions of 
the mutations are far away enough from each other such that they cannot make any non-
predictable interaction, e.g., mutations D269H and T214R.  
 
Selective binding to different receptors. 
Receptor binding experiments using SPR and competition ELISA experiments confirmed 
the modeling predictions. Variants D269H, D269H/E195R, D269K and D269R are between 
70 to150 fold more selective for the DR5 receptor than for the DR4 when compared with 
rhTRAIL WT. The D269H/T214R variant showed no binding to the DR4 receptor at the 
highest concentration used in the assay (250 nM). The dissociation rates of TRAIL and the 
DR5 selective variants in complex with the DR5 and DR4 receptor were, however, too slow 
to measure accurately using SPR, thereby precluding the accurate determination of affinity 
constants.  In  the  competition  ELISA  experiment,  DR4  was  unable  to  compete  with 
immobilized DR5 for the binding to these designed selective variants, demonstrating that in 
the presence of both DR4 and DR5 these variants are markedly more selective towards 
DR5. The net gain in DR5 selectivity of these variants is the sum of both an increased 
preference for the DR5 and a reduced preference for the DR4 receptor, exemplifying both 
positive and negative design principles
86. 
Binding of the D269H and D269H/E195R variants to the decoy DcR1 receptor was more 
than 20 fold reduced when compared to rhTRAIL WT. The D269H/T214R variant showed 
no binding to the DcR1 receptor at the highest concentration used in the assay (250 nM). 
Although  binding  of  the  D269H  and  D269H/E195R  variants  toward  the  decoy  DcR2 
receptor  was  reduced,  the  effect  was  much  less  pronounced  when  compared  to  the 
reduction in binding as observed with the other receptors. The different environment of 
Lys120  in  receptor  DcR2  when  compared  to  DR4  and  DcR1  could  explain  why  the 
decrease in affinity is smaller in this case, in contrast to our predictions. However, the 
D269H/T214R variant showed a ~80% decrease in receptor binding to the DcR2 receptor 
when compared to rhTRAIL WT.  
 
DR5 receptor produces apoptosis without additional cross-linking requirements 
Using several different cancer cell lines, receptor selective behavior of the DR5 selective 
variants could also be demonstrated in several in vitro biological assays. In cells with the 
DR4 receptor as major mediator of TRAIL induced apoptosis (ML-1 and EM-2 cells), DR5 
selective variants were unable to induce apoptosis even at high concentrations (200 ng/ml). 
These variants could however, induce apoptosis in cells with DR5 as the major mediator of 
TRAIL  induced  apoptosis  (Colo205)  and  this  induction  could  be  antagonized  using  a 
neutralizing anti-DR5 antibody. The cell death inducing activity against Colo205 cells was 
comparable to rhTRAIL WT (EC50 ~8.6 ng/ml) in the case of D269H/T214R (EC50 ~5.1 
ng/ml), or more than 5-fold increased in the case of D269H/E195R (EC50 ~1.5 ng/ml). In 
the DR5 positive and DR4 negative A2780 cells the increase in cell death inducing activity 
of the DR5 selective variants was even more pronounced. Using the various BJAB cell 
lines  it  could  be  confirmed  that  D269H/E195R  mediated  induction  of  cell  death  was 
dependant on the presence of the DR5 receptor and it was observed that the presence of the 
DR4 receptor only was not sufficient to induce cell death for this DR5 selective variant. Designed DR5 selective TRAIL variants 
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Taken  together,  the  in  vitro  biological  activity  data  convincingly  demonstrates  that 
differences in receptor selectivity as measured in the in vitro receptor binding assay is both 
relevant and significant in the in vitro biological context.  
Both  our  results  and  results  recently  published
109  suggest  that  cross-linking  TRAIL  or 
membrane bound TRAIL are not an absolute prerequisite for DR5 mediated induction of 
apoptosis,  as  was  concluded  by  others
190,191.  A  10-fold  improvement  in  DR5  mediated 
activity of  flag  tagged TRAIL upon  cross-linking was demonstrated, however this also 
resulted in toxicity in normal Cynomolgus monkey hepatocytes
109. Our soluble trimeric 
DR5 selective TRAIL variants are capable of inducing DR5 receptor mediated apoptosis at 
lower concentrations than rhTRAIL  WT, thus eliminating any requirement for antibody 
mediated cross-linking.  
 
Designed versus Selected Variants 
Other DR5 receptor selective TRAIL variants were recently isolated using phage display
109. 
These variants were selected from saturation mutagenesis libraries that were constructed on 
the basis of a previously performed alanine scan
17. Remarkably, the best DR5 selective 
mutant (DR5-8) contained 6 amino acid substitutions. Mutations found by us (e.g. D269H, 
E195R,  T214R)  to  induce  DR5  selectivity  were  not  identified  by  the  phage  display 
approach. In a partial dissection to determine the role of each mutation in selectivity Kelley 
et al. could not eliminate any of the mutations without losing selectivity and/or biological 
activity
109.  It  was  concluded  that  to  achieve  receptor  selectivity  multiple  amino  acid 
substitutions were required. However our results clearly demonstrate that in case of the 
D269H/T214R variant, only two amino acid substitutions are required to obtain complete 
receptor  selectivity.  Having  fewer  mutations  relative  to  the  wild-type  sequence  appears 
favorable in view of a potential use of the DR5 selective variants as anticancer therapeutics, 
since fewer mutations are likely to reduce the risk of an immunogenic response.  
 
￿ ￿ ￿￿ ￿ ￿ ￿ ￿ ￿ ￿￿
 
This study shows that computational redesign of the receptor binding interface of TRAIL to 
obtain DR5 selective variants is achievable. In vitro analysis demonstrates that our DR5 
selective mutants have increased affinity for DR5 whereas they do not bind to DR4. Our 
DR5 selective variants show high activity towards DR5 responsive cancer cells without the 
need  for  additional  cross-linking.  Consequently,  these  variants  are  of  interest  for  the 
development  as  a  potential  anti-cancer  therapeutic.  Previously,  we  designed  TRAIL 
variants  with  improved  thermal  stability  using  a  computational  redesign  strategy
65. 
Computational protein redesign methods are therefore a valuable addition to other protein 
engineering  methodologies,  such  as  directed  evolution  or  experimental  high  throughput 
approaches, as a tool for the improvement of protein properties. Combining computational 
and  experimental  screening  methods,  is  a  powerful  approach  in  protein  engineering,  a 
preliminary  computational  screening  on  proteins  helps  to  identify  the  most  important 
positions involved in protein-protein interactions and therefore decreases the number of 
variants to screen. 
 Chapter 4 
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!￿ ￿ ￿ ￿ ￿ ￿ ￿
 
All reagents were of analytical grade unless specified otherwise. Recombinant TRAIL Ig 
receptor fusion proteins were ordered from R&D systems (R&D systems). PBS pH 7.4 and 
RPMI-1640  were  obtained  from  Invitrogen.  All  other  chemicals  were  from  Sigma.  All 
buffers used in SPR, ELISA and biological activity assays were of physiological pH and 
ionic strength. 
 
Computational design of the mutants 
Homology  models  of  DR4,  DcR1  and  DcR2  were  built  using  the  WHAT  IF
186  web 
interface  based  on  human  TRAIL  in  complex  with  the DR5  ectodomain
18.  Afterwards, 
these models were refined using the protein design options of FOLD-X, removing incorrect 
torsion angles, Van der Waal’s clashes and accommodating TRAIL and receptor residues to 
their new interface and to build up the putative interactions between TRAIL and the three 
non-crystallized receptors through rotamer substitution. The crystal complex structure of 
TRAIL  with  DR5  receptor  was  also  refined  this  way  (see  supplementary  methods).  A 
detailed description of the empirical force field FOLD-X is available elsewhere
160 (and at 
http://fold-x.embl-heidelberg.de).  
 
In addition, the modified version of FOLD-X used in this work
150 is able to perform amino 
acid  mutations  accommodating  this  new  residue  and  its  surrounding  amino  acids  the 
following way: It first mutates the selected position to alanine and annotates the side chain 
energies of the neighbour residues. Then it mutates this alanine to the selected amino acid 
and  re-calculates  the  side  chain  energies  of  the  same  neighboring  residues.  Those  that 
exhibit an energy difference are then mutated to themselves to see if another rotamer will 
be more favorable. This new feature allows proceeding through the whole computational 
design process using just one single force field. The method does not guarantee a global 
minimum, but we have found that it is able to find the WT side chain conformations when 
doing  side  chain-reconstruction  from  a  poly-Ala  backbone  (Stricher,  F.  &  Serrano,  L 
“manuscript in preparation”). 
 
Side directed mutagenesis, Expression and Purification of selectivity mutants 
cDNA  corresponding  to  human  soluble  TRAIL  (aa  114-281)  was  cloned  in  pET15B 
(Novagen) using NcoI and BamHI restriction sites. Mutants were constructed by PCR as 
described before.
65 Homotrimeric TRAIL proteins were purified using a 3 step purification 
as described before
65. 
 
Determination of Receptor binding 
Binding experiments were performed using a surface plasmon resonance-based biosensor 
Biacore 3000 (Biacore AB, Uppsala, Sweden). Immobilization of the DR4-Ig and DR5-Ig 
receptors on the sensor surface of a Biacore CM5 sensor chip was performed following a 
standard amine coupling procedure according to the manufacturer’s instructions. Receptors 
were coated at a level of ~600-800 RU. Eighty ml TRAIL and variants were injected in 
three-fold at concentrations ranging from 250 nM to 0.1 nM at 70 ml/min and at 37
 oC using 
PBS pH 7.4 supplemented with 0.005% v/v P20 (Biacore) as running and sample buffer. 
Binding  of  ligands  to  the  receptors  was  monitored  in  real-time.  Due  to  the  very  slow Designed DR5 selective TRAIL variants 
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dissociation of the TRAIL-receptor complex, only pre-steady state binding data could be 
obtained. Furthermore, a  fast initial dissociation  was observed directly after the end  of 
injection, pointing at some heterogeneity in complex formation. In order to obtain data that 
represent proper high-affinity complex formation, the response at each concentration was 
recorded 30 s after the end of the injection. The response data as a function of TRAIL 
concentration  were  fitted  using  a  four  parameter  equation  to  give  an  apparent  affinity 
constant. Between injections the receptor/sensor surface was regenerated using 3 M sodium 
acetate pH 5.2 injections. DcR1-Ig and DcR2-Ig were captured using a protein A (Sigma) 
modified CM5 sensor chip and the protein A sensor surface was regenerated using 0.5 M 
glycine pH 2. For the pre-screening assay, 1:50 diluted clarified E. coli BL21 extracts were 
injected at 50 ml/min (see supplementary methods). 
 
Biological activity 
Cell line and treatment: Colo205 colon cancer cells, A2780 ovarium cancer cells, ML-1 
myeloid leukaemia cells and the BJAB cell lines were maintained in RPMI1640 medium, 
10% FCS, 1% penicillin, 1% streptomycin in humidified incubator, 37 °C, in 5 %CO2 
environment. In the medium of BJAB
DR5 DEF+DR5 cells puromycin (Sigma) was added to a 
final concentration of 1 mg/ml. TRAIL receptor inhibitors (neutralising antibodies) were 
always added 1h before TRAIL addition.  
Annexin V staining: The Colo205 cells and ML-1 cells were seeded the day before the 
experiment at 10
5 cells/ml in 24 well plates (1ml/well) were treated with 1 mg/ml of anti-
DR4 and/or anti-DR5 neutralising antibodies for 1h. 100 ng/ml  rhTRAIL  WT, D269H, 
D269H/E195R  or  D269H/T214R  was  added  to  the  cells  and  incubated  for  2h  and  30 
minutes. After treatment, the cells were harvested by scraping them gently off the wells and 
spun down. Control or treated Colo205 cells and ML-1 cells were harvested and collected 
by centrifugation, washed once in Annexin V incubation buffer and resuspended in 400ml 
fresh  incubation buffer. 1  ml Annexin V was added to the samples, incubated  at  room 
temperature for 10 minutes and measured immediately on a FACSCalibur Flow cytometer 
(Beckton Dickinson), results being expressed as % of Annexin V positive cells. 
MTT  assay:  MTT  assay  was  performed  as  described  before
65.  BJAB  cell  lines  were 
incubated with 1, 10 or 100 ng/ml TRAIL or D269H/E195R in the presence of 0.33 ug/ml 
cycloheximide (Sigma) and for the EC50 determination Colo205 cells were treated with 
serial dilutions (25 ng/ml-0 ng/ml) of TRAIL or mutants and cytotoxicity was determined 
as described before
65. EC50 values were calculated using a four parameter fit. 
 
￿ ￿ ￿ ￿ ￿ ￿ ￿￿ ￿￿ ￿ ￿ ￿ ￿!￿ ￿ ￿ ￿ ￿ ￿ ￿
 
Modeling of TRAIL-receptor Complexes. At present only crystal structures of TRAIL in 
complex with the DR5 receptor are known. The template selected was 1D4V
18, a structure 
at 2.2 Å resolution of human TRAIL in complex with the ectodomain of DR5 (TRAIL-R2) 
receptor. The complex of homotrimeric TRAIL and DR5 was generated using the protein 
quaternary  structure  server  from  the  European  Bioinformatics  Institute  (EBI) 
(http://pqs.ebi.ac.uk), using the symmetry coordinates in the PDB file. From the sequence 
alignment (Fig. 5A) of the different TRAIL receptors
187, it is observed that the receptor Chapter 4 
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cysteine-rich domains (CRDs) involved in the interaction with TRAIL (CRD2 and CRD3) 
are  highly  conserved,  with  the  exception  of  the  soluble  receptor  OPG.  Indeed,  when 
compared to DR5, the sequence identity of any other membrane-attached TRAIL receptor 
is >50% in each case, and there are neither insertions nor deletions in the sequence (with 
the exception of a glycine deletion in the middle of the CRD3 in DcR1). In addition, all the 
cysteines involved in the formation of internal disulfide bridges are conserved and share the 
same  sequence  position.  Thus  it  is  possible  to  build  homology  models  of  all  TRAIL 
receptors except for OPG. 
 
The  homology  models  were  built  using  the  WHAT  IF
186  web  interface 
(http://swift.cmbi.kun.nl/WIWWWI//).  The  receptor  models  were  superimposed  on  the 
DR5 receptor in complex with TRAIL, and after removal of the template receptor the initial 
complex models were obtained. Main chain conformation was not allowed to change during 
the homology modeling. After the reconstruction of the binding interfaces of TRAIL with 
the four different receptors a minimization round of 20 steps was performed, using Swiss-
Pdb viewer (http://www.expasy.org/spdbv/) (4). This procedure reduces the possibility of 
having false energetic values due to slight van der Waals clashes produced by the binding 
interface  reconstruction  without  changing  the  main  chain  conformation  significantly. 
Afterward,  these  models  were  refined  using  the  protein  design  options  of  FOLD-X, 
removing incorrect torsion angles, eliminating van der Waals clashes and accommodating 
TRAIL and  receptor  residues to their new interface.  Similar  results are obtained if  the 
whole modeling exercise is done directly with FOLD-X; however, with the current FOLD-
X version, the modeling is faster if WHAT IF is first used to place the side chains and 
subsequently followed by the use of FOLD-X to refine the structure (data not shown). 
 
The FOLD-X force field calculates the free energy of unfolding (￿G) of a target protein or 
protein complex combining the physical description of the interactions with empirical data 
obtained from experiments on proteins (5). Force field components (polar and hydrophobic 
solvation energies, van der Waals interactions, van der Waals clashes, H-bond energies, 
electrostatics in the complex and its effects on the rate of association (kon) and backbone 
and side chain entropies) are calculated evaluating the properties of the structure, such as its 
atomic  contact  map,  the  accessibility  of  its  atoms  and  residues,  the  backbone  dihedral 
angles,  the  H-bond  network  and  the  electrostatic  network  of  the  protein  (6).  Water 
molecules making two or more H-bonds with the protein are also taken into account
183. In 
addition, the modified version of FOLD-X used in this work
150 is able to perform amino 
acid  mutations  accommodating  this  new  residue  and  its  surrounding  amino  acids  the 
following way: It first mutates the selected position to alanine and annotates the side chain 
energies of the neighboring residues. Then it mutates this alanine to the selected amino acid 
and recalculates the side chain energies of the same neighboring residues. Those residues 
that exhibit an energy difference are then mutated to themselves to see whether another 
rotamer will be more favorable. This new feature allows proceeding through the whole 
computational  design  process  by  using  just  a  single  force  field,  avoiding  the  use  of 
PERLA
158,159 for rotamer substitution used in similar methodology works
65,85. 
 
Screening  for  selectivity  variants.  TRAIL  variant  constructs  were  transformed  to 
Escherichia coli BL21 (DE3) (Invitrogen). Variants and rhTRAIL WT were grown at a 10 Designed DR5 selective TRAIL variants 
 
  - 65 - 
ml scale by using a 2x LB medium. As controls, extracts of Escherichia Coli BL21 (DE3) 
without an overexpression plasmid and of an E. coli BL21 (DE3) culture with plasmid 
overexpressing SH3 domain were used. Cultures were grown as described in ref. 11. Cells 
were harvested by centrifugation. Pellet was resuspended in extraction buffer [PBS pH 7.4, 
10% (vol/vol) glycerol and Complete Protease Inhibitor Cocktail (Roche)] in 25% of the 
original volume. Cells were disrupted by using sonication, and extracts were clarified by 
centrifugation at 20,000 g. TRAIL variant protein  expression was assessed using SDS-
PAGE. Clarified extracts of variants that were well expressed were subsequently diluted 
1:50 in HBS-EP buffer (Biacore). These dilutions of the rhTRAIL WT and TRAIL variants 
were injected two-fold at a flow rate of 50 ml/min on a Biacore 2000. A Biacore CM5 
sensor chip coated with ￿1500 Resonance Units (RU) of the TRAIL receptors DR4-Ig and 
DR5-Ig.  A  channel  coated  with  ￿1500  RU  of  RANK-Ig  receptor  was  used  as  control 
surface. Binding of ligands to the receptors was monitored in real time. The receptor/sensor 
surface was regenerated using 3 M sodium acetate (pH 5.2) injections. Ratios of binding for 
the different receptors were calculated relative to DR4 or DR5 binding. 
 
Competitive ELISA. Nunc Maxisorb plates were coated for 2 h with DR5-Ig (100 ng per 
well) in 0.1 M sodium carbonate/bicarbonate buffer (pH 8.6), and remaining binding places 
were subsequently blocked with 2% BSA for 1 h. After washing for six times with Tris 
buffered saline/0.5% Tween 20 (TBST) (pH 7.5), preincubated (30 min) serial dilutions of 
soluble DR4-, DR5-, or DcR1-Ig (0-500 ng per well) and TRAIL or variants (10 ng per 
well) in PBS (pH 7.4) were added to the wells and incubated for 1 h at room temperature. 
After washing six times with TBST, a 1:200 dilution of anti-TRAIL antibody  (R & D 
systems) was added and incubated for 1 h at room temperature, and, after washing six times 
with TBST, subsequently incubated with a 1:25,000 dilution of a horse radish peroxidase-
conjugated swine-anti-goat antibody. After washing six times with TBST, 100 ml of 1-step 
Turbo TMB solution (Pierce) was added, and after ￿15 min, the reaction was quenched 
with 100 ml 1 M sulfuric acid. The absorbance was measured at 450 nM on a microplate 
reader  (Thermolab systems, Breda, The Netherlands).  Binding of TRAIL or variants to 
immobilized DR5-Ig with 0 ng per well of the soluble receptors was taken as 100%, and 
binding at other concentrations of soluble receptors was calculated relative to 0 ng per well 
of soluble receptor. 
 
￿ ￿ ￿ ￿￿ "￿ ￿ ￿ ￿ ￿ ￿￿ ￿￿ ￿ ￿
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￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿
Tumor  necrosis  factor-related  apoptosis  inducing  ligand  (TRAIL)  is  a  potential 
anticancer  drug  that  selectively  induces  apoptosis  in  a  variety  of  cancer  cells  by 
interacting  with  death  receptors  DR4  and  DR5.  TRAIL  can  also  bind  to  decoy 
receptors  (DcR1,  DcR2  and  OPG  receptor)  that  cannot  induce  apoptosis.  The 
expression levels of DR4 and/or DR5 can be up-regulated in cancer cells in response to 
certain chemotherapeutic drugs. DR4 and DR5 receptor specific TRAIL variants will 
permit  new  and  tumor  selective  therapies.  The  existence  of  certain  cancer  cells 
exclusively  responding  to  DR4-mediated  apoptosis,  prompted  us  to  make  a  DR4 
selective TRAIL variant using computational protein design. Technically, the design 
of DR4 receptor selective TRAIL variants is still a considerable challenge due to the 
lack of a crystal structure  of the TRAIL-DR4 complex. Nevertheless, our cell line 
assays  indicate  that  the  first  designed  variants  induce  apoptosis  preferentially  via 
DR4. Towards the design of a DR4 selective TRAIL variant 
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￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿
Tumor  necrosis  factor  (TNF)  related  apoptosis  inducing-ligand  (TRAIL)  is  currently 
attracting great interest as a potential anti-cancer therapeutic. TRAIL in its soluble form 
selectively  induces  apoptosis  in  tumor  cells,  in  vitro  and  in  vivo,  by  a  death  receptor 
mediated process. Unlike other apoptosis inducing TNF family members, soluble TRAIL 
appears  to  be  inactive  against  normal  healthy  tissue
13.  TRAIL  shows  a  high  degree  of 
promiscuity as it binds to five cognate receptors; DR4 (TRAIL-R1) and DR5 (TRAIL-R2) 
and to the decoy receptors DcR1 (TRAIL-R3), DcR2 (TRAIL-R4) and Osteoprotegerin 
(OPG)
19. Upon binding to TRAIL, DR4 and DR5 receptors recruit Fas associated death 
domain (FADD)
20-22, which bind and activate the initiator caspases 8 and 10, leading to 
apoptosis
23-26. DcR1 or DcR2 do not contain a death domain or contain a truncated death 
domain, respectively, and binding to these receptors does not induce apoptosis. In contrast, 
decoy receptors could prevent apoptosis by sequestering available TRAIL or by interfering 
in the formation of a TRAIL-DR4 or -DR5 signaling complex
30. 
 
Use of DR4-receptor selective variants could permit better tumor specific therapies through 
escape from the decoy receptor-mediated antagonism, resulting in a higher efficacy with 
possibly less side effects as compared to rhTRAIL WT
179-181. Receptors DR4 and/or DR5 
were  shown  to  be  up-regulated  after  treatment  with  DNA  damaging  chemotherapeutic 
drugs  and  the  response  to  TRAIL-induced  apoptosis  was  significantly  increased
19,182. 
Previously, we described the design of DR5 selective TRAIL variants
108. These variants 
showed an increased affinity for the DR5 receptor and decreased affinities for the DR4 and 
decoy receptors. The existence of certain cancer cells only responding to DR4-mediated 
apoptosis
108 and favorable results obtained with agonistic anti-DR4 antibodies
192, prompted 
us to design a DR4 selective TRAIL variant. Moreover, it was recently demonstrated that 
primary cells isolated from patients with chronic lymphocytic leukemia and mantle cell 
lymphoma were almost exclusively sensitive to DR4 mediated apoptosis
193,194.  
 
In view of the observed lower affinity of rhTRAIL WT for DR4 than DR5
108,188, the design 
of  an  effective  DR4  selective  TRAIL  variant  preferably  not  only  aims  at  decreased 
affinities  for  DR5  and  decoy  receptors,  but  also  at  an  enhanced  affinity  for  DR4. 
Consequently,  it  is  essential  to  combine  a  positive  design  strategy  strengthening  the 
interactions  between  TRAIL  and  DR4  with  a  negative  strategy  that  designs  mutations 
disrupting  interactions  between  TRAIL  and  the  other  receptors.  Generally,  it  is  less 
demanding to disrupt an existing interaction (or create an unfavorable one) by an amino 
acid substitution, than to create a new favorable interaction. A high quality structural model 
describing  all  the  relevant  interactions  between  the  interacting  partners  is  therefore  of 
paramount importance. As no crystal structure of the TRAIL-DR4 complex is available, the 
design  of  a  DR4  selective  variant  therefore  critically  depends  on  the  quality  of  the 
homology model of the TRAIL-DR4 complex. We demonstrate here that the computational 
design of DR4-specific rhTRAIL variants is possible using a high quality homology model. 
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￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿
 
Selectivity Design 
For the design of a DR4 selective TRAIL variant, the procedure as previously used for the 
design of the DR5 selective TRAIL variants was used
108. In short, the receptor binding 
interface of TRAIL was screened for single amino acid substitutions increasing the affinity 
for the DR4 receptor (=decreasing interaction energy (￿￿Gi)) or decreasing the affinity for 
DR5 and the decoy receptors. For the TRAIL-DR5-receptor complex a crystal structure was 
used and for the TRAIL-DR4-receptor complex a homology model consisting of TRAIL in 
complex with cysteine rich domains (CRDs) 2 and 3 of DR4 was constructed based on the 
TRAIL-DR5-receptor complex. FOLD-X was used to model and refine the TRAIL-DR4 
receptor complex model. The accuracy of the models and the force field was tested using 
the  affinity  data  derived  from  the  alanine  scanning  of  rhTRAIL  WT  as  performed  by 
Hymowitz  et  al. 
17.  The  predictions  of  the  energy  change  in  the  complex  formation 
correlates with the changes in the dissociation constants measured
108. This implies that our 
method can reliably predict mutations at residue positions located at the receptor binding 
interface which will most severely affect the complex formation. 
The  FOLD-X  design  process  proposed  several  TRAIL  receptor  interface  positions  and 
(single)  amino-acid  substitutions  important  for  obtaining  DR4  selectivity.  One  of  the 
proposed mutations, K201R, was already present in a sextuple mutant selected by Kelley et 
al.,
109 again underlining the correctness of the DR4 model. In addition, new amino acid 
substitutions were calculated that have not been described before. From these, the D218Y 
and D218H mutations were predicted to cause the highest change in DR4 selectivity by 
improving the interaction with DR4 and decreasing the interaction with DR5 (figure 1). All 
mutations were made, produced and purified as described before
65,108. 
 
Figure 1. Results of FOLD-X calculation. A negative DDGi indicates an improvement in receptor binding and a 
positive DDGi indicates a decrease in receptor binding. 
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Receptor binding 
Binding of the purified ligands to immobilized DR4- and DR5-Ig receptor chimeras was 
assessed  in  real-time  using  surface  plasmon  resonance  (SPR).  Receptor  binding  curves 
were recorded ranging from 0.5 nM to 250 nM (D218H) or 1 nM to 500 nM (D218Y) at 25
 
oC. The binding of D218Y and D218H towards immobilized DR5 Ig was more than 7-fold 
decreased  when  compared  to  rhTRAIL  WT  (rhTRAIL  WT).  In  contrast,  binding  to 
immobilized DR4 Ig remained almost unchanged (figure 2A and B). These results show 
that the D218Y and D218H variants have become DR4 selective compared to rhTRAIL 
WT. As the DR4- and DR5-Ig chimera preparations were formulated with bovine serum 
albumin (BSA) upon lyophilization to stabilize the receptor chimera proteins, it was hard to 
precisely determine the exact amount of immobilized receptor chimeras. From maximum 
binding  responses,  it  could  be  estimated  that  approximately  10  %  of  the  immobilized 
protein was receptor-Ig conjugate. 
 
Figure 2. (A) Receptor binding of rhTRAIL WT and D218Y towards DR5-Ig as determined by SPR. (B) or 
towards DR4-Ig. (C) Receptor binding of rhTRAIL WT and D218Y or (D) towards DR4-Ig. Receptor binding was 
determined at 25 
oC. DR4-Ig and DR5-Ig preparations formulated with BSA were immobilized on the sensor 
surface. Binding is calculated relative to the response of rhTRAIL WT at 250 nM. 
 
In  order  to  increase  the  signal  to  noise  ratio  it  was  decided  to  use  DR4-  and  DR5-Ig 
receptor  chimeras  lyophilized  without  additional  BSA.  This  allowed  a  more  precise 
determination of the amount of receptor chimera immobilized on the SPR sensor surface. A 
SPR sensor chip was coated with ~800 RU of DR4 and DR5-Ig receptors, and receptor 
binding curves were recorded at 25
 oC in real time at concentrations ranging from 0.5 nM to 
250 nM of rhTRAIL WT, D218H and D218Y, respectively. As expected the measured 
response (in RU) was substantially increased. Unexpectedly, in this experiment the affinity 
of D218Y and D218H variants appeared to be decreased not only for the DR5 but also for 
the DR4 receptor (Figure 3A and B). Under these experimental conditions no change in 
receptor  selectivity  could  be  determined.  The  observed  decrease  in  affinity  for  both 
receptors appeared not to change the DR4/DR5 receptor binding ratio. At this moment the 
reason for these deviating binding curves in presence and absence of BSA is not clear. It 
seems not logical that the presence of BSA would influence the DR4/DR5 binding ratio due 
to  non  specific  interactions  since  binding  to  both  DR4  and  DR5  was  simultaneously 
recorded.  Any  non  specific  interactions  should  then  have  been  observed  in  both Chapter 5 
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sensorgrams. It should be realized that the SPR assay used for TRAIL-DR4 and -DR5 is not 
a simple 1:1 binding event; the injected TRAIL trimer has three receptor binding interfaces 
and the immobilized DR4- and DR5-Ig receptors are dimeric Fc construct based chimeras. 
Receptor chimera coating density dependent ligand binding effects can not be excluded, as 
it  has been shown that several TNF-R family  members including  the TRAIL  receptors 
contain a pre-ligand assembly domain (PLAD)
7,31, causing receptor oligomerization in the 
absence of ligand. Such effects are not easily detected since differences in immobilization 
densities  not  necessarily  correlate  to  differences  in  physical  densities  on  the  flow  cell 
surface; immobilization may primarily occur at the beginning of the flow cell, depending 
on the flow during immobilisation. Further testing is needed to clear this.  
 
Figure 3. (A) Receptor binding of rhTRAIL WT, D218H and D218Y towards DR5-Ig as determined by SPR at 25 
oC. (B) or towards DR4-Ig at 25 
oC. DR4 and DR5-Ig preparations formulated without BSA were immobilized on 
the sensor surface. Binding is calculated relative to the response of rhTRAIL WT at 250 nM. 
Interestingly, it has been reported that the affinity between rhTRAIL WT and especially 
DR4 is strongly dependent on temperature
188. However, no significant changes in binding 
to DR4 or DR5 were observed for rhTRAIL WT, D218H and D218Y when repeating the 
assay at a temperature of 37
 oC (Figure 4 A and B). 
 
Figure 4. (A) Receptor binding of rhTRAIL WT, D218H and D218Y towards DR5-Ig as determined by SPR at 37 
oC. (B) or towards DR4-Ig at 37 
oC. DR4 and DR5-Ig preparations formulated without BSA were immobilized on 
the sensor surface. Binding is calculated relative to the response of rhTRAIL WT at 250 nM. Towards the design of a DR4 selective TRAIL variant 
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Extra experiments need to be performed to determine the cause of the observed differences 
between DR4 and DR5-Ig preparations with and without BSA. Visual inspection of the 
sensorgrams measured at 25
  oC revealed that rhTRAIL WT virtually lacked an off-rate 
while  both  D218H  and  D218Y  showed  an  initial  increased  off-rate  at  both  receptors. 
However, the off-rate of D218H at DR4 appeared to be smaller than the off-rate of D218Y 
at DR4 while having approximately the same off-rate at the DR5 receptor, indicating that 
the affinity of D218H for DR4 might be higher than the affinity of D218Y for DR4 (Figure 
5). 
 
 
Figure 5. Time versus response SPR sensorgrams. (A) Receptor binding of rhTRAIL WT, D218H and D218Y 
towards DR5-Ig as determined by SPR at 25 
oC. (B) or towards DR4-Ig at 25
 oC. Depicted are the responses to 
concentrations of TRAIL or variants ranging from 250 nM to 0.5 nM. 
 
Biological activity 
To test the biological activity of D218Y and D218H variants, Colo205 and EM-2 cells were 
treated with this variant.  Previously, it was established that Colo205 cells are sensitive 
towards TRAIL-induced apoptosis primarily mediated by DR5
108. ML-1 cells, in contrast, 
are mainly sensitive towards TRAIL-induced apoptosis mediated by DR4
108. The EM-2 cell 
line expresses only the DR4 receptor and hence is only sensitive towards TRAIL-induced 
apoptosis  mediated  by  the  DR4  receptor
108.  In  Colo205  a  large  decrease  in  apoptosis 
inducing activity of D218Y and D218H was observed when compared to rhTRAIL WT and 
the DR5 selective D269HE195R variant (figure 6a). In contrast, in cell lines EM-2 and ML-
1, D218Y and D218H variants were able to efficiently induce apoptosis at concentrations 
above 100  ng/ml  (Figure  6B  and C)  whereas  the  DR5 selective  variant  D269H/E195R 
essentially  lacks  apoptosis  inducing  activity.  The  D218H  showed  enhanced  apoptosis 
inducing activity when compared to D218Y but both variants are considerably less active 
than  rhTRAIL  WT.  With  regard  to  potential  DR4  selective  behavior  it  is  important  to 
correct for rhTRAIL WT sensitivity and to determine at what concentration the variants in 
comparison  with  rhTRAIL  WT  start  to  induce  apoptosis  (figure  7).  In  Colo205  cells Chapter 5 
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rhTRAIL WT induces a maximum level of apoptosis at a protein concentration of ~20 
ng/ml. In ML-1 and EM-2 cells rhTRAIL WT induces a maximum level of apoptosis at a 
concentration of ~100 ng/ml.  
 
 
Figure  6.  Biological  activity  of  rhTRAIL  WT,  D218Y  and  D218H  variants  and  the  DR5  selective  ligand 
D269HE195R in DR5 sensitive Colo205 cells and in DR4 sensitive ML-1 and EM-2 cells. Percentage apoptosis 
was measured as percentage Annexin V positivity after 3 hrs of incubation. 
While  in  Colo205  cells  no  significant  apoptosis  is  induced  by  the  D218Y  variant  at  a 
concentration of 20 ng/ml, the D218Y variant is able to induce a significant amount of 
apoptosis  in  EM-2  cells  and  in  ML-1  cells  at  a  concentration  of  100  ng/ml.  This  is 
illustrated  in  figure  6  for  rhTRAIL  WT,  D218Y  and  the  DR5  selective  variant 
D269H/E195R. Whereas the D218Y ligand is able to efficiently induce apoptosis in EM-2 
cells, it shows a marked decrease in biological activity in Colo205 cells (figure 6). Taken 
together,  these  results  indicate  that  the  D218Y  and  D218H  variants  induce  apoptosis 
preferentially via DR4. 
 
 ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿
 
TRAIL interacts with five different receptors of the TNF-R family; however, only receptors 
DR4 and DR5 transmit the apoptosis inducing signal. Interestingly, it was shown that the 
expression levels of DR4 and/or DR5 were up-regulated  in cancer cells in  response to Towards the design of a DR4 selective TRAIL variant 
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certain  chemotherapeutic  drugs
19.  Previously  we  used  computational  protein  design  to 
construct a DR5 receptor selective TRAIL variant
108. The existence of certain cancer cells 
exclusively responding to DR4-mediated apoptosis
108 and favorable results obtained with 
agonistic anti-DR4 antibodies
192, encouraged us to design a DR4 selective TRAIL variant 
using computational protein design. 
 
Figure 7. Biological activity of rhTRAIL WT, the D218Y variant and the DR5 selective ligand D269H/E195R in 
DR5 sensitive Colo205 cells and in DR4 sensitive EM-2 cells. Percentage apoptosis was measured as percentage 
Annexin V positivity after 3 hrs of incubation with 20 ng/ml (Colo205) or 100 ng/ml (EM-2) of rhTRAIL WT or 
variant. These concentrations were chosen as these are the concentrations were rhTRAIL WT starts to show its 
maximum apoptosis inducing activity. Apoptosis inducing activity is calculated relative to the apoptosis inducing 
activity of rhTRAIL WT at these concentrations. 
 
It was demonstrated by us and  others that computational protein design  methods  are  a 
valuable addition to other established protein engineering methodologies, such as directed 
evolution methods using phage display, as a tool for the improvement and modification of 
protein-protein interactions
85-87,89,104,108. Kelley et al., recently described a DR4 selective 
TRAIL  variant  selected  from  a  TRAIL  saturation  mutagenesis  library  using  phage 
display
109. However, subsequent analysis revealed that this DR4 selective TRAIL variant—
comprising of 6 mutations relative to rhTRAIL WT—was biologically largely inactive
194. 
Biological activity was restored partially after changing one of the mutations back to the 
wild-type amino acid
194. In this study we focused on position Asp 218 predicted by the 
FOLD-X  algorithm  to  be  important  for  selectivity  towards  the  DR4  receptor  and  not 
identified before with the phage-display approach of Kelley et al. Although the biological 
activity data indicate that the D218Y and D218H variants induce apoptosis preferentially 
via DR4 and thus seem DR4 selective, the SPR receptor binding data prevent any definitive 
conclusions with regard to receptor binding. Additional experiments have to be performed 
to resolve remaining questions; e.g. DR4 receptor coating density dependent effects on 
ligand binding have to be investigated. In addition, the biological activity of the D218H and 
D218Y variants should also be determined in a DR5 deficient cell line, e.g. A2780, as at 
higher protein concentrations Colo205 cells are sensitive towards DR4 mediated TRAIL-
induced apoptosis. In any case, the goal to design a high affinity DR4 selective variant has 
not been fully reached yet. The lack of clear success in the design of a DR4 selective Chapter 5 
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TRAIL variant with high affinity for the DR4 receptor can, at least in part, be attributed to 
the quality of the TRAIL-DR4 homology model. Despite the validation of the currently 
used TRAIL-DR4 model, apparently not all important interactions are correctly captured in 
this model. As the computational protein design process critically depends on the quality of 
this DR4 homology model, improving the accuracy of the model is therefore of paramount 
importance.  Allowing  protein  backbone  flexibility  in  the  construction  of  the  binding 
interface between TRAIL and the DR4 receptor will probably already improve the quality 
of  the  model.  Additional  options  are  also  available,  short  of  determining  the  crystal 
structure  of  the  TRAIL-DR4  complex.  Although  computationally  demanding,  recent 
advantages in homology modeling
195, in de novo protein structure prediction
149 and protein-
protein docking will eventually allow the prediction of more accurate structural models of 
target complexes
196. This in turn will allow more accurate designs with a reduced amount of 
false  positive  and  false  negative  predictions.  An  alternative  approach  would  be  to  use 
computational design to construct a library of (putative) receptor selective TRAIL variants 
enriched for structural stability and combing this with an in vitro screening or selection 
procedure to select the most receptor selective variants. Such an enriched library approach 
would allow the use of relatively coarse homology  models to populate the library with 
amino acid substitutions having a putative receptor selective effect. High resolution crystal 
structural data of TRAIL can be used to assess the structural stability of the proposed amino 
acids substitutions  and  finally  include  only  the  structural  favorable  ones  in  the  library. 
Structural stability of TRAIL can already be predicted as demonstrated by us in a previous 
work
65 and the concept of using computational design to devise “enriched libraries” has 
also been successfully demonstrated
100,146. 
 
In summary, the first design predictions for DR4 selective rhTRAIL variants resulted in 
variants  that  do  show  DR4  specificity  in  cell  line  assays.  Preliminary  analytical  SPR 
binding tests showed under standard conditions (immobilized receptor in presence of BSA) 
a lowered DR5 affinity and unchanged DR4 affinity in concert with the increased DR4 
specificity.  However, these binding studies  were not conclusive in experiments without 
BSA. 
In order to design a variant with higher affinity for the DR4 receptor the currently used 
homology  model  of  the  TRAIL-DR4  complex  needs  to  be  refined.  The  computational 
method used in our study is based on general applicable principles and it can be used on 
any other protein as template structure, spanning the whole sequence and structure space of 
protein families and protein folds. This was convincingly demonstrated in other protein 
design works using FOLD-X
65,85,108,183-185,197. From a practical point of view, the FOLD-X 
computational design algorithm enables one to modify several key properties of proteins 
within a short time frame. Using directed evolution methods, the time from creating initial 
target diversity to obtain—by several rounds of selection—the final target can take several 
months to complete. In contrast, the time from initial design to the final target using a 
computational  design  method  is  substantially  shorter.  However,  these  methods  are  not 
necessarily  mutually  exclusive;  combining  computationally  designed  “quality  enriched 
libraries”  and  in  vitro  screening  or  selection  techniques  combines  the  best  of  both 
methodologies,  especially  in  cases  when  accurate  structural  information  is  lacking. 
Computational design methods in combination with de novo structure prediction methods Towards the design of a DR4 selective TRAIL variant 
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and/or in combination with traditional screening or selections methods will become tools of 
increasing importance in the development of successful protein therapeutics. 
 
!￿ ￿ ￿ ￿ ￿ ￿ ￿
￿
All  reagents  were  of  analytical  grade  unless  specified  otherwise.  Isopropyl-b-D-1-
thiogalactoside  (IPTG),  ampicillin  and  dithiotreitol  (DTT)  were  from  Duchefa. 
Chromatographic  columns  and  media  were  from  Amersham  Biosciences.  Restriction 
enzymes used were purchased from New England Biolabs. Recombinant TRAIL-receptor 
Ig fusion proteins formulated with and without BSA were ordered from R&D systems. All 
other chemicals were from Sigma.  
 
Modeling of TRAIL-receptor complexes 
At present only crystal structures of TRAIL in complex with the DR5 receptor are known. 
The template selected was 1D4V
18, the structure at 2.2 Å resolution and of monomeric 
human  TRAIL  in  complex  with  the  ectodomain  of  DR5  (TRAIL-R2)  receptor.  The 
homotrimer  was  generated  using  the  protein  quaternary  structure  server  from  the  EBI 
(http://pqs.ebi.ac.uk), having the symmetry coordinates in the PDB file. From the sequence 
alignment of the different TRAIL receptors
187 it is observed that the receptor cysteine rich 
domains (CRDs) involved in the interaction with TRAIL (CRD2 and CRD3) are highly 
conserved, with the exception of the soluble receptor OPG
108. Indeed, when compared to 
DR5, the sequence identity of any other membrane-attached TRAIL receptor is higher than 
50% in each case, and there are neither insertions nor deletions in the sequence (with the 
exception of a glycine deletion in the middle of the CRD3 in DcR1). In addition, all the 
cysteines involved in the formation of internal disulfide bridges are conserved and share the 
same  sequence  position.  Thus  it  is  possible  to  build  homology  models  of  all  TRAIL 
receptors except for OPG. The homology models were built using the WHAT IF
186 web 
interface (http://swift.cmbi.kun.nl/WIWWWI//), using the above mentioned template. The 
receptor models were superimposed on the structure of the TRAIL-DR5 complex, and after 
removal of the template receptor the initial complex models were obtained. Afterwards, 
these models were refined using the protein design options of FOLD-X, removing incorrect 
side chain torsion angles, eliminating Van der Waals clashes and accommodating TRAIL 
and receptor residues to their new interface (see Methods). Similar results are obtained if 
the whole modelling exercise is done directly with FOLD-X, however with the current 
FOLD-X version the modelling is faster if WHAT IF is used first to place the side chains, 
subsequently followed by the use of FOLD-X to refine the structure (data not shown). 
 
Computational design of the mutants 
A detailed description of the empirical force field FOLD-X is available elsewhere
160 (and at 
http://fold-x.embl-heidelberg.de).  Briefly,  this  force  field  calculates  the  free  energy  of 
unfolding (￿G) of a target protein or protein complex combining the physical description of 
the interactions with empirical data obtained from experiments on proteins. Force  field 
components (polar and hydrophobic solvation energies, van der Waals’ interactions, van 
der Waals clashes, H-bond energies, electrostatics in the complex and its effects on the kon 
and  backbone  and  side  chain  entropies)  are  calculated  evaluating  the  properties  of  the 
structure, such as its atomic contact map, the accessibility of its atoms and residues, the Chapter 5 
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backbone dihedral angles, the H-bond network and the electrostatic network of the protein. 
Water  molecules  making  two  or  more  H-bonds  with  the  protein  are  also  taken  into 
account
183. 
 
In addition, the modified version of FOLD-X used in this work
150 is able to perform amino 
acid  mutations  accommodating  this  new  residue  and  its  surrounding  amino  acids  the 
following way: It first mutates the selected position to alanine and annotates the side chain 
energies of the neighbour residues. Then it mutates this alanine to the selected amino acid 
and  re-calculates  the  side  chain  energies  of  the  same  neighboring  residues.  Those  that 
exhibit an energy difference are then mutated to themselves to see if another rotamer will 
be more favorable. 
 
This procedure was also used to reconstruct the binding interface of TRAIL in complex 
with the modeled receptors DR4, DcR1 and DcR2 in order to repair residues with bad 
torsion angles or with Van der Waals’ clashes between TRAIL and receptor residues, and to 
build up the putative interactions between TRAIL and the three non-crystallized receptors 
through rotamer substitution (see above). The crystal complex structure of TRAIL with 
DR5 receptor was also refined this way. 
 
This new feature allows proceeding through the whole computational design process using 
just one single force field, avoiding the use of PERLA
158,159 for rotamer substitution used in 
similar methodology works
65,85.  
 
 
Side directed mutagenesis, Expression and Purification of selectivity mutants 
cDNA  corresponding  to  human  soluble  TRAIL  (aa  114-281)  was  cloned  in  pET15B 
(Novagen) using NcoI and BamHI restriction sites. Mutants were constructed by PCR as 
described before.
65 Homotrimeric TRAIL proteins were purified using a 3 step purification 
as described before
65. 
 
Determination of Receptor binding 
Binding experiments were performed using a surface plasmon resonance-based biosensor 
Biacore 3000 (Biacore AB, Uppsala, Sweden), at 25
 oC or at 37
 oC. Immobilization of the 
DR4-Ig and DR5-Ig receptors on the sensor surface of a Biacore CM5 sensor chip was 
performed following a standard amine coupling procedure according to the manufacturer’s 
instructions at 25
 oC. Receptors or receptors and BSA were coated at a level of ~600-800 
RU.  Purified  TRAIL  and  TRAIL  mutants  were  injected  in  three-fold  at  concentrations 
ranging from 250 nM to 0.1 nM at 70 ml/min flow rate. Binding of ligands to the receptors 
was monitored in real-time. Between injections the receptor/sensor surface was regenerated 
using  3  M  sodium  acetate  pH  5.2  injections  in  case  of  DR4-Ig  and  DR5-Ig  chimeras 
formulated with BSA or with a 1:1 mixture of 10  mM  glycine, 1.5 M NaCl pH2 and 
ethylene  glycol  in  case  of  regenerating  immobilized  DR4-Ig  and  DR5-Ig  chimeras 
formulated without BSA. 
 Towards the design of a DR4 selective TRAIL variant 
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Biological activity 
Cell line and treatment: Colo205 colon cancer cells, ML-1 myeloid leukaemia cells and the 
EM-2  cell  lines  were  maintained  in  RPMI1640  medium,  10%  FCS,  1%  penicillin,  1% 
streptomycin in humidified incubator, 37 °C, in 5 % CO2 environment. Annexin V staining: 
The Colo205 cells, EM-2 cells and ML-1 cells were seeded the day before the experiment 
at 10
5 cells/ml in 24 well plates (1ml/well). Concentrations ranging from 10-250 ng/ml 
rhTRAIL WT, D269HE195R, D218H or D218Y was added to the cells and incubated for 
2h and 30 minutes. After treatment, the cells were harvested by scraping them gently off the 
wells and spun down. Control or treated Colo205 cells, EM-2 cells and ML-1 cells were 
harvested and collected by centrifugation, washed once in Annexin V incubation buffer and 
resuspended in 400 ml fresh incubation buffer. 1 ml Annexin V was added to the samples, 
incubated  at  room  temperature  for  10  minutes  and  measured  immediately  on  a 
FACSCalibur  Flow  cytometer  (Beckton  Dickinson),  results  were  expressed  as  %  of 
Annexin V positive cells.  
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￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿
Combination treatment with radiation therapy or chemotherapy can sensitize TRAIL 
resistant tumor cells and vice versa. In this study, we show that treatment of TRAIL 
resistant HeLa S3 cells with 10 m m m mM of the proteasome inhibitor MG132 combined with 
a low concentration (10 ng/ml) of a DR5 selective TRAIL variant is able to induce 
apoptosis  in  this  cell  line  in  a  synergistic  fashion.  Moreover,  this  combination  is 
significantly  more  potent  than  similar  concentrations  of  MG132  and  rhTRAIL. 
Preliminary results suggest that also  the  sequential combination of  10  Gg g g g ionizing 
radiation and low concentrations (5-10 ng/ml) of the DR5 selective TRAIL variant is 
able to induce significantly more apoptosis in HeLa S3 cells than either treatment 
alone and that this combination is more potent than 10 Gg g g g ionizing radiation and 5-10 
ng/ml rhTRAIL. Although the exact molecular mechanism of the enhanced potency of 
the DR5 selective TRAIL variant when used in combination with radiotherapy or a 
proteasome  inhibitor  remains  to  be  elucidated,  DR5  receptor  selective  TRAIL 
variants permit novel targeted and tumor selective anti-cancer therapies. Enhanced anti-cancer activity of a DR5 selective TRAIL variant 
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￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿
Tumor  necrosis  factor  (TNF)  related  apoptosis  inducing-ligand  (TRAIL)  is  currently 
attracting  great  interest  as  a  potential  cancer  therapeutic.  TRAIL  in  its  soluble  form 
selectively  induces  apoptosis  in  tumor  cells  in  vitro  and  in  vivo  in  several  preclinical 
models
19. TRAIL binds to five cognate receptors; to the death receptors DR4 (TRAIL-R1) 
and DR5 (TRAIL-R2) and to the decoy receptors DcR1 (TRAIL-R3), DcR2 (TRAIL-R4) 
and osteoprotegerin (OPG)
19. Binding of TRAIL to the DR4 and DR5 receptors induces 
apoptosis by activating the cell-extrinsic or death receptor-mediated apoptosis pathway. 
Upon binding with TRAIL the death receptors trimerize and an intracellular death-inducing 
signaling complex (DISC) is assembled; the intracellular death domains of DR4 and DR5 
recruit Fas associated death domain (FADD)
20-22, which bind and activate the apoptosis 
initiator caspases 8 and 10
23-26. This leads to the activation of the apoptosis executioner 
caspase 3, followed by the activation of other proteases and nucleases resulting finally in 
apoptosis
27,28. This process can be inhibited by the cellular FLICE like-inhibitory protein 
(cFLIP), an inhibitor of caspase activation, or by inhibitor of apoptosis proteins (IAPs) such 
as  X-IAP
29.  DcR1  or  DcR2  do  not  contain  an  intracellular  death  domain  or  contain  a 
truncated death domain, respectively. Binding to these receptors does not induce apoptosis, 
in contrast, it could prevent apoptosis by sequestering available TRAIL or by interfering in 
the formation of a TRAIL DR4 or DR5 signaling complex
30. The physiological relevance 
of the third decoy receptor OPG is unclear; this soluble receptor is able to bind TRAIL 
although the affinity at physiological temperature is rather low
188. Recently, we designed 
DR5 selective TRAIL variants, which show reduced binding to the DR4 receptor as well as 
reduced binding to both decoy receptors and OPG
108. 
 
It  has  been  shown  that  TRAIL  treatment  enhances  the  efficacy  of  irradiation  and 
chemotherapeutic  treatment  or,  alternatively,  these  treatments  can  resensitize  TRAIL 
resistant tumor cells
198. Moreover, in experimental anti-cancer treatment, the receptors DR4 
and/or DR5 were shown to be up-regulated after treatment with chemotherapeutic drugs or 
irradiation  and  the  response  to  TRAIL-induced  apoptosis  was  significantly 
increased
19,107,182. Exposure to most anticancer chemotherapeutics and irradiation triggers 
the cell-intrinsic or mitochondrial apoptosis pathway, this in contrast to TRAIL treatment 
which  induces  the  cell-extrinsic  or  death  receptor-mediated  apoptosis  pathway
28.  Upon 
activation  of  the  cell-intrinsic  or  mitochondrial  pathway  by  DNA  damaging 
chemotherapeutics  or  irradiation,  apoptogenic  factors  such  as  cytochrome-c  and 
smac/diablo are released from the mitochondria into the cytosol by pro-apoptotic members 
of  the  Bcl-2  family.  Cytochrome-c  binds  in  the  cytosol  the  adaptor  protein  apoptosis–
activating  factor-1  (Apaf-1),  forming  an  “apoptosome”  resulting  in  the  recruitment  and 
activation of apoptosis initiator caspase—caspase 9—of the cell-intrinsic pathway. Similar 
to the activation of the initiator caspase of the death receptor-mediated apoptosis pathway, 
activation of caspase 9 also results in the activation of the downstream “executioner” or 
effector caspases (caspase 3, 6 and 7), ultimately resulting in apoptosis
105,199. 
 
The death receptor-mediated pathway and the mitochondrial pathway are connected via the 
pro-apoptotic Bcl-2 family member Bid, a substrate of caspase 3 and 8. Depending on the 
particular cell type, activation of the effector caspases (e.g. caspase 3) is induced directly 
after stimulating the death-receptor pathway and subsequent activation of caspase 8 (type I Chapter 6 
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cells).  However  in  type  II  cells,  amplification  via  the  mitochondrial  pathway  through 
activated truncated Bid (tBid) is required to activate the effector caspases. Translocation of 
tBid  to  the  mitochondria  triggers  the  release  of  cytochrome-c  and  smac/diablo,  in 
cooperation with two other pro-apoptotic Bcl-2 family members Bak or Bax. A decrease in 
expression  levels  of  these  pro-apoptotic  Bcl-2  family  members  or  increases  in  the 
expression levels of anti-apoptotic Bcl-2 family members such as Bcl-2 or Bcl-xL, disrupts 
apoptotic  signaling  of  the  cell-intrinsic  pathway  and  causing  resistance  to  anticancer 
therapy
19,29,198. 
 
Whereas apoptosis induction by the intrinsic pathway often depends on the presence of 
functional p53, TRAIL has been shown to induce apoptosis independently of p53 function. 
Irradiation appears to specifically up-regulate DR5 receptor expression and the combination 
of  irradiation  and  TRAIL  treatment  has  been  demonstrated  to  have  an  additive  or 
synergistic effect
107,200. Up-regulation of DR5 receptor expression in response to irradiation 
was  demonstrated  being  both  dependent  as  well  as  independent  on  the  presence  of 
functional p53
200-202. Treatment with proteasome inhibitors have also been reported to up-
regulate  DR5 and/or DR4 receptor expression
203-205. Proteasome inhibitors can sensitize 
tumor cells to TRAIL-mediated apoptosis by several mechanisms including, inactivation of 
the nuclear factor kappa Beta (NF-kB) pathway, modulating the balance between pro- and 
anti-apoptotic  Bcl-2  members  resulting  in  the  accumulation  of  pro-apoptotic  members, 
reducing levels of IAPs (e.g. X-IAP), reduction of cFLIP levels, or reduced degradation of 
p53.  In  the  present  study,  we  have  investigated  the  co-treatment  of  TRAIL  or  a  DR5 
selective variant in combination with a proteasome inhibitor or irradiation in the human 
cervical  cancer  cell  line  HeLa  S3.  We  reasoned  that  a  DR5  receptor  selective  TRAIL 
variant in combination with irradiation or a proteasome inhibitor might show enhanced 
synergistic or additive activity when compared to rhTRAIL WT in apoptosis induction. The 
HeLa S3 cell line has a wild type functional p53
206 and harbors the HPV18 oncogene
207. 
This oncogene encodes the HPV E6 protein which inactivates p53 by targeting it to the 
proteasome for degradation
208. In addition, this cell line is only slightly sensitive to TRAIL 
induced  apoptosis  but  can  be  sensitized  when  treated  with  a  proteasome  inhibitor
205. 
Preliminary results indicate an enhanced synergistic behavior between the DR5 selective 
TRAIL variant in combination with a proteasome inhibitor or irradiation when compared to 
rhTRAIL WT. Combination of a DR5 selective TRAIL variant with a proteasome inhibitor 
or irradiation could therefore be a highly complementary treatment strategy. 
 
￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿
Treatment with radiation therapy and rhTRAIL WT or D269H/E195R. 
The viability of HeLa cells upon treatment with rhTRAIL WT or DR5 selective TRAIL 
variant D269H/E195R in combination with 10 Gg ionizing radiation was determined using 
a  MTT  assay.  After  exposing  the  cells  to  the  required  dose  of  ionizing  radiation  (0.9 
Gy/min, 10 Gy total) the cells were further incubated with 5, 10 or 50 ng/ml rhTRAIL WT 
or D269H/E195R. Cells treated only with 5 or 50 ng/ml rhTRAIL WT or D269H/E195R 
were used as control. After treatment the viability of the cells was assessed using a MTT 
assay. Upon treatment with only rhTRAIL WT or D269H/E195R the viability of the HeLa Enhanced anti-cancer activity of a DR5 selective TRAIL variant 
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cells  was  hardly  affected,  at  the  highest  concentration  tested  (50  ng/ml)  rhTRAIL  WT 
reduces the viability with less than 20% and D269H/E195R causes a reduction in viability 
of less than 5%. This low sensitivity of HeLa cells for rhTRAIL WT is in agreement with a 
previous study of Hougardy et al.,
205. Conversely, after an accumulated dose of 10 Gy of 
ionizing irradiation the response to rhTRAIL WT treatment was markedly increased. The 
decrease in viability of the HeLa cells sequentially treated with 10 Gy of irradiation and 50 
ng/ml rhTRAIL WT was more than doubled when compared to cells only treated with 50 
ng/ml rhTRAIL WT (Figure 1a). The combination of D269H/E195R and radiotherapy gave 
even  a  more  pronounced  effect.  Although  the  maximum  effect  on  viability  of 
D269H/E195R in combination with radiation therapy was equal to the effect of rhTRAIL 
WT at 50 ng/ml in combination with radiation therapy, this effect was already reached at 5 
ng/ml while rhTRAIL WT reached the same level of effect only at 50 ng/ml (Figure 1a). In 
a  second  experiment  the  more  potent  effect  of  D269H/E195R  in  combination  with 
radiotherapy was confirmed, at concentrations of both 1 ng/ml and 5 ng/ml the decrease in 
viability was more pronounced than that of similar concentrations of rhTRAIL WT (Figure 
1b).  
 
Figure 1. A and B. Cell death induced by radiation therapy in combination with rhTRAIL WT or a DR5 selective 
TRAIL variant in HeLa cells. Cells were sequentially treated with 10 Gy of irradiation and 1-50 ng/ml rhTRAIL 
WT or D269H/E195R. Figure 1A and 1B are two independent experiments; the error bars depict the variation 
(standard deviation) within a single experiment. Legend; WT: rhTRAIL WT; D/E: D269H/E195R; T: treated with 
1-50 ng/ml rhTRAIL WT or D269H/E195R; R: 10 Gy of irradiation. 
In order to confirm that the observed increase in cell death upon treatment with rhTRAIL 
WT or D269H/E195R in combination with radiotherapy was indeed caused by apoptosis, 
HeLa cells were treated with 10 ng/ml rhTRAIL WT or D269H/E195R with and without 10 
Gy  ionizing radiation and apoptosis was determined with acridine orange staining. The 
combination of 10 ng/ml rhTRAIL WT or D269H/E195R with 10 Gy ionizing radiation 
induces a high level of apoptosis (>50%) while when treating cells with only 10 ng/ml 
rhTRAIL WT or D269H/E195R only 5% of the cells appear to be apoptotic (Figure 2). 
Taken together, these results suggest that the DR5 selective TRAIL variant might be more 
potent  than  rhTRAIL  WT  when  combined  with  radiotherapy.  Both  the  DR5  selective 
variant and rhTRAIL WT when combined with radiotherapy appear to exert their effect by 
an increase in the level of apoptosis.  Chapter 6 
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Figure 2. Apoptosis induced in HeLa cells by radiation therapy in combination with rhTRAIL WT or a DR5 
selective TRAIL variant. Cells were sequentially treated with 10 Gy of irradiation and 10 ng/ml rhTRAIL WT or 
D269H/E195R. Legend; WT: rhTRAIL WT; D/E: D269H/E195R; -RT: no radiation therapy; +RT: 10 Gy of 
irradiation. 
Treatment with proteasome inhibitor and rhTRAIL WT or D269H/E195R 
Recently, it was demonstrated that co-treatment of HeLa cells with the proteasome inhibitor 
MG132 could sensitize these cells for TRAIL induced apoptosis
205. Both the DR5 receptor 
and, to a lesser extend, the DR4  receptor  were found  to be upregulated in response to 
treatment with MG132. However, the apoptotic inducing capability of rhTRAIL WT upon 
co-treatment with MG132 could partially be inhibited by an antagonistic DR4 antibody
205. 
To examine the efficacy of a DR5 selective TRAIL variant in this setting, HeLa cells were 
pretreated with 10 mM of the proteasome inhibitor MG132. After 2 hr, 10 ng/ml rhTRAIL 
WT or D269H/E195R were added to the cells and incubated for another 4 and 6 hours. 
Untreated  HeLa  cells  and  HeLa  cells  treated  only  with  10  ng/ml  rhTRAIL  WT, 
D269H/E195R or 10 mM MG132 were used as controls. Following incubation the number 
of apoptotic cells was determined using acridine orange staining. After incubation for 4 and 
6 hours, cells treated with only rhTRAIL WT, D269H/E195R or MG132 showed only a 
small increase in the number of apoptotic cells when compared to the untreated cells, in all 
cases the percentage of apoptotic cells was well below 10% (Figure 3). Treatment with 
MG132 and rhTRAIL WT for 6 h, caused a ~2-fold increase in the number of apoptotic 
HeLa cells when compared to the controls. In cells treated with MG132 and D269H/E195R 
this effect was much more pronounced. Even after 4 h of incubation with D269H/E195R 
the number of apoptotic cells was more than 3-fold higher then after treatment with only 
MG132 or D269H/E195R. A 7-fold increase in the number of apoptotic cells was observed 
after 6 h of incubation with D269H/E195R and MG132 (Figure 3). Both at 4 h as well as at 
6 h of treatment with D269H/E195R in combination with MG132, this combination was 
significantly more potent than the combination of rhTRAIL WT and MG132 (p = 0.006 and 
p = 0.02, for 4 and 6 h treatment, respectively). These results demonstrate that TRAIL 
variants can be used to trigger apoptosis through a DR5 receptor mediated pathway when 
combined with a proteasome inhibitor in HeLa cells in a synergistic fashion. Moreover, the Enhanced anti-cancer activity of a DR5 selective TRAIL variant 
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DR5  selective  TRAIL  variant  shows  higher  potency  than  rhTRAIL  WT  when  used  in 
combination with a proteasome inhibitor. 
 
Figure 3. Combined treatment of proteasome inhibitor and rhTRAIL WT or DR5 selective TRAIL variant in 
HeLa cells. Legend; WT: 10 ng/ml rhTRAIL WT; D/E: 10 ng/ml D269H/E195R; PI: proteasome inhibitor MG132 
(10 mM). Apoptosis was determined after 4 and 6 hr of treatment with rhTRAIL WT or D269H/E195R. Mean and 
standard error of three independent experiments. 
 ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿
 
TRAIL interacts with five different receptors of the TNF-R family; however, only DR4 and 
DR5 transmit the apoptosis inducing signal. Furthermore, it was shown that the expression 
levels of DR5 were up-regulated in cancer cells in response to certain chemotherapeutic 
drugs (15) and in response to ionizing radiation (16). Therefore, we recently developed 
DR5 receptor selective variants of TRAIL in order to permit novel tumor selective anti-
cancer therapies
108. 
 
Treatment  of  HeLa  cancer  cells  with  either  rhTRAIL  WT,  D269H/E195R  or  the 
proteasome inhibitor MG132 only gave a marginal effect. However, treatment of HeLa 
cells with MG132 followed by treatment with rhTRAIL WT or D269H/E195R was shown 
to have a synergistic effect, this treatment resulted in a manifest increase in cell death when 
compared to either treatment alone. Radiotherapy as well sensitized HeLa cells towards 
apoptosis  induced  by  rhTRAIL  WT  or  D269H/E195R.  In  this  study  we  compared  the 
efficacy  of  rhTRAIL  WT  and  the  DR5  selective  TRAIL  variant  D269H/E195R,  the 
combination  of  the  proteasome  inhibitor  MG132  and  D269H/E195R  was  shown  to  be 
significantly more potent in the induction of apoptosis than the combination MG132 and 
rhTRAIL  WT.  Furthermore,  the  available  data  indicates  that  the  combination  of 
radiotherapy  and  D269H/E195R  might  be  more  potent  than  the  combination  of 
radiotherapy and rhTRAIL WT. 
Sensitization  of  TRAIL  resistant  cancer  cells  by  chemotherapeutics  or  radiotherapy  are 
mediated by both p53 dependent and p53 independent mechanisms
202. Activation of p53 by 
DNA damaging stressors or inhibition of p53 degradation by using proteasome inhibitors, Chapter 6 
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causes  an  increase  in  the  expression  levels  of  several  proteins  implicated  in  apoptosis 
signaling
198,209. DNA damage induced p53 activation results in transcriptional activation of 
FAS and DR5 death receptors through their p53 transactivation sites in the genes encoding 
these death receptors. Other examples are the activation in a p53 dependent manner of Bax, 
Bid, Noxa and other pro-apoptotic Bcl-2 members and the p53 dependent transcriptional 
activation of caspase 10
29,198,209. Chemotherapeutic drugs induce the expression levels of 
DR4 and DR5 and enhance the efficacy of TRAIL induced apoptosis, both in p53 wild-type 
and p53 negative or mutant cells
198,210,211. DR5 up-regulation in response to treatment with 
the proteasome inhibitor MG132 was found to be induced both at the transcriptional level 
and  protein  level  through  the  CCAAT/Enhancer-binding  protein  homologues  protein 
(CHOP)  and  this  up-regulation  was  (probably)  independent  from  p53  function
212.  Up-
regulation of DR5 receptor expression in response to irradiation was demonstrated being 
both  dependent  as  well  as  independent  on  the  presence  of  functional  p53
107,200-202,213. 
However, the surface expression level of DR4 or DR5 receptors does not always correlate 
with  the  sensitivity  for  TRAIL  induced  apoptosis  mediated  by  those  receptors
108,214. 
Similarly, no tight correlation was observed between irradiation induced DR5 up-regulation 
and tumor cell sensitization to TRAIL
200. Apart from DR4 and DR5 receptor expression 
levels and the involvement of p53, the direct contribution of pro-apoptotic Bcl-2 members 
in the sensitization to TRAIL induced apoptosis in response to irraditiation or treatment 
with  proteasome  inhibitors  is  equally  complex.  In  irradiation-induced  sensitization  to 
TRAIL induced apoptosis the levels of Bax and Bak were upregulated in a prostate cancer 
model
202, in another prostate cancer model and in a colon cancer model Bax was reported to 
be essential and Bak to be dispensable for the synergy between TRAIL induced apoptosis 
and irradiation
215, and in a mesothelioma cancer model Bid was found to be essential
216. 
The sensitization to TRAIL induced apoptosis in response to treatment with the proteasome 
inhibitor MG132 was reported to be independent of Bax in a colon cancer model
204. The 
pro-apoptotic Bcl-2 family member Bik was reported to be involved in the sensitization 
toward  TRAIL  induced  apoptosis  upon  treatment  with  proteasome  inhibitors  in  colon 
cancer models
217. 
In a recent study, Hougardy et al., examined the effects of combination treatment of a 
proteasome inhibitor with rhTRAIL WT in HeLa cells
205. Treatment with the proteasome 
inhibitor  MG132  strongly  sensitized  cells  to  TRAIL  induced  apoptosis.  In  response  to 
treatment with MG132 both the DR5 receptor and, to a lesser extend, the DR4 receptor 
were up-regulated. DR5 receptor up-regulation was found to be partially dependent on p53 
up-regulation  while  DR4  up-regulation  was  independent  of  p53,  as  was  the  effect  on 
TRAIL induced apoptosis. In addition, inactivation of XIAP was found to contribute to 
proteasome inhibitor-induced sensitization to TRAIL-induced apoptosis
205. Radiotherapy 
also  induced  DR5  membrane  expression  levels  in  HeLa  cells  without  affecting  DR4 
receptor expression levels (Maduro et al., manuscript in preparation). The increase in DR5 
receptor membrane expression levels was found to be dependent on an increase in p53 
expression  levels  and  the  increase  in  apoptosis  after  irradiation  was  not  dependent  on 
increased p53 expression levels. Irradiation did not change the expression levels of the pro- 
and  anti-  apoptotic  mitochondrial  proteins  like  Bax,  Bak  or  Bcl2.  Surprisingly,  using 
siRNA to block DR4 and DR5 receptor expression, it was found that both the DR4 and 
DR5 receptors mediate the TRAIL induced apoptosis after irradiation rather than the DR5 
receptor (Maduro et al., manuscript in preparation). In the present study we demonstrate Enhanced anti-cancer activity of a DR5 selective TRAIL variant 
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that triggering of the DR5 receptor mediated pathway by a DR5 selective TRAIL variant 
also efficiently induces apoptosis after sensitization by a proteasome inhibitor or ionizing 
radiation.  How  to  explain  the  results  in  the  present  study  with  the  observed  DR4 
dependency  in  the  previous  study?  Blocking  experiments  with  siRNA  and  antagonistic 
antibodies in the previous study revealed that at least a fraction of the cell death could still 
be mediated by the DR5 receptor. A partial explanation of the observed efficacy of the DR5 
selective TRAIL variant could then be the higher affinity of D269H/E195R for the DR5 
receptor and the  lower affinity for decoy receptors
108, allowing D269H/E195R to make 
more efficiently use of the available (functional) DR5 receptors than similar concentrations 
of rhTRAIL WT. Additionally, the observed efficacy of the DR5 selective TRAIL variant 
could also be in part due to utilizing DR5 receptor-induced Caspase 10 mediated apoptosis. 
It was previously demonstrated that at low TRAIL concentrations or at early assessed time 
points TRAIL could induce caspase 10 mediated apoptosis via a DR5-mediated mechanism 
but not via a DR4-mediated mechanism
218. The DR5 selective variant could possibly trigger 
this particular route with enhanced efficacy compared to rhTRAIL WT due to its higher 
affinity for DR5 and its inability to form DR4/DR5 heteromeric complexes as, in contrast, 
has  been  demonstrated  for  rhTRAIL  WT
23.  Further  research  using  receptor  specific 
antagonistic antibodies and siRNA experiments should further elucidate the role of each 
death  and  decoy  receptor  and  of  intracellular  components  responsible  for  the  observed 
potency of the DR5 selective TRAIL variant. Despite the uncertainty of the exact molecular 
mechanism responsible for the observed potency of the DR5 selective TRAIL variant in 
HeLa cells, the DR5 receptor is a viable target for receptor mediated apoptosis by DR5 
selective  ligands  in  combination  with  radiotherapy  or  a  proteasome  inhibitor.  Several 
examples support this notion; Buchsbaum and co-workers successfully used the agonistic 
anti-DR5 mAb TRA-8 in combination with radiotherapy and/or chemotherapy in vitro and 
in  vivo  in  breast  cancer  models  and  in  cervical  cancer  models
219,220.  Treatment  with  a 
proteasome  inhibitor  or  radiotherapy  was  able  to  enhance,  in  additive  or  synergistic 
manner,  the  apoptosis  inducing  activity  of  the  agonistic  anti-DR5  mAb  HGS-ETR2  in 
various cell lines
214,221,222. In an in vivo Colo205 xenograft model this latter antibody was 
found to have a higher activity than the agonistic anti-DR4 mAb HGS-ETR1
222.  
 
Unlike  other  apoptosis  inducing  TNF  family  members,  soluble  TRAIL  appears  to  be 
inactive  against  normal  healthy  tissue
13.  Reports  in  which  TRAIL  induces  apoptosis in 
normal cells could be attributed to the specific preparations of TRAIL used
14,15. The few 
available tests regarding DR5 selective TRAIL variants
108,109 and the extensive available 
information regarding several TRAIL death receptor specific antibodies (see for example 
Ichikawa et al.,
180) indicate that death receptor specific ligands, just as normal promiscuous 
rhTRAIL  WT, also have low toxicity in normal cells. In this respect, rhTRAIL  WT  is 
currently  evaluated  in  a  phase  I  clinical  trial  and  a  death  receptor  specific  ligand  (the 
agonistic anti-DR4 mAb HGS-ETR1) is currently already being evaluated in a phase II 
clinical trail in combination with the proteasome inhibitor bortezomib (PS-341). However, 
combination treatment with chemotherapeutics or radiotherapy might also sensitize normal 
healthy tissues to TRAIL induced apoptosis. This must be properly investigated for both 
rhTRAIL WT as well as any death receptor specific ligands, especially in cases when both 
treatments have to be systemically administered or applied. Encouragingly, sensitization to Chapter 6 
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TRAIL induced apoptosis in combination with 10 Gy irradiation could not be demonstrated 
using a panel of several normal non-cancer cell lines including hepatocytes
200.  
 
In conclusion, our results show that a combination of the DR5 selective TRAIL variant 
D269H/E195R and the proteasome inhibitor MG132 is significantly  more potent in the 
induction of apoptosis than the combination MG132 and rhTRAIL WT. Preliminary results 
also suggest that the combination of radiotherapy and D269H/E195R is more potent than 
the  combination  of  radiation  therapy  and  rhTRAIL  WT.  Although  the  exact  molecular 
mechanism of the enhanced potency of the DR5 selective TRAIL variant when used in 
combination with radiation therapy or with a proteasome inhibitor remains to be elucidated 
and safety of these combination treatment regimens towards non cancer cells needs to be 
addressed, this DR5 receptor selective TRAIL variant permits novel targeted and tumor 
selective anti-cancer therapies. 
 
!￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿ ￿￿ ￿!￿ ￿ ￿ ￿ ￿ ￿ ￿
￿
Reagents and chemicals 
Dulbecco's MEM and Nutrient Mixture F-12 (HAM) were obtained from Invitrogen-Life 
Technologies (Merelbeke, Belgium) and fetal calf serum (FCS) from Bodinco (Alkmaar, 
the  Netherlands).  3-(4,  5-dimethylthiazol-2-yl)  2,  5-diphenyltetrazolium  bromide  (MTT) 
was  purchased  from  Sigma-Aldrich  (Zwijndrecht,  the  Netherlands),  dimethyl  sulfoxide 
(DMSO)  from  Merck  (Amsterdam,  the  Netherlands),  trypsin  stock  (10×)  solution  and 
EDTA  from  Invitrogen-Life  Technologies  and  the  proteasome  inhibitor  MG132  from 
Calbiochem (Breda, the Netherlands). RhTRAIL WT and the DR5 selective TRAIL variant 
D269H/E195R
108 were produced following a protocol described previously
65.  
 
Cell line and cell culture 
The human cervical carcinoma cell line HeLa S3 (HeLa) was obtained from the American 
Type  Culture  Collection  (ATCC,  Manassas,  VA,  USA).  This  HeLa  cell  line  is  human 
papillomavirus  type  18  (HPV-18)  positive
207  and  contains  wild-type  p53
206.  Cells  were 
grown at 37
oC in a humidified atmosphere with 5% CO2 in 1:1 DMEM/HAM medium 
supplemented with 10% FCS. Cells were detached with 0.05% trypsin/0.5 mM EDTA in 
phosphate-buffered saline (PBS, 0.14 M NaCl, 2.7 M KCl, 6.4 M Na2HPO4. 2H2O, 1.5 M 
KH2PO4, pH 7.4). 
 
Irradiation 
Cells were irradiated with a 137 Cesium ￿-ray machine (IBL 637, CIS Bio International 
Gif/Yvette, France) at 0.9 Gy/ min. After receiving the required dose of ionizing radiation 
(10 Gy) the cells were treated with 5, 10 or 50 ng/ml rhTRAIL WT or D269H/E195R. Cells 
treated only with 5 or 50 ng/ml rhTRAIL WT or D269H/E195R were used as control. To 
correct for loss of viability due to irradiation and to compare the efficacy of the TRAIL and 
D269H/E195R treatment, data was normalized to 100% viability at 0 ng/ml rhTRAIL WT 
or D269H/E195R and for each treatment all other values were calculated relative to the 
value at 0 ng/ml. 
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Cytotoxicity assay 
The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used 
to determine the cytotoxic activity of rhTRAIL WT in combination with irradiation. In a 
96-well culture plate, 3,000 cells per well (to obtain logarithmic cell growth at day 4) were 
incubated  in  a  total  volume  of  200  ￿l.  Treatment  consisted  of  irradiation  followed  by 
continuous  incubation  with  rhTRAIL  WT  in  various  concentrations.  Cytotoxicity  was 
determined after 4 days by adding 20 ￿l MTT-solution and incubated for 3.5 h at 37°C. 
After centrifugation, the culture supernatant was discarded and the blue formazan crystals, 
which are only formed in living cells by oxidation, were dissolved by adding DMSO. The 
plate was read immediately at 520 nm using a microtiter plate spectrometer (Benchmark 
Microplate  Reader,  Bio-Rad  Laboratories  Inc.,  Veenendaal,  the  Netherlands).  Controls 
consisted of media without cells. Cell survival was defined as the growth of treated cells 
compared to untreated cells. The assay was performed in quadruplicate. 
Proteasome inhibition 
In a 96-wells culture plate 15,000 cells per well were seeded in 100 ￿l culture medium. 
Cells  were  pretreated  for  2  hr  with  10  µM  MG132  (dissolved  in  DMSO)  followed  by 
treatment with 10 ng/ml rhTRAIL WT or D269H/E195R for 4 hr and 6 hr. At the end of the 
experimental period acridine orange was added and apoptotic cells were counted using a 
fluorescence microscope.  Apoptosis was defined by  the appearance of apoptotic bodies 
and/or chromatin condensation. Results are expressed as the percentage of apoptotic cells in 
a culture (by counting at least 300 cells per well). This assay was performed three times. 
 
Statistical analysis 
Statistical analysis was performed using the two sample t-test. Differences associated with 
p-values < 0.05 were considered significant. 
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￿￿￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿ ￿￿
Tumor necrosis factor (TNF) ligand family members and their corresponding receptors of 
the TNF receptor family activate several signaling pathways, eliciting activities ranging 
from cell-proliferation to the induction of apoptosis. TNF ligands and TNF receptors are 
involved  in  a  variety  of  biological  processes,  such  as  host  defense,  development, 
(auto)immunity, inflammation and tumor surveillance. Many TNF ligand and TNF receptor 
family members are attractive drug targets for treating autoimmune diseases and cancer. 
Blocking TNF-a signaling is a clinically well established treatment strategy for rheumatoid 
arthritis and some other auto-immune diseases. The inhibition or, reversely, activation of 
other signaling pathways modulated by members of TNF ligand and TNF receptor families 
are currently under investigation as potential treatment strategies to combat cancer or to 
alleviate autoimmune diseases.  
 
One member of the TNF ligand family, Tumor necrosis factor (TNF) related apoptosis 
inducing-ligand  (TRAIL), is  currently attracting  great  interest as a potential  anti-cancer 
therapeutic. TRAIL in its soluble form selectively induces apoptosis in tumor cells in vitro 
and  in  vivo  in  several  preclinical  models.  Unlike  other  apoptosis  inducing  TNF  ligand 
family  members,  soluble  TRAIL  appears  to  be  inactive  against  normal  healthy  tissue. 
TRAIL binds to five cognate receptors of the TNF receptor family; to the death receptors 
DR4 and DR5 and to the decoy receptors DcR1, DcR2 and osteoprotegerin (OPG). Binding 
of TRAIL to the DR4 and DR5 receptors induces apoptosis by activating the cell-extrinsic 
or death receptor-mediated apoptosis pathway. Binding to the decoy receptors and OPG 
does not induce apoptosis; in contrast, it could prevent apoptosis. 
 
Currently, approximately twenty five percent of all new therapeutics entering the market 
are protein based therapeutics. Since endogenous proteins are not “designed” by Nature to 
function  as  therapeutic  agents,  additional  optimization  might  be  required.  Modifying  a 
protein’s  amino  acid  sequence  can  be  a  useful  strategy  to  improve  several  properties 
relevant  to  a  potential  protein  drug,  such  as  stability,  affinity,  specificity,  solubility, 
immunogenicity and pharmacokinetic (PK) properties, in order to obtain a variant with the 
desired characteristics. Both classical protein engineering approaches (expert design) and 
directed evolution methods have been successfully applied in the development of improved 
protein therapeutics. More recently, structure based computational protein design methods 
combine computer design steps with in silico screening/selection, permitting screening of a 
much  larger  fraction  of  sequence  space  (up  to  10
80)  than  is  experimentally  possible. 
Structure based computational design algorithms employ usually an inverse protein folding 
approach, i.e. the algorithm determines which amino acid sequence is most compatible with 
a protein 3-dimensional backbone structure. A particular 3-dimensional backbone structure 
will have many sequences compatible with it while any given amino acid sequence has only 
one  compatible  3-dimensional  structure.  Computational  design  methods  have  been 
successfully employed to improve various properties of several proteins but have yet hardly 
been applied to improve the efficacy of (prospective) protein therapeutics. In this thesis, 
structure based computational design methods are used to improve the structural stability of 
TRAIL and to modify the receptor binding characteristics of TRAIL in order to enhance its 
efficacy. 
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Stability is an important property  for protein therapeutics. Protein stability is important 
throughout the production process and for the shelf-life of the final product. In addition, 
stability  influences  pharmacokinetic  and  pharmacodynamic  properties  of  a  protein 
therapeutic  and  increasing  the  structural  stability  can  also  be  constructive  in  reducing 
potential immunogenicity by decreasing protein aggregation. The shelf-life of a  protein 
therapeutic  can  be  enhanced  using  proper  formulation  technology,  increasing  physical 
stability and chemical stability for prolonged periods of time and pharmacokinetic- and 
immunogenic  properties  can  for  example  be  improved  using  pegylation  technology. 
However, it is also possible to increase the intrinsic stability of a protein by modifying its 
amino acid sequence. Chapter 3 reports the design of rhTRAIL WT variants with higher 
thermostability. Using a crystal structure of TRAIL as a template, stabilizing amino acid 
substitutions were selected by employing a computational design algorithm. Information 
derived  from  a  TNF-ligand  family  alignment  was  used  to  focus  the  design  on  non-
conserved residues only. Conserved residues are often retained in a protein family for good 
reason,  such  as  structural  stability.  Focusing  on  non-conserved  residues  only  left  the 
existing stability causing amino acid residue networks intact and, as additional benefit, this 
approach  also  reduced  the  use  of  computational  resources.  The  automated  design 
algorithms  PERLA/FOLD-X  were  subsequently  employed  to  identify  favorable 
substitutions at those non-conserved residue positions. Various biophysical and biological 
assays were performed to assess the thermostability of the TRAIL variants as a read out for 
structural stability. A rhTRAIL variant (M1) containing only 2 mutations showed an 8 
oC 
increase in thermal stability when compared to rhTRAIL WT. In an accelerated thermal 
stability study this rhTRAIL variant retained full biological activity upon incubation for 1 
hour at 73 
oC while rhTRAIL WT was all but inactivated within 30 minutes of incubation at 
73 
oC. Importantly, we could demonstrate that computational design techniques can involve 
both residues involved in inter-chain contacts as well as residues involved in intra-chain 
contacts to successfully stabilize the quaternary structure of a protein. In particular, it was 
shown  that  stabilization  of  the  CD  loop  in  a  single  TRAIL  monomer  resulted  in 
stabilization of the entire trimeric molecule. 
 
In chapter 4 the design of DR5 selective TRAIL variants is described. Use of TRAIL 
receptor selective variants could permit novel tumor-specific therapies. The computational 
design of DR5 selective TRAIL variants was facilitated by the available crystal structures 
of TRAIL in complex with the DR5 receptor. However, no crystal structures were available 
of TRAIL in complex with the other receptors. Structures of these complexes were derived 
by  homology  modeling.  Using  the  FOLD-X  protein  design  algorithm,  amino  acid 
substitutions  were  selected  (and  combined)  which  contributed  favorably  to  the  binding 
energy between TRAIL and DR5 and disfavored binding to the other receptors, resulting in 
DR5 selective TRAIL  variants. A fast surface plasmon resonance (SPR)  based in vitro 
receptor  binding  screen  was  used  to  further  refine  the  in  silico  selection  to  select  for 
variants  having  favorable  DR5  over  DR4  binding  ratios.  Subsequent  receptor  binding 
experiments using surface plasmon resonance (SPR) and competition ELISA experiments 
confirmed the modeling predictions. Several variants were between 70 to 150 fold more 
selective for the DR5 receptor than for the DR4 when compared with rhTRAIL WT, one 
double mutant variant did not bind to DR4 at all. Many DR5 specific TRAIL variants had a 
higher affinity for the DR5 receptor when compared to rhTRAIL WT. This study revealed Chapter 7 
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that residues 269 and 214 of TRAIL are important in determining specificity for the DR5 
receptor. Biological activity assays showed that these variants did not induce apoptosis in 
DR4-responsive cell lines but, in contrast, the DR5 selective variants show high activity 
towards  DR5  responsive  cancer  cells  without  the  need  for  additional  cross-linking. 
Consequently, these variants are of interest for the development as a potential anti-cancer 
therapeutic. 
 
Chapter 5 discusses the design of DR4 selective TRAIL variants. In contrast to the design 
of  DR5  selective  TRAIL  variants  no  crystal  structure  is  available  of  the  TRAIL-DR4 
complex and a homology model of the TRAIL-DR4 complex needs to be used. This makes 
the  design  of  a  DR4  selective  variant  with  improved  affinity  for  the  DR4  receptor,  in 
addition to decreased affinity for the other receptors, much harder. The FOLD-X design 
process  proposed  several  TRAIL  receptor  interface  positions  and  (single)  amino-acid 
substitutions important for obtaining DR4 selectivity. Amino acid substitutions at position 
218 of TRAIL (D218Y and D218H) were predicted to cause the highest change in DR4 
selectivity by improving the interaction with DR4 and decreasing the interaction with DR5. 
Although  the  receptor  binding  assays  needs  further  work,  biological  activity  assays 
indicated that both variants induce apoptosis preferentially via DR4. However, to make 
these variants more potent in inducing apoptosis, the affinity of both variants for DR4 needs 
to increase. The lack of success in the design of a high affinity DR4 selective TRAIL 
variant  can,  at  least  in  part,  be  attributed  to  the  quality  of  the  TRAIL-DR4  homology 
model;  not  all  important  interactions  are  apparently  modeled  correctly.  Improving  the 
accuracy of the TRAIL-DR4 model by crystallization is therefore of paramount importance 
in obtaining high affinity DR4 selective TRAIL variants. 
 
Combination  treatment  with  radiation  therapy  or  chemotherapy  can  sensitize  TRAIL 
resistant tumor cells and vice versa. Furthermore, it was shown that the expression levels of 
DR5 were up-regulated in cancer cells in response to certain chemotherapeutic drugs and in 
response  to  ionizing  radiation  (radiation  therapy).  Chapter  6  reports  on  the  treatment 
efficacy of a DR5 selective TRAIL variant in combination with a proteasome inhibitor or 
radiation therapy in a cervical cancer model. In this study it was shown that treatment of 
TRAIL resistant HeLa S3 cells with the proteasome inhibitor MG132 combined with a low 
concentration  of  the  DR5  selective  TRAIL  variant  D269H/E195R  was  able  to  induce 
apoptosis  in  this  cell  line  in  a  synergistic  fashion.  Moreover,  this  combination  was 
significantly  more  potent  than  similar  concentrations  of  rhTRAIL  WT  and  MG132. 
Preliminary results suggest that also the sequential combination of ionizing radiation and 
low concentrations of the DR5 selective TRAIL variant were able to induce apoptosis in 
HeLa S3 cells in a synergistic manner and that this combination was more potent than 
ionizing  radiation  and  rhTRAIL  WT.  This  study  strongly  suggests  that  DR5  receptor 
selective TRAIL variants permit novel targeted and tumor selective anti-cancer therapies. 
 
In conclusion, the results described in this thesis demonstrate that the use of computational 
protein design methods is a successful approach to enhance protein thermostability and 
modifying protein-protein interactions. The use and development of computational design 
algorithms provides new insights into the fundamentals of protein structure, folding and 
function.  From  a  practical  point  of  view,  computational  protein  design  methods  are  a Summary and general discussion 
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valuable addition to other protein engineering methodologies, such as directed evolution, as 
a tool for the improvement and modification of protein properties. However, the importance 
of using accurate high quality  structural information as a template, which is  especially 
critical in the design of energetically favorable interactions, is being demonstrated in the 
design of DR4 receptor selective TRAIL variants that still needs improvement. Structural 
genomics initiatives and regular structural biology studies are determining an increasing 
amount of structures of proteins and protein complexes, making more and more proteins 
directly  amenable  to  design  or  providing  templates  with  high  sequence  identity  for 
structurally  similar  targets  allowing  the  modeling  of  more  accurate  homology  models. 
Moreover, recent advantages in homology modeling, de novo protein structure prediction 
and protein-protein docking will eventually allow the prediction of more accurate structural 
models  of  target  complexes.  These  developments  will  allow  successful  designs  with  a 
reduced amount of false positive and false negative predictions. 
 
The demonstrated apoptosis inducing efficacy of DR5 receptor selective TRAIL variants in 
DR5 responsive cancer cells or in combination with a proteasome inhibitor or radiation 
therapy, indicate that these DR5 receptor selective TRAIL variants might be a potential 
anti-cancer  therapeutic.  Additional  preclinical  efficacy  and  safety  studies  are  currently 
being established to determine and validate its use as a potential anti-cancer therapeutic. 
These DR5 receptor selective TRAIL variants are promising potential anti-cancer agents, 
permitting novel targeted and tumor selective anti-cancer therapies, both as single treatment 
or in combination with chemotherapeutics or radiation therapy. 
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Het  humane  eiwit  TRAIL  (“Tumor  necrosis  factor-related  apoptosis-inducing  ligand”) 
wordt beschouwd als veelbelovend toekomstig antikankermiddel. In tegenstelling tot veel 
van de huidige generatie antikankermiddelen induceert TRAIL alleen celdood (apoptose) in 
bepaalde typen kankercellen zonder gezonde cellen aan te tasten. In dit proefschrift wordt 
onderzocht  of  het  TRAIL-eiwit  ook  geoptimaliseerd  kan  worden  voor  gebruik  als 
geneesmiddel,  als  een  zogenaamd  therapeutisch  eiwit,  door  gebruik  te  maken  van  een 
nieuwe technologie, te weten computergestuurde eiwit-ontwerp-technologie). 
 
Therapeutische eiwitten vormen een  steeds belangrijker  onderdeel van het  beschikbare 
geneesmiddelenarsenaal. Bekende voorbeelden van therapeutische eiwitten zijn: insuline, 
groeihormoon, erytropoëtine (EPO; Eprex) en infliximab (Remicade). Deze middelen zijn 
onmisbaar in de behandeling van respectievelijk, diabetes, dwerggroei, diverse vormen van 
anemie  en  reuma.  Tot  de  jaren  80  van  de  vorige  eeuw  werden  de  toen  beschikbare 
therapeutische  eiwitten  gezuiverd  uit  materiaal  afkomstig  van  humane,  dierlijke  of 
microbiële oorsprong. Dit had verschillende nadelen, zoals bijvoorbeeld het optreden van 
immuunreacties  tegen  de  lichaamsvreemde  dierlijke  of  microbiële  eiwitten,  gebrek  aan 
donormateriaal  en  het  risco  op  besmetting  met  virale  infectieziektes  zoals  AIDS  en 
hepatitus C. De ontwikkeling van recombinant DNA (rDNA) technieken sinds het begin 
jaren  70  maakte  het  mogelijk  om  humane  eiwitten  in  bijvoorbeeld  bacteriële  of 
zoogdiercelcultures te produceren. Door rDNA-technieken kan het gen dat codeert voor een 
bepaald eiwit in een ander organisme worden ingebracht. Door introductie van deze rDNA-
technieken  kan  het  geneesmiddel  onder  gecontroleerde  omstandigheden  worden 
geproduceerd, worden virale infecties voorkomen en kan het risico van een immuunreactie 
worden  verkleind.  In  1982  werd  het  eerste  humane  recombinante  therapeutische  eiwit 
geïntroduceerd. Dit was humaan insuline, voorheen werd dit uit de alvleesklier van varkens 
geïsoleerd.  Inmiddels  zijn  in  de  tussenliggende  25  jaar  meer  dan  70  recombinante 
therapeutische  eiwitten  op  de  markt  verschenen  en  zijn  er  op  dit  moment  ongeveer  80 
andere in verschillende stadia van klinische ontwikkeling. Tegenwoordig is ongeveer een 
kwart van alle nieuwe geneesmiddelen die op de markt worden toegelaten een therapeutisch 
eiwit. 
 
Is het gebruik van recombinante (humane) therapeutische eiwitten al een grote verbetering, 
het betekent niet dat recombinante eiwitten per definitie geschikt zijn als geneesmiddel. 
Aan een therapeutisch eiwit kunnen / moeten geheel andere eisen aan eigenschappen zoals 
stabiliteit,  selectiviteit  en  kinetiek  worden  gesteld  dan  het  eiwit  onder  fysiologische 
omstandigheden  bezit.  Bovendien  moet  het  eiwit  makkelijk  te  produceren  zijn  en 
gedurende langere tijd houdbaar en stabiel zijn. Een eiwit is opgebouwd uit een keten van 
20 verschillende bouwstenen (aminozuren) en deze aminozuurketen is opgevouwen tot een 
unieke driedimensionale structuur die de uiteindelijke werking van het eiwit bepaald. Tot 
voor kort waren er grofweg twee methodes om eiwitten te veranderen. De eerste methode 
van rationeel ontwerp berust op het gericht introduceren van een aminozuursubstitutie in de 
aminozuurketen door het introduceren van een specifieke mutatie  in het voor het eiwit 
coderende  gen.  Aan  de  hand  van  een  alignment  van  de  aminozuurketen  met  de 
aminozuurketens  van  verwante  eiwitten  of  op  basis  van  de  driedimensionale  structuur 
wordt bepaald op welke positie van het eiwit een aminozuur veranderd dient te worden in 
een  ander  aminozuur.  Nadeel  van  deze  methode  is  dat  slechts  een  klein  aantal Samenvatting 
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veranderingen geprobeerd kan worden. De tweede methode, gerichte evolutie, berust op het 
aanbrengen  van  willekeurige  mutaties  in  het  voor  het  eiwit  coderende  gen.  Bij  deze 
methode wordt een mutantenbank gemaakt van een heleboel verschillende varianten van 
het gen (vaak meer dan een miljard). Veel van deze genvarianten zullen echter een eiwit 
coderen dat in eigenschappen niet verschilt of juist slechter is dan het oorspronkelijke eiwit 
en slechts een klein aantal varianten zal over verbeterde eigenschappen beschikken. Om dit 
kleine  aantal  verbeterde  varianten  te  isoleren  uit  het  vele  malen  grotere  aantal  niet 
verbeterde  varianten  wordt  een  selectiemethode  toegepast  waarbij  het  gen  van  de 
verbeterde variant een grotere overlevingskans heeft dan de niet verbeterde varianten. Door 
dit  selectieproces  een  aantal  malen  te  herhalen  worden  de  varianten  met  de  verbeterde 
eigenschappen  verrijkt  ten  opzichte  van  de  niet  verbeterde  varianten  en  kunnen  de 
verbeterde varianten  geïsoleerd worden.  Nadeel  van deze techniek is dat  men over een 
goede  selectietechniek  dient  te  beschikken  en  deze  zijn  niet  altijd  voor  alle  gewenste 
eigenschappen  beschikbaar.  Tegenwoordig  is  een  derde  methode  in  opkomst,  te  weten 
computational  protein  design  (of  computergestuurde  eiwit-ontwerp-technologie).  Deze 
methode  maakt  gebruik  van  computeralgoritmes  voor  het  ontwerpen  van  eiwitten  en 
combineert een rationeel aspect met de mogelijkheid om heel veel verschillende varianten 
te beoordelen. In deze algoritmes is veel kennis samengebracht over wat de wetenschap de 
afgelopen decennia over eiwitten en eiwitstructuren heeft geleerd. Aan de hand van een 
gegeven driedimensionale structuur kan algoritme vaststellen wat het beste aminozuur is op 
een bepaalde positie in de aminozuurketen van het eiwit. Ook bezitten deze algoritmes 
efficiente  zoekfuncties  waardoor  heel  veel  verschillende  varianten  van  een  eiwit 
doorgerekend  kunnen  worden;  veel  meer  dan  ooit  mogelijk  is  om  met  experimentele 
technieken te maken en te selecteren. Uit de vele doorgerekende varianten selecteert het 
algoritme  de  varianten  met  de  beste  score  en  deze  kunnen  vervolgens  daadwerkelijk 
gemaakt  en  getest  worden.  In  hoofdstuk  2  worden  recente  toepassingen  van 
computergestuurde eiwit-ontwerp-algoritmes beschreven. 
 
TRAIL behoort tot de tumor necrosis factor (TNF) ligand familie. Deze TNF-ligand familie 
bestaat  bij  de  mens  uit  ongeveer  negentien  verschillende  eiwitten.  Deze  eiwitten  zijn 
verwant  aan  elkaar.  De  aminozuurketens  van  deze  eiwitten  hebben  onderling  veel 
overeenkomsten  en  net  als  de  driedimensionale  structuur  van  deze  eiwitten.  Biologisch 
actieve  TNF-liganden  zijn  trimeren;  ze  zijn  opgebouwd  uit  drie  identieke  eiwitketens 
(monomeren) en de driedimensionale vorm van een TNF-ligand lijkt een beetje op een 
scheepsklok.  Dit  geldt  dus  ook  voor  TRAIL.  Aangezien  deze  driedimensionale  vorm 
essentieel  is  voor  de  celdood  inducerende  activiteit  van  TRAIL,  is  het  voor  een 
therapeutische toepassing van belang om deze structuur zo stabiel mogelijk te maken.  
 
TNF-liganden vertonen een breed spectrum aan activiteiten. Sommige TNF-ligand eiwitten 
kunnen celgroei en –deling bevorderen, terwijl andere TNF-ligand eiwitten juist celdood 
induceren.  TNF-liganden  fungeren  als  boodschappermoleculen  tussen  verschillende 
celtypes, nadat een TNF-ligand bindt aan een voor de ligand specifiek receptoreiwit op de 
celmembraan  van  een  doelwitcel  wordt  het  signaal  doorgegeven.  Deze  receptoreiwitten 
voor  TNF-ligand  eiwitten  behoren  tot  de  TNF  receptorfamilie.  TRAIL  behoort  tot  de 
subgroep van TNF-ligand eiwitten die doelwitcellen aanzet tot geprogrammeerde celdood 
(“apoptose”). TRAIL induceert apoptose door te binden aan de “death receptors” DR4 en Samenvatting 
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DR5. Deze “death receptors” behoren tot de TNF receptorfamilie. Naast het binden aan 
deze receptoren kan TRAIL ook binden aan de “decoy receptors” DcR1, DcR2 en OPG,. 
Binding aan deze receptoren voorkomt echter de inductie van apoptosis. Ook is het bekend 
dat bepaalde chemotherapieën de hoeveelheid DR4- en/of DR5-receptoren op de kankercel 
kunnen verhogen en radiotherapie (“bestraling”) verhoogt selectief de hoeveelheid DR5-
receptoren  op  de  kankercel.  Voor  een  therapeutische  toepassing  zou  het  dus  gewenst 
kunnen zijn om een variant te ontwikkelen die selectief aan of de DR5-receptor of de DR4-
receptor, bindt en niet aan de overige decoy-receptoren. 
 
Hoofdstuk  3  beschrijft  het  ontwerpen  en  testen  van  recombinante  humane  (rh)TRAIL 
varianten  met  een  hogere  (thermische)  stabiliteit.  De  computergestuurde  eiwit-ontwerp-
algoritmes PERLA en FOLD-X werden gebruikt om aminozuursubstituties te selecteren die 
voor een grotere stabiliteit zorgen. Hiervoor werd de driedimensionale kristalstructuur van 
TRAIL  als  sjabloon  gebruikt.  Na  doorrekenen  van  een  groot  aantal  verschillende 
mogelijkheden,  werden  de  vijf  TRAIL-varianten  met  de  hoogst  scorende 
aminozuursubstituties voor stabiliteit gemaakt. Omdat eiwitten door verwarming kunnen 
ontvouwen (denatureren), werd de temperatuur waarbij de TRAIL eiwitten ontvouwen als 
maat voor de stabiliteit genomen. Uit de experimenten bleek dat vier van de vijf gemaakte 
varianten inderdaad de gewenste hogere stabiliteit bezaten. Deze varianten behielden bij 
hogere  temperatuur  zowel  de  driedimensionale  structuur  als  de  apoptosis  inducerende 
activiteit.  Terwijl  voor  rhTRAIL  WT  bij  deze  hogere  temperatuur  zowel  de 
driedimensionale  structuur  als  de  biologische  activiteit  verloren  ging.  rhTRAIL  WT 
denatureerde bij 73 
oC, terwijl de twee beste varianten (M1 en C1) pas bij 81
 oC begonnen 
te  ontvouwen.  Wanneer  deze  twee  stabielere  varianten  gedurende  een  uur  werden 
verwarmd bij 73 
oC, behielden deze hun structuur en biologische activiteit. rhTRAIL WT 
verloor  binnen  dertig  minuten  zowel  structuur  als  biologische  activiteit.  Nu  zal  een 
geneesmiddel  nooit  bij  73 
oC  worden  bewaard  of  toegediend,  echter  bij  hogere 
temperaturen verlopen diverse degradatiereacties sneller. Door verwarmen bij 73 
oC kon in 
korte tijd worden getest of de TRAIL varianten inderdaad stabieler waren dan rhTRAIL 
WT,  terwijl  dit  bij  kamertemperatuur  veel  langer  zou  hebben  geduurd.  Deze  hogere 
stabiliteit van de TRAIL M1 en C1 varianten kan betekenen dat ze veel langer houdbaar 
zijn dan rhTRAIL WT en als geneesmiddel in het lichaam veel langer actief blijven. 
 
Hoofdstuk  4  en  5  beschrijven  ontwerp  en  ontwikkeling  van  receptorselectieve  TRAIL-
varianten die alleen binden aan één van de twee celdood inducerende receptoren DR4 of 
DR5.  Om  deze  TRAIL-varianten  te  ontwerpen  is  gebruik  gemaakt  van  het    FOLD-X 
algoritme.  In  hoofdstuk  4  werd  het  ontwerp  van  DR5-selectieve  TRAIL-varianten 
beschreven. Voor het ontwerp van deze varianten kon gebruik worden gemaakt van de 
kristalstructuur van TRAIL in complex met de DR5-receptor. Met het FOLD-X algoritme 
zijn vervolgens enkele duizenden TRAIL-varianten in silico (in de computer) doorgerekend 
op  verbeterde  bindingsaffiniteit  voor  de  DR5-receptor  en  een  verminderde 
bindingsaffiniteit  voor  de  DR4-  en  decoy-receptoren.  Enkele  van  de  hoogstscorende 
varianten  werden  gemaakt  en  vervolgens  getest.  Deze  varianten  bleken  inderdaad  de 
voorspelde eigenschappen te bezitten: een verbeterde affiniteit voor de DR5-receptor en een 
verminderde affiniteit voor de overige receptoren. Voor het verkrijgen van selectiviteit voor 
de DR5-receptor waren slechts 2 aminozuursubstituties nodig ten opzichte van de natuurlijk Samenvatting 
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voorkomende variant. Door het kleine aantal substituties wordt de kans op een eventuele 
immunogene  respons  verminderd.  Deze  DR5-selectieve  TRAIL-varianten,  en  in  het 
bijzonder  de  D269H/E195R-variant,  bleken  een  sterkere  antikankeractiviteit  tegen 
kankercellen met een actieve DR5-receptor te bezitten dan rhTRAIL WT, terwijl ze veel 
minder werkzaam zijn tegen kankercellen met alleen een actieve DR4-receptor. Net als 
rhTRAIL WT zijn deze nieuwe varianten niet toxisch voor normale cellen. De verhoogde 
activiteit en selectiviteit op kankercellen met een actieve DR5-receptor maken dat deze 
varianten  interessant  zijn  voor  verdere  ontwikkeling  als  potentieel  anti-kankergenees-
middel. 
 
Om ook kankercellen te kunnen bestrijden die alleen een actieve DR4-receptor bezitten, 
werd  besloten  om  ook  DR4-selectieve  TRAIL-varianten  te  ontwikkelen  (hoofdstuk  5). 
Hiervoor  werd  wederom  het  FOLD-X  algoritme  gebruikt.  Bij  het  ontwerp  van  DR5-
selectieve  TRAIL-varianten  kon  gebruik  worden  gemaakt  van  de  kristalstructuur  van 
TRAIL in complex met de DR5-receptor, helaas bestaat er echter nog geen kristalstructuur 
van TRAIL in complex met de DR4-receptor. Er moest volstaan worden met een model van 
TRAIL in complex met de DR4-receptor Dit model kon gebasseerd worden op de structuur 
van TRAIL in complex met DR5, omdat DR4 en DR5 een aantal overeenkomsten bezitten. 
Helaas is het maken van een driedimensionale structuur op basis van een model doorgaans 
veel minder nauwkeurig dan een kristalstructuur. FOLD-X voorspelde dat twee varianten 
(D218H en D218Y) een gunstig effect op de selectiviteit van TRAIL voor de DR4 receptor 
zouden hebben. Hoewel receptorbindingsexperimenten geen eenduidig resultaat lieten zien 
met betrekking tot een grotere selectiviteit voor de DR4 receptor, gaven experimenten met 
kankercellen aan dat er waarschijnlijk wel grotere selectiviteit voor de DR4 receptor is. 
Deze DR4 selectieve varianten zijn zowel tegen kankercellen met alleen een actieve DR5-
receptor  als  tegen  kankercellen  met  alleen  een  actieve  DR4-receptor  minder  actief  dan 
rhTRAIL WT. Echter tegen kankercellen met alleen een actieve DR5-receptor zijn ze veel 
minder  actief  dan  tegen  kankercellen  met  alleen  een  actieve  DR4  receptor.  Om  als 
uitgangspunt voor een potentieel geneesmiddel te kunnen dienen moet echter de activiteit 
van deze varianten nog wel vergroot worden. Door het aanpassen van het TRAIL-DR4-
model zullen meer accurate voorspellingen door FOLD-X gedaan kunnen worden, wat tot 
sterker werkende DR4 selectieve rhTRAIL varianten zal leiden. 
 
In  hoofdstuk  6  worden  de  voordelen  van  de  DR5  selectieve  rhTRAIL  variant 
D269H/E195R ten opzichte van rhTRAIL WT in combinatie met radio- en een bepaalde 
vorm  van  chemotherapie  beschreven.  Sommmige  typen  kankercellen  zijn  resistent  voor 
behandeling  met  rhTRAIL  WT.  Door  combinatie  met  chemotherapie  of  radiotherapie 
kunnen kankercellen weer gevoelig worden gemaakt voor behandeling met rhTRAIL en 
bovendien  kan  het  effect  van  de  combinatie  groter  zijn  dan  van  beide  behandelingen 
afzonderlijk.  Dit  laatste  wordt  ook  wel  een  synergystisch  effect  genoemd.  De 
baarmoederhalskanker cellijn HeLa is slechts matig gevoelig voor TRAIL geïnduceerde 
celdood. Eerder onderzoek toonde aan dat deze cellijn weer gevoelig gemaakt kon worden 
voor TRAIL door de HeLa-cellen voor te behandelen met de proteasoomremmer MG132. 
Wanneer HeLa-cellen alleen werden behandeld met rhTRAIL D269H/E195R of MG132 
trad er nauwelijks celdood op. De combinatie tussen rhTRAIL D269H/E195R en MG132 
zorgde voor een sterke stijging in celdood. Het effect van deze DR5 selectieve variant in Samenvatting 
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combinatie met MG132 was veel sterker dan het effect van rhTRAIL WT in combinatie 
met  MG132.  Ook  radiotherapie  kan  HeLa-cellen  weer  gevoelig  maken  voor  TRAIL 
geïnduceerde celdood. Gecombineerd met radiotherapie liet een lage concentratie rhTRAIL 
D269H/E195R al een sterker effect zien dan dezelfde concentratie rhTRAIL WT. 
 
De in dit proefschrift beschreven ontwikkeling van DR5 selectieve rhTRAIL varianten is 
een veelbelovend startpunt voor de ontwikkeling van een nieuw anti-kankergeneesmiddel. 
Deze  receptor  selectieve  TRAIL  varianten  maken  een  tumorselectieve  behandeling 
mogelijk, zowel als monotherapie of in combinatie met radiotherapie of chemotherapie. 
Voordat een DR5 selectieve rhTRAIL variant kan worden toegepast als geneesmiddel dient 
er  echter  nog  veel  aanvullend  onderzoek  plaats  te  vinden.  Zo  moet  er  nog  in  vivo 
proefdieronderzoek plaatsvinden om de toxiciteit en effectiviteit te beoordelen. Hierna kan 
pas  met  klinische  onderzoeken  worden  begonnen,  waarin  de  effectiviteit  en  mogelijke 
bijwerkingen in patientstudies worden beoordeeld. Pas nadat al deze onderzoeken / stadia 
met goed gevolg zijn doorlopen kan de DR5 selective rhTRAIL variant als geneesmiddel 
worden toegelaten.  
 
Dit  proefschrift  toont  aan  dat  het  gebruik  van  computeralgoritmes  een  waardevolle 
aanvulling  is  op  de  reeds  beschikbare  methodes  voor  optimalisatie  van  therapeutische 
eiwitten.  De  effectiviteit  en  efficiëntie  van  deze  technologie,  zoals  beschreven  in  dit 
proefschrift, maakt de methode bij uitstek geschikt om ook andere eiwitten voor gebruik als 
geneesmiddel te ontwikkelen. 
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Na  een  aantal  weken  stevig  doorploeteren  met  het  schrijven  en  lay-outen  van  de 
voorgaande  hoofdstukken,  kan  ik  dan  eindelijk  het  meest  gelezen  onderdeel  van  een 
proefschrift schrijven: het dankwoord.   
 
De  afgelopen  jaren  zijn  voorbij  gevlogen.  Ik  heb  met  veel  plezier  aan  het  onderzoek 
gewerkt dat in dit proefschrift staat beschreven. Graag wil ik iedereen bedanken die mij, op 
welke manier dan ook, hebben geholpen om mijn promotie-onderzoek te volbrengen. 
 
Beste Wim, ik wil je bedanken voor de mogelijkheid om binnen de groep farmaceutische 
biologie te promoveren en de vrijheid die je me hebt gegeven om me tot een zelfstandig 
onderzoeker te ontwikkelen. 
 
I  would  like  to  thank  the  reading  committee  (Afshin  Samali,  Klaas  Poelstra  and  Luis 
Serrano) for evaluating my thesis manuscript. 
 
Dear Mags, I owe you a lot. As my former supervisor you introduced me to the world of 
science. You initiated the TRISKEL EU project and this enabled me to “harvest” most of 
the results described in this thesis. Thanks. Above all, you were also a good colleague and 
friend. We always had good discussions, both science related and unrelated. Unfortunately, 
I did not fulfill your wish of me having kids, my wedding and defending my thesis in the 
same year. I hope this does not disappoint you too much. Because we were always mixing 
Dutch and English also a few words in Dutch: Veel succes met het afronden van je MBA. 
Nu ik het proefschrift “uit de weg” heb hoop ik jou, Luigi en Orla snel een keer te kunnen 
bezoeken in Utrecht. 
 
Beste Robbert, Naast kamergenoot  was je ook mijn klankbord en heb je veel bijgedragen 
aan de totstandkoming van dit proefschrift. Bedankt. Veel succes met TRISKEL ltd./b.v. en 
de DR5 selectieve TRAIL varianten. Mijn excuses voor de papierlawine die altijd je kant 
op dreigde te komen. 
 
Meelezers  Barry,  Mattijs,  Robbert  en  Ykelien;  Bedankt  voor  het  corrigeren  van  het 
manuscript. Mattijs, bedankt voor het aanleveren van de template, dat heeft heel wat stress 
gescheeld. Carlos and Borgir, thank you for the nice cover design. Ykelien, bedankt voor 
het kleuradvies.  
 
Beste Janita, Wim, Niesko, Oliver, Rein, Freeke, Albert, Elfahmi, Ronald van M., Mattijs, 
Monique, Aaron, Henco, Anna Margareta, Mark, Nikolay, Klazien, Bea, Johanna, Charles, 
Linda, Michiel (aka DJ Miguel), Dolf, Mags, Melloney, Ykelien, Robbert, Carlos, Lidia, 
Ronald D., Geeske, Peter, Mariana, Ilse, Jean-Yves, Helga, Patty, Asia, Agata, Jan Maarten 
en Sieb. Ik heb met heel veel plezier bij farmaceutische biologie gewerkt, bedankt voor de 
gezelligheid, zowel binnen als buiten het lab, en alle hulp in de afgelopen jaren! Ik hoop dat 
de “nieuwe ploeg” (Gerrit and the new batch of PhD students; Mariette, Marieke, Remco, 
Evelina,    Pol  and  Luis)  evenzeer  met  veel  plezier  bij  “FaBio”  zal  werken.  Ykelien, 
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Figure  2.  Chapter  1.  Structure  of  the  TRAIL  trimer  and  DR5.  A)  Sideview  of  the  TRAIL  trimer,  the 
individual TRAIL monomers are depicted in different shades of green. The zinc atom in the center of the TRAIL 
trimer is depicted as a red sphere. B) DR5 receptor monomer, disulphide bridges are depicted in yellow. In this 
orientation, the cell membrane of the DR5 containing cell is at the bottom of the figure. Picture is based on the 
structure of Cha et al.,
12. 
 
Figure 3. Chapter 1. Structure of the 3:3 TRAIL-DR5 complex. A) side view (same orientation as in figure 1). 
B) top view along the N-terminal to C-terminal axis of the DR5 receptor (i.e. looking towards the cell surface of 
DR5). Picture is based on the structure of the TRAIL-DR5 complex of Cha et al.,
12. 
 
Figure 1. Chapter 3 A) Side view of the TRAIL trimeric complex, showing the three monomers in red, blue and 
green. B) Top view of the same complex but viewed along the longitudinal axis, depicting the different sets used 
for design. Structure figures were generated using MOLMOL
167.  
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Figure 2. Chapter 3. A) Comparison, between rhTRAIL WT and M1, of the local environment around residues 
194 and 196. B) Comparison between rhTRAIL WT and M2. Backbones of the two adjacent monomers are in 
green and blue, respectively, and the backbone of the DR5 receptor is in grey. Hydrogen bond interactions are 
depicted in dashed green lines. 
 
Figure 1. Chapter 4. (A) Sequence alignment of the four different TRAIL membrane receptors. Position Asp 120 
of DR5 and corresponding residues of the other receptors are depicted in bold, residues of CRD2 in red and 
residues of CRD3 in orange. Identical amino acids to DR5 are boxed. (B) Side view of TRAIL receptor binding 
interface formed by two TRAIL monomers, highlighted in light red are all amino acids selected for the in silico 
screening. Tyr216 (depicted in green) was used as a reference and control. 
 
 
Figure 9. Chapter 4. Area of interaction of TRAIL and 
DR4/DR5 receptor around position 269: A) TRAIL; B) 
D269H variant and around position 214: C) TRAIL; D) 
T214R variant. Ribbons color is red for receptor and 
blue  for  TRAIL.  Residues  in  DR5-complexes  are  in 
dark  green  and  residues  in  DR4-complexes  in  light 
green.  Arg  191  and  Asp  267  are  key  TRAIL  amino 
acids  for  DR5  receptor  binding  in  the  corresponding 
binding  pocket  of  the  receptor,  as  observed  in  the 
crystal structure of TRAIL in complex with DR5. 
 
  
 
 
 
 
 
 